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Riassunto 
 
L’epidermide è un tessuto epiteliale pluristratificato la cui omeostasi dipende da un 
preciso equilibrio fra proliferazione, differenziamento e morte cellulare. Lo studio dei 
meccanismi che regolano la vitalità e la crescita delle cellule che lo compongono ha 
un forte impatto su una serie di settori di interesse biotecnologico come la cosmesi e  
la riparazione tissutale.  
Gli epiteli pluristratificati sono costituiti da più ordini di cellule sovrapposte e svolgono 
funzioni di rivestimento e di protezione. 
Nell’epidermide si distinguono, dalla profondità alla superficie, uno strato basale, uno 
strato spinoso, uno strato granuloso, uno strato lucido e uno strato corneo. Come in 
tutti gli epiteli, le cellule basali, tipicamente staminali, si moltiplicano per mitosi e 
danno origine a nuove cellule che, differenziando, si spostano verso la superficie. Le 
cellule che risalgono negli strati sovrabasali non proliferano più, si modificano nella 
struttura e nella funzione ed esprimono particolari proteine, le cheratine, che si 
accumulano nel citoplasma sottoforma di filamenti intermedi. Il processo ha termine 
con la formazione di lamelle cornee appiattite. Questo fenomeno prende il nome di 
cheratinizzazione e le cellule coinvolte sono chiamate cheratinociti (Rosati and 
Colombo, 2003.)  
La pelle è un organo complesso, metabolicamente attivo e che svolge diverse 
funzioni. Essa, infatti, costituisce una barriera fisica dell’organismo verso l’ambiente 
esterno, regola il passaggio di acqua e di altre sostanze, fornisce protezione contro 
micro-organismi, agenti tossici, raggi ultravioletti e insulti meccanici (Randall, 2006).  
Alterazioni a carico dei processi che regolano l’omeostasi dell’epidermide possono 
contribuire all’insorgenza di tumori. I tumori della pelle sono classificati in non-
melanoma skin cancer (NMSC) e melanoma. I primi sono suddivisi in epiteliali o 
squamous cell carcinoma  (SCC) e non epiteliali o basal cell carcinoma (BBC) (Yun-
Hsuan Ouyang, 2010).  
Il carcinoma squamoso (SCC) è un tumore resistente ai trattamenti terapeutici che si 
origina negli epiteli della pelle, dell’esofago, del polmone e delle cavità orali ed è 
frequentemente associato ad inattivazione mutazionale di p53 e ad over-espressione 
dell’oncoproteina Np63 codificata dal locus genico di TP63 (Hibi, 2000). Questo 
locus, mediante l’uso di promotori alternativi, origina due categorie di isoforme, 
chiamate TA e (Yang, 1998), mentre eventi di splicing alternativo al C-terminale 
generano almeno tre varianti di p63 (  e ) in ciascuna classe (Blanpain and 
Fuchs, 2007). Il locus di TP63 risulta amplificato nell’88% dei tumori al polmone e 
nell’80% dei carcinomi squamosi cutanei e Np63è la principale isoforma 
iperespressa (Hibi, 2000; Reis-Filho, 2002; Rocco, 2006).  
In condizioni fisiologiche Np63è espressa in modo predominante nello strato 
basale dell’epidermide adulta ed è un importante fattore pro-proliferativo nonchè un 
marker della staminalità. Durante il differenziamento del cheratinocita la sua 
espressione si riduce fino a scomparire e se, a causa di alterazioni del programma 
differenziativo, ciò non si verifica si determina iperplasia che predispone alla 
trasformazione maligna (Moll, 2004).  
In studi comparativi sull’espressione di p63 tra tumori primari e metastatici 
Np63risulta iper-espressa nell’89% dei tumori primari della pelle, ma solo 
nell’11% delle metastasi cutanee (Kanitakis, 2007). E’ stato inoltre dimostrato che 
l’inattivazione delle funzioni di p63 incrementa il potenziale metastatico mediato da 
TGFβ (Adorno, 2009) e ciò sostiene l’ipotesi che la perdita, piuttosto che l’over-
espressione, di Np63sia associata al fenomeno della metastasi (Rocco, 2006). 
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L’espressione di Np63può essere indotta da diversi “pathway” di trasduzione del 
segnale come quello dell’FGFR2 (Ramsey, 2013),  di PI3K (Barbieri, 2003) e 
dell’EGFR (Ripamonti, 2013). Tuttavia, l’ inibizione di ciascuno di questi  “signaling” 
non si è rivelata efficace nel trattamento del carcinoma squamoso (Ramsey,  2013). 
Nel complesso queste osservazioni suggeriscono che potrebbe essere interessante 
valutare i “partner” molecolari di Np63per comprendere meglio le funzioni della 
proteina nel controllo della proliferazione e valutare nuovi approcci terapeutici per le 
neoplasie caratterizzate dalla sua iper-espressione. Ciò ha spinto il gruppo di ricerca 
presso il quale ho svolto il mio progetto di dottorato ad intraprendere un approccio di 
proteomica funzionale che ha portato alla identificazione della proteina YB-1 come 
potenziale interattore di Np63(Amoresano, 2010).  
YB-1 o YBX-1 (Y Box Binding protein 1) è una proteina espressa nella maggior parte 
dei tessuti umani e il suo knockout in topi è letale a livello embrionale per anomalie 
nella chiusura del tubo neurale (Uchiumi, 2006). YB-1 è una proteina che si muove 
tra il citoplasma e il nucleo in risposta ad un’ampia varietà di stimoli, quali quelli di 
crescita, di stress e di danno al DNA (Kim, 2013). In studi clinici è stato dimostrato 
che la sua localizzazione nucleare è associata alla progressione tumorale e a 
prognosi negativa, in particolare nei tumori ovarici (Panupinthu, 2013), nel 
glioblastoma (Faury, 2007), nel melanoma (Shittek, 2007) e nel carcinoma squamoso 
(Lasham, 2013). YB-1, infatti, è un fattore di trascrizione di geni correlati alla 
proliferazione delle cellule staminali tumorali come CD44 e CD49f , reprime 
l’oncosoppressore p16INK4A e attiva geni pro-proliferativi quali PCNA, MDR1, EGFR e 
la ciclina B1 (To, 2010; Fotovati, 2011; Lasham, 2013).  
Nel citoplasma, invece, YB-1 agisce come regolatore negativo della proliferazione 
inibendo la traduzione cap-dipendente di molti mRNA correlati alla crescita, quali le 
cicline D1 ed E, c-myc, c-jun, c-fos, PDGFR-, TGF- (Sutherland, 2005). Nel 
contempo la componente citoplasmatica della proteina YB-1 è responsabile 
dell’incremento del potenziale metastatico di cellule di carcinoma mammario, 
inducendo la traduzione IRES-dipendente di mRNA coinvolti nella transizione 
epitelio-mesenchima come Snail1, Slug e Twist (Evdokimova, 2006).  
Infine dati recenti dimostrano l’esistenza di frammenti proteolitici di YB-1 secreti da 
cellule mesangiali, monocitiche e renali in seguito a stimoli infiammatori che 
interagendo con il recettore Notch-3 (Rauen, 2009) possono avere effetti mitogenici e 
promigratori (Frye, 2009).  
Dal momento che la proteina YB-1 è coinvolta in diversi “pathway” oncogenici e pro-
infiammatori essa è ritenuta un interessante target terapeutico. In particolare, sono 
stati sviluppati differenti approcci molecolari per interferire direttamente con la 
funzione della proteina o con quella di alcuni suoi regolatori (Law, 2010; Shen, 2011). 
Un esempio interessante e molto recente è la scoperta di una molecola ricavata da 
alcuni frutti e vegetali, chiamata FISETIN, che agisce come inibitore di YB-1 in cellule 
di carcinoma prostatico riducendone la proliferazione (Khan, 2014).   
 
Sulla base di tutte queste considerazioni il mio progetto di dottorato ha avuto lo 
scopo di caratterizzare le relazioni funzionali tra le proteine Np63e YB-1 nella 
patogenesi dei carcinomi squamosi al fine di implementarne gli approcci terapeutici. 
Durante lo svolgimento del mio progetto di dottorato ho contribuito a validare 
l’esistenza dell’interazione fisica tra Np63e YB-1 in cheratinociti primari 
immortalizzati (HaCaT) ed in cellule di carcinoma squamoso (SCC011). Ho verificato 
che tale specifica associazione fisica comporta l’accumulo nucleare di YB-1 ed 
influenza le funzioni che YB-1 svolge in questo compartimento. Ho inoltre dimostrato 
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che l’assenza di Np63in cellule di carcinoma squamoso aumenta la migrazione 
cellulare attraverso un meccanismo YB-1 dipendente (Di Costanzo, 2012).  
In secondo luogo, il mio progetto di ricerca si è focalizzato sullo studio degli effetti 
dell’assenza di YB-1 in cheratinociti proliferanti e in differenziamento. Il silenziamento 
di YB-1 in cheratinociti immortalizzati ed in cellule di carcinoma squamoso non 
metastatiche influenza drammaticamente la vitalità e l’adesione cellulare, con 
concomitante diminuzione dei livelli di espressione di Np63e di CD44. Al 
contrario, in cellule di carcinoma squamoso altamente metastatiche, come le 
SCC022, ho osservato un effetto diametralmente opposto: l’assenza di YB-1 
comporta l’attivazione del pathway di sopravvivenza cellulare PI3K/AKT. Questa 
parte della mia attività sperimentale ha contribuito alla conoscenza del network 
molecolareche governa la sopravvivenza e l’adesione delle cellule epiteliali e alla 
consapevolezza che Np63e YB-1 possono essere rilevanti nella patogenesi dei 
tumori squamosi (Troiano, 2014) 
 
 
Ho trascorso parte del secondo anno di dottorato presso il Blizard Institute 
dell’univeristà Queen Mary di Londra per avviare un progetto di collaborazione con il 
gruppo di ricerca del professor Daniele Bergamaschi. Egli e i suoi collaboratori 
avevano recentemente dimostrato, per la prima volta, la stabilizzazione delle 
isoforme TA e N di p63 nel nucleo e nei mitocondri di cellule di melanoma, in 
risposta a stress genotossici. In particolare, avevano osservato che l’espressione di 
entrambe le isoforme è associata a fenomeni di chemioresistenza in questo tipo di 
tumore (Matin, 2013).  
Il melanoma è una forma tumorale particolarmente aggressiva che insorge nei 
melanociti della pelle, la cui incidenza è rapidamente incrementata nelle ultime 
decadi. Come in altri tumori, anche in melanoma la proteina YB-1 risulta iper-
espressa e la sua traslocazione nucleare è associata alla progressione, alla 
migrazione e alla chemioresistenza del tumore (Shittek, 2007).  
La collaborazione con il gruppo del Prof. Bergamaschi è nata al fine di verificare se 
p63 e YB-1 fossero coinvolti anche nella patogenesi e/o progressione del melanoma 
cutaneo. 
Sebbene i dati da me ottenuti siano ancora preliminari, essi dimostrano l’esistenza in 
cellule di melanoma di peptidi di YB-1 a basso peso molecolare, la cui abbondanza e 
localizzazione dipende dall’espressione di p63. Questi peptidi-limite sono 
particolarmente interessanti e indubbiamente necessitano di essere studiati in 
maniera più approfondita, ad esempio valutandone il potenziale pro-proliferativo 
come già osservato in altri sistemi. Inoltre, i miei esperimenti di silenziamento di YB-1 
in cellule di melanoma hanno dimostrato che, anche in queste cellule, esiste un 
cross-talk fra YB-1 e p63 importante per il controllo della vitalità e sopravvivenza 
delle cellule di melanoma.  
 
Durante lo svolgimento del mio progetto di dottorato ho avuto l’opportunità di 
collaborare con la Prof.ssa Piera Quesada, esperta studiosa dell’enzima PARP 
(polyADP-ribose-polymerase) e del suo ruolo nel “signaling” indotto dal danno al 
DNA.  La nostra collaborazione è nata allo scopo di valutare la risposta dei membri 
della famiglia di p53 all’uso di inibitori di PARP e di Topoisomerasi I in cellule di 
carcinoma mammario e squamoso. In particolare, il nostro obiettivo è stato quello di 
descrivere possibili meccanismi di chemioresistenza in cui fossero coinvolte alcune 
isoforme di p63.   
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L’enzima PARP è il principale membro di una famiglia di 18 proteine multifunzionali 
in grado di catalizzare la reazione di ADP-ribosilazione su proteine bersaglio 
(O’Brien, 2006).  
La poli-ADP-ribosilazione è una modifica post-traduzionale dipendente dal danno al 
DNA, caratteristica di alcuni istoni e proteine nucleari e che contribuisce alla 
sopravvivenza cellulare. La proteina PARP ha un ruolo critico nel meccanismo di 
riparo del danno a singolo filamento del DNA; essa infatti lega il sito di rottura a 
singolo filamento, modifica le proteine nelle vicinanze e recluta in prossimità del sito 
di taglio il complesso di enzimi coinvolti nella riparazione del DNA (Davar, 2012).  
Gli inibitori di PARP sono il frutto più recente del paradigma terapeutico della letalità 
sintetica nello sviluppo di farmaci anti-tumorali, ovvero la teoria secondo la quale due 
difetti considerati benigni in cellule tumorali possono diventare letali se combinati 
(Davar, 2012). Se, infatti, danni a singolo filamento non vengono riparati, durante la 
duplicazione cellulare, possono diventare danni a doppia catena che innescano la 
risposta di altri meccanismi specifici di riparo del DNA. Se, però, gli inibitori di PARP 
sono usati in cellule in cui uno di questi meccanismi è già compromesso, la loro 
combinazione può diventare letale per la cellula tumorale. Gli inibitori di PARP sono 
utilizzati in monoterapia nei carcinomi mammari di tipo 1 e 2 (BRCA1 e BRCA2) o in 
combinazione con altri agenti chemioterapici di danno al DNA, come la Camptotecina 
(CPT) e  il  suo derivato Topotecano (TPT), noti inibitori della Topoisomerasi I 
(Malanga, 2004). 
Il mio lavoro ha messo in evidenza che in cellule di carcinoma mammario MCF7 il 
trattamento combinato dell’inibitore di PARP, PJ34, con l’inibitore della 
Topoisomerasi I, TPT, causa un forte incremento dei livelli delle isoforme TAp63 e 
in particolare, TAp63 è un potente induttore di apoptosi. Inoltre, ho contribuito a 
chiarire i meccanismi molecolari innescati dai trattamenti singoli e combinati di tali 
inibitori. E’ stato, infatti, dimostrato che, mentre il singolo trattamento con TPT induce 
il reclutamento di p53 sul promotore di p21WAF e ne attiva la trascrizione, il 
trattamento combinato TPT+PJ34 imprime un cambiamento nel destino cellulare 
inducendo l’espressione di geni pro-apoptotici come BAX.  
Infine, ho osservato che nelle cellule di carcinoma squamoso SCC022 che non 
esprimono p53, il trattamento TPT+PJ34 comporta la degradazione della 
proteinaNp63, senza però indurre apoptosi. Se, però, il trattamento combinato è 
concomitante all’ iper-espressione dell’ isoforma  TAp63 la cellula recupera la sua 
capacità di andare in apoptosi inducendo geni pro-apoptotici come BAX.  
I dati da me ottenuti per questa parte del progetto sono confluiti in due pubblicazioni 
dal titolo “p63 involvement in poly(ADP-ribose) polymerase 1 signaling of 
topoisomerase I-dependent DNA damage in carcinoma cells” e “Effect of poly(ADP-
ribose) polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent 
survival of carcinoma cells” (Montariello, 2013; Montariello, 2015). 
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SUMMARY 
Skin homeostasis is dependent on a tightly coordinated network of signaling 
pathways, resulting in a spatial and temporal balance of proliferation, growth 
arrest, differentiation, senescence and apoptosis. The knowledge of mechanisms 
that regulate keratinocyte growth and proliferation is attractive for several 
biotechnological fields, such as cosmetics, tissue engineering and skin 
regeneration.  
Np63, as critical pro-proliferative factor and marker of epidermal stemness, is 
essential for morphogenesis of organs/tissues developing by epithelial-
mesenchimal interactions such as the epidermis, teeth, hair and glands (Mills, 
1999). Using a proteomic approach my research group had identified YB-1 as a 
Np63molecular partner (Amoresano, 2010). Y Box Binding protein 1 (YB-1) is 
a transcription/translation factor involved in a wide variety of cellular functions, 
including cell proliferation and migration, DNA repair, multidrug resistance and 
stress response to extracellular signals (Lyabin, 2014).  
My PhD project was aimed to advance in the characterization of the functional 
interplay between Np63 and Y-box binding 1 proteins using in cell approaches 
to elucidate their roles in skin proliferation. 
First, I have validated Np63-YB-1 interaction in distinct cell contexts and 
demonstrated that this interaction causes accumulation of YB-1 into the nuclear 
compartment and influences its localization-dependent functions (Di Costanzo, 
2012). 
Then, I extended our knowledge on the YB-1 and Np63 functional interplay 
demonstrating that, being able to sustain Np63 gene expression, YB-1 is part 
of a complex molecular network linking Np63 to the PI3K/AKT/PTEN pathway 
and that establishment of a positive feedback loop, coupling induction of Np63 
expression with PI3K/AKT activation, may be a relevant step in the progression of 
squamous carcinogenesis (Troiano, 2015).  
During my PhD program, I have spent six months at the Blizard Institute - Queen 
Mary University of London collaborating with Professor Bergamaschi’s team. 
Based on my experience on squamous carcinoma I explored if p63 and YB-1 are 
also involved in melanoma pathogenesis and/or progression.  
Although my data are still preliminary, they show that Np63 controls YB-1 
protein integrity and nuclear localization also in melanoma cells and their 
functional cross-talk plays a role in melanoma cell survival.  
Finally, thanks to the collaboration with Prof. Piera Quesada’s team, I had the 
opportunity to perform experiments aimed to investigate on the role of p53 family 
members in the response of cancer cells to Topoisomerase I and poly(ADP-
ribose)polymerase (PARP1) inhibitors.  
My results point to a role for p63 in the cell response to treatment with TOP I and 
PARP-1 inhibitors. Highlighting the different outcome (i.e cell cycle arrest vs 
apoptosis) of PARP-1 activation/inhibition, my studies give right of the use of 
PARP inhibitor as chemotherapic adjuvant and/or in monotherapy also in 
TAp63/Np63 proficient cancer cells (Montariello, 2013; Montariello, 2015). 
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1.INTRODUCTION  
 
 
 
1.1 STRATIFIED SQUAMOUS EPITHELIA 
 
A stratified epithelium consists of many layers of epithelial cells; in a stratified 
squamous epithelium the cells of the outer layers are flat (squamous). Stratified 
squamous epithelia function as coats in order to withstand abrasion and shear forces 
(Rosati and Colombo, 2003). Cells of the basal layer are small and cuboidal-to-
columnar, however they gradually become larger and flat as the cells migrate to the 
apical layer. Cells of the apical layer are continuously replaced by the epithelial cells 
of deeper layers (Randall, 2006).  
In the human body there are two major subtypes of stratified squamous epithelia: 
Non-keratinizing: The apical surface of this epithelium is bathed by mucus, derived 
from glands and the cells lack large quantities of the protein keratin, therefore it is 
able to protect the underlying tissue only against relatively mild or moderate degree 
of abrasion. A non - keratinizing stratified squamous epithelium is found lining three 
prominent sites in the human body:  
 
 the esophagus, the pharynx 
 the sides and floor of the oral cavity 
 the vagina, male and female urethra 
 
  
Keratinizing: The surface of this epithelium is characteristically dry and free of 
mucus and keratinocytes represent the vast majority of cells in this epithelium. They 
actively synthesize  keratin, a mechanically tough and fibrillar protein of the 
intermediate filament family of cytoskeletal proteins (Bensouillah, 2012), which 
enables the tissue to withstand high degrees of mechanical stresses. The cells also 
produce and secrete  glycolipids that adsorb to the extracellular surface of the 
plasma membrane to fill interstitial spaces, making the tissue waterproof 
(Bensouillah, 2012) 
 
The most important keratinizing squamous epithelium is the epidermis, the outer 
layer of the skin.  
 
 
1.1.1 Skin anatomy  
 
The skin is the largest organ of the body, making up 16% of body weight, with a 
surface area of 1.8 m2 (Bensouillah, 2012). In the skin there are three structural 
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layers: the epidermis, the dermis and subcutis. Hair, nails, sebaceous, sweat and 
apocrine glands are regarded as derivatives of skin. 
The epidermis is the outer layer, serving as the physical and chemical barrier 
between the interior body and exterior environment; the dermis is the deeper layer 
providing the structural support of the skin; the subcutis or hypodermis is an 
important site of fat storage (Bensouillah, 2012). 
 
Epidermis  
Epidermal keratinocytes are connected by protein bridges called desmosomes. They 
are in a constant state of transition from the deeper layers to the superficial one. 
Moving from the inner layer to the surface, the four strata of the epidermis are named 
(Figure A): 
 - stratum basale (basal or germinativum) 
 - stratum spinosum (spinous or prickle)  
 - stratum granulosum (granular) 
 - stratum corneum (horny) 
 
 
FIGURE A 
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                                   FIGURE A. REPRESENTATIVE SCHEME OF EPIDERMIS  
 
 
In addition, the stratum lucidum is a thin layer of translucent cells seen in thick 
epidermis. It represents a transition from the stratum granulosum and stratum 
corneum and is not usually seen in thin epidermis. Together, the stratum spinosum 
and stratum granulosum are sometimes referred to as the Malpighian layer (Rosati 
and Colombo, 2003). 
 
 
Stratum basale  
In this layer, cells have stemness features and high rate of proliferation. The basal  
layer is adjacent to the dermis and includes dividing and non-dividing keratinocytes, 
attached to the basement membrane by hemi-desmosomes and inter-connected by 
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desmosomes. As keratinocytes divide, one cell remains in the basal layer and the 
other one differentiates, moving towards the surface. The process of differentiation 
starts with the loss of integrins, which mediate the adhesion to the basal membrane. 
The basal layer also contains Merkel cells. They are closely associated with 
cutaneous nerves and seem to be involved in light touch sensation (Bensouillah, 
2012) 
 
Stratum spinosum  
As basal cells reproduce and mature, they move upwards forming the stratum 
spinosum. Under light microscope the cells seem to be connected by intercellular 
bridges, which appear as `prickles', from whose the name of the layer. Instead, 
electronic microscopy has shown that cells are not connected by cytoplasmic 
protrusions, but rather by fibril structures. The outset cells of the stratum spinosum 
start to produce involucrin, the main component of cornified lining, typical of terminal 
differentiated keratinocytes (Randall, 2006). 
A small proportion of the cell population in the basal and spinosum layer is 
represented by melanocytes, which produce the pigment melanin. Melanin 
accumulates in melanosomes that are transferred to the adjacent keratinocytes, 
where they remain as granules. Melanin pigment provides protection against 
ultraviolet (UV) radiation, in fact, chronic exposure to light increases the ratio of 
melanocytes to keratinocytes. The number of melanocytes is the same in equivalent 
body sites in white and black skin, but the distribution and rate of production of 
melanin is different (Bensouillah, 2012). 
Moreover, the inner layers of the epidermis contain Langerhans cells, derived from 
hematopoietic progenitors of bone marrow. They are specialized in antigen 
presentation and belong to the skin immune system (SIS). Actually, they acquire 
antigens in peripheral tissues, transport them to regional lymph nodes, present to 
naive T cells and initiate adaptive immune response (Romani, 2012).  
 
Stratum granulosum 
Continuing their transition to the surface, the cells continue to flatten, lose their nuclei 
and their cytoplasm and acquire a granular aspect. In this layer, the cells are able to 
secrete the filaggrin, a phosphorylated protein which interacts with keratin fibers and 
is essential for the regulation of epidermal homeostasis (Bensouillah, 2012; Steinert, 
1993). 
 
Stratum corneum 
The final outcome of keratinocyte maturation is found in the stratum corneum,  made 
up of layers of hexagonal-shaped, non-viable cornified cells, known as corneocytes. 
Each corneocyte is surrounded by a protein envelope, is filled with water-retaining 
keratin proteins and in the extracellular space there are overlapping layers of lipids 
(Bensouillah, 2012; Steinert, 1993). The resulting structure provides the natural 
physical and water-retaining barrier of the skin. The movement of epidermal cells to 
this layer usually takes about 28 days and is known as the epidermal transit time 
(Bensouillah, 2012). 
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1.1.2 Skin functions 
 
The skin is a complex metabolically active organ and has several functions, in fact it 
creates a physical barrier to the environment, allowing and limiting the inward and 
outward passage of water, electrolytes and other substances and it provides 
protection against micro-organisms, ultraviolet radiation, toxic agents and mechanical 
insults (Bensouillah, 2012). 
Fillagrin and keratin molecules are responsible for skin barrier function. In the 
granular layer the protein fillagrin complexed with keratin and, as the degenerating 
cells move towards the stratum corneum, enzymes break down the keratin-fillagrin 
complex: fillagrin forms on the outside of the corneocytes, while the water retaining 
keratin remains inside (Bensouillah, 2012). When the skin is dry, fillagrin breaks 
down in order to control the osmotic pressure and the amount of water it holds. The 
free amino acids of fillagrin, along with other components such as lactic acid, urea 
and salts, are known as `natural moisturising factors' (NMF) and are responsible for 
keeping the skin moist and pliable due to their ability to attract and hold water 
(Randall, 2006). Shedding of the corneocytes is an important factor in maintaining 
skin integrity and smoothness and in normal healthy skin there is a balance between 
the production and shedding of these cells. In diseases such as psoriasis, 
characterized by increased corneocyte production and decrease in their shedding, 
the skin results dry and rough, as the corneocytes accumulate (Bensouillah, 2012). 
Moreover, in the inner layers of the epidermis melanocytes and melanin, creating a 
protective shield over the nuclei of the keratinocytes, have important roles in the UV 
protection, which induce keratinocyte proliferation and DNA damage. 
Finally, skin plays an important role in the immunological surveillance, containing all 
the elements of cellular immunity, with the exception of B cells and in the 
thermoregulation, maintaining a constant body temperature (Bensouillah, 2012). 
 
 
1.1.3 Skin cancer  
 
Skin homeostasis, as well as for every tissue, is dependent on a tightly coordinated 
network of signaling pathways, resulting in a spatial and temporal balance of 
proliferation, growth arrest, differentiation, senescence and apoptosis. Aberrant 
regulation of any of these biological processes can contribute to the onset and 
progression of tumorigenesis (Weinberg, 2002).  
Skin cancer is the most common malignancy in the United States and makes up 
about one third of all cancers diagnosed.  
The common skin cancers are divided into non-melanoma skin cancers (NMSCs) 
and melanoma. NMSCs are classified in two subcategories: epithelial and non-
epithelial skin cancers. Squamous cell carcinoma (SCC) and basal cell carcinoma 
(BCC) are, by far, the most frequent pathologic types of NMSC, included in non-
epithelial skin cancers (Marks, 1995). 
 
The most important factor involved in the pathogenesis of NMSC is the cumulative 
amount of exposure to ultraviolet radiation (UVR), in particular the wavelength range 
290 to 320 nm is the most carcinogenic (Buzzell, 1993).  Other risk factors including 
radiation exposure, long-term intake of arsenic or fair-skinned people may contribute 
to the development of NMSC. In addition, NMSC may arise from preexisting 
conditions such as scars, chronic ulcers (Marjolin's ulcer), sinuses (Johnson, 1992) or 
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two rare genetic syndromes—xeroderma pigmentosa and nevoid basal cell 
carcinoma syndrome (Shumrick, 1993). Finally, an increased incidence of NMSC, 
especially SCC, of the head and neck has also been found in transplant recipients. 
These SCCs are more likely to behave aggressively and have a high rate of 
metastasis (Padgett, 2001). 
 
Basal Cell Carcinoma 
The most common skin cancer is BCC, accounting for 70 to 75% of skin cancers. 
There are five clinical types of BCC (Yun-Hsuan Ouyang, 2010): 
 
 nodulo-ulcerative  
 superficial  
 morpheaform  
 pigmented  
 fibroadenoma. 
The first three of these are mentioned with the greatest frequency. The nodulo-
ulcerative lesions are the most common type, accounting for 75% of cases of BCC. 
The typical clinical appearance is a well-circumscribed nodule or plaque with pearly 
border and overlying telangiectasia and may be combined with rodent ulcer. 
Superficial BCC represents ∼10% of BCC. The clinical presentation is discrete 
erythematous macules or plaques with scaly change and a thin rolled border (Yun-
Hsuan Ouyang, 2010; Kirkuam, 2005). 
BCC tends to share the common histopathologic features of a predominant basal cell 
type, peripheral palisading of lesional cell nuclei, and a mucinous stroma with 
artificial cleft between the epithelial island and the stroma. In addition, there are 
variable degrees of cytologic atypia and mitotic activity (Kirkuam, 2005). 
The incidence of metastasis in BCC is very rare, occurring in 0.0028 to 0.1% of 
patients. Review of the literature shows that morpheaform, adenocystic, metatypical, 
and basosquamous types of BCC have a relatively high local recurrence rate 
(Ratushny, 2012). 
 
Squamous Cell Carcinoma  
Squamous cell carcinoma (SCC) is a treatment-refractory malignancy arising within 
the epithelium of the skin, lung, esophagus, oral cavity and upper aero-digestive 
tract. 
In particular, cutaneous squamous cell carcinoma (cSCC) is the second most 
common human cancer with over 250.000 new cases annually in the US and is 
second in incidence only to basal cell carcinoma. cSCC typically manifests as a 
spectrum of progressively advanced malignancies, ranging from a precursor actinic 
keratosis (AK) to squamous cell carcinoma (SCC) in situ (SCCIS), invasive cSCC 
and finally metastatic SCC (Yun-Hsuan Ouyang, 2010).  
AKs are defined at the histological level by dysplasia and consist of keratinocytes 
manifesting atypical nuclei that are enlarged, irregular and hypercromatic. AKs are 
also display disorganized growth, abnormal differentiation with thickened stratum 
corneum (Ratushny, 2012). 
According to the classic multistep model of carcinogenesis the progression from AK 
to cSCC may be described as several and consequent steps: mutation in one gene, 
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often a tumor suppressor, may lead to the development of a precursor lesion with 
increased genetic instability or loss of cell cycle control. Additional mutations in other 
drivers oncogenes allow the emergence of more neoplastic properties, leading to 
invasive carcinoma. The number of genetic changes required to transition from 
benign epithelium to metastatic carcinoma internal malignancies is thought to range 
from four to six (Ratko, 2014). 
In contrast to several internal malignancies, where p53 mutation is a late event in 
neoplastic evolution, in keratinocytes genomic instability results mainly from UVB-
induced inactivation of p53. In fact p53 is commonly mutated in AKs indicating that 
p53 loss occurred in pre-neoplastic lesions (Baker, 1990). Aberrant activation of 
EGFR and Fyn, a Src-family tyrosine kinase, and Ras activating mutations or 
amplification have also been commonly found in SCC. Important determinants of 
tumorigenesis in cSCC are the interactions between tumor cells, their extracellular 
matrix and the basement membrane zone (Loyo, 2013; Ramsey , 2013).  
Finally, one common finding in SCCs is the overexpression of the p63 protein, that is 
associated with amplification of the p63 locus at chromosome 3q27-29. Accordingly, 
p63 genomic sequence was found to be amplified in lung (88%), head and neck 
(80%) and cutaneous squamous carcinomas and the predominant splice variant of 
p63 expressed was Np63 (Hibi, 2000; Reis-Filho, 2002; Rocco, 2006). 
 
 
 
 
1.2 TP63 
 
1.2.1 p63 gene and protein structure 
 
The human TP63 locus spreads over about 220 kB on chromosome 3q27–29 and it 
belongs to p53 gene family. The locus consists of 15 exons and has two different 
promoters, the first located upstream the exon 1 and the second on the third intron.  
The promoters give rise to two categories of isoforms, TA- or ΔN- aminotermini 
transcripts, with an acidic transactivation domain or without it, respectively.  The 
complexity of the locus is enriched by alternative splicing at the carboxy-terminal (C-
terminal) which generates at least three p63 variants (  and ) in each class. The 
different C-termini of , , and  isoforms contribute to the diversity of p63 proteins; α, 
but not β and γ, isoforms contain a Sterile Alpha-Motif (SAM) domain that functions 
as a protein–protein interaction module in other proteins (Yang, 1998; Thanos, 1999; 
Barbieri, 2006). 
All p63 proteins show a DNA-binding domain which is approximately 60% identical at 
the aminoacid level to the DNA binding domain of p53, and an oligomerization 
domain with about 37% identity to that of p53. According to their high structural 
homology to p53 in the DNA binding domain, p63 proteins can bind to p53 DNA 
binding sites in vitro and in vivo (Westfall, 2003; Flores, 2002).  
The TA isoforms also have a N-terminal transactivation domain similar to p53, and 
can transactivate genes through a canonical p53-responsive element. ΔNp63 
proteins lack this domain and can act as dominant negative against p53 and TAp63 
proteins (Yang, 1998). Recent studies have shown that Np63 also possess 
transcriptional activity (Ghioni, 2002).  
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1.2.2 p63 in development and maintenance of squamous epithelia 
 
The critical role of p63 in limb morphogenesis and stratified tissue development was 
unveiled by studies on p63 knockout mice (Mills, 1999; Yang, 1999). p63 -/- mice die 
shortly after birth, because of their striking developmental defects. They lack all 
stratified squamous epithelia and their derivatives, such as epidermal appendages 
and mammary, lacrimal, and salivary glands (Mills, 1999; Yang, 1999). In addition, 
p63 −/− mice display truncated limb due to the inability to maintain or differentiate the 
apical ectodermal ridge, a structure required for limb outgrowth. Moreover, these 
mice exhibit craniofacial abnormalities, including cleft lip and palate and a lack of 
teeth (Mills, 1999; Yang, 1999).  
Similarly to what observed in mice, disruption of ΔNp63 in zebrafish resulted in lack 
of epidermal morphogenesis and fin truncations (Lee, 2002).  
 
Mutations in the p63 gene cause at least five autosomal dominantly inherited human 
syndromes, with a strong genotype-phenotype correlation. The p63 syndrome family 
includes the EEC, AEC, ADULT, LSM and SHFM syndromes1 which present various 
combinations of limb abnormalities, orofacial clefting and ectodermal dysplasia 
(Brunner, 2002). The mutations patterns are characteristic for each of these 
disorders, for example, EEC syndrome is caused by missense mutations in the p63 
DNA binding domain, whilst AEC syndrome is associated with missense or frameshift 
mutations in the SAM domain (Celli, 1999; McGrath, 2001).  
Finally, regarding the correlation with the environment, the phenotypes associated to 
p63 mutations can be affected by other modifying genetic or external factors as 
suggested by their incomplete penetrance and variable expressivity (van Bokhoven, 
2001). All together these observations indicate that different p63 mutations can affect 
distinct developmental events, all ascribable to ectodermal developmental defects.  
 
In normal adults, p63 protein expression lies in the basal layers of the stratified 
epithelial structures, such as epidermis, oral mucosa, and cervical epithelium, as well 
as transitional epithelium in the mucosa of the urinary bladder and complex glands, 
including the prostate and mammary, salivary, and lacrimal glands. Remarkably, p63 
is often over-expressed in cancers derived from these tissues (Di Como, 2002). 
During epidermal morphogenesis Np63 isoforms are expressed at higher levels 
than the TAp63 isoforms (McDade and McCance, 2010) and interestingly, depletion 
of Np63 isoforms produces tissue hypoplasia and defects in the expression of skin 
differentiation markers as following pan-p63 siRNA. On the contrary, knockdown of 
TAp63 isoforms give no detectable effects on proliferation, but only incomplete 
differentiation of the granular layer and stratum corneum (Truong, 2006).  
ΔNp63α is the predominant isoform in the basal layer of adult skin, where it plays a 
role in maintaining the viability and proliferative capacity of basal epithelial cells.    
Keratinocyte differentiation results in the down-regulation of ΔNp63α transcript, 
                                                 
1
 EEC = ectrodactyly, ectodermal dysplasia, facial clefting (MIM 129900); AEC = ankylopblepharon, 
ectodermal dysplasia and clefting (MIM 106260); ADULT = acro-dermato-ungual-lacrimal-tooth syndrome 
(MIM 103285); LSM = limb-mammary syndrome (MIM 603543); SHFM = split hand/foot malformation (MIM 
183600). 
 
22 
 
consistent with the loss of p63 protein in the more differentiated suprabasal layers of 
the epidermis (Westfall, 2003).  
Additional mechanisms have been proposed to reduce Np63 level during the 
differentiation process as proteolysis (Melino, 2006; Di Costanzo, 2011)  or 
microRNA mir-203-mediated silencing (Yi, 2008). 
The PI3K/Akt survival pathway, instead, prevents downregulation of ΔNp63α 
expression and inhibits keratinocyte terminal differentiation (Barbieri, 2003; Vivanco, 
2002) 
 
 
1.2.3 ΔNp63α and cancer 
 
Several studies on human patient-derived tumours have been performed to explore 
the role of p63 in cancer.  p63 was found to be highly expressed in the nucleus of 
different tumour types, such as head and neck cancers (Rocco, 2006), B cell 
lymphoma (Hedvat, 2005), bladder carcinoma (Compèrat, 2007), but also in the 
cytoplasm of prostate carcinoma cells (Weinstein, 2002). To distinguish between TA 
and Np63 proteins, antibodies against different p63 epitopes or isoform-specific 
PCR primers have been used in order to understand the role of the distinct p63 
isoforms in cancer pathogenesis and progression. Taken together, the results 
obtained point to the oncogenic role of Np63, in fact these isoforms are highly 
expressed in tumors  (Nylander, 2002; Barbieri, 2006) while TAp63 isoforms are 
absent or barely detectable (Compérat, 2007). 
Among all Np63 isoforms, ΔNp63α is the predominant isoform found in cancer, 
although its role in tumorigenesis is still controversial.  Np63 protein is over-
expressed in basal cell skin carcinoma and up to 80% of primary Squamous Cell 
Carcinomas (SCCs) of the head and neck, cervix, lung and esophagus (Hibi, 2000).  
Multiple mechanisms can sustain high and persistent levels of Np63 expression. 
Expression of Np63 is known to be induced by the FGFR2 (Ramsey, 2013), the 
EGFR/STAT3 (Ripamonti, 2013)  and PI3K pathways (Barbieri, 2003) although the 
time, the tissue context and precise stimuli triggering one or the other pathways have 
still to be defined. In contrast to a role in promoting tumorigenesis, Np63 
expression is a positive prognostic factor in cancer progression and is associated 
with favorable prognosis in patients with lung cancers (Massion, 2003). Lately, an 
increasing number of data are coming out claiming that Np63 is a metastasis 
suppressor. For instance, Np63 knockdown in squamous carcinoma cells was 
associated to a loss of cell adhesion and metastatic spread (Barbieri, 2006), while in 
prostate and breast, where only basal myoepithelial cells display intense Np63 
staining, invasive breast carcinomas are consistently devoid of nuclear p63 
(Barbareschi, 2001). Barbieri and colleagues hypothesize that ΔNp63α acts to 
promote early steps in tumorigenesis by protecting cells from growth arrest and 
apoptosis, while at same time acts as a metastasis suppressor by maintenance of 
the epithelial characteristics of cancer cells (Barbieri, 2006). 
 
 
1.2.4 p63 and its molecular partners 
 
Proteins usually play their functions in the cell as macromolecular complexes. 
Interaction with distinct factors might arrange the protein structure, specify its 
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subcellular localization or binding affinity to nucleic acids and/or cellular structure and 
ultimately define its functions.  
To get insights into the p63 biology it is important to identify and characterize its 
molecular partners. This field of p63 biology has only been very partially explored,  
Itch/AIP4, Fbw7, PIN are some p63 interactors that have been characterized to 
regulate p63 stability and function (Rossi, 2006; Galli, 2010). 
My research group using a functional proteomic approach by mass spectrometry has 
revealed a set of 50 potential Np63 partner in HaCaT keratinocytes (Amoresano,  
2010). Among the potential interactors there was a set of RNA-binding proteins, 
including the multifunctional Y-box binding protein 1.   
 
 
 
1.3 YB-1  
 
     1.3.1 YB-1 protein structure 
The YB-1 gene  resides on chromosome 1p34, it is structured in 8 exons (Toh, 1998)  
with a long 5′ UTR, involved in the regulation of gene expression (Kohno, 2003). The 
mRNA of YB-1, 1.5 kb long, encodes a protein of 324 amino acids with an expected 
molecular weight of 36 kDa (Didier, 1988; Kuwano, 2004.). However, its apparent 
molecular weight in SDS-PAGE is 50 kDa. The Y-box-binding protein 1 (YB-1, YBX1) 
is a member of the DNA/RNA binding protein family, with an evolutionarily ancient 
and conserved cold shock domain (Kohno, 2003). 
YB-1 protein consists of three domains: the alanine/proline-rich N-terminal domain 
(A/P domain), the cold shock domain (CSD) and the large C-terminal domain (CTD) 
with alternating clusters of positively and negatively charged amino acid residues   
(Lyabin, 2014). 
The CSD structure is represented by five-stranded β-barrel with consensus 
sequences RNP-1 (K/N-G-F/Y-G-F-I/V) and RNP-2 (V-F-V-H-F) through which it  
binds to RNA and DNA (Lasham, 2013).  
Instead, the A/P domain and the CTD have no regular secondary structure; 
neverthless, YB-1 realizes the interactions with the majority of its protein partners  
through the CTD domain by a poly(Pro) II conformation (Rath, 2005), as well as by its 
positively charged amino acid residues arranged as clusters (Lyabin, 2014).  
The carboxyl-terminal domain has, also, multiple phosphorylation, acetylation and 
ubiquitylation sites involved in the regulation of various protein functions (Inoue, 
2011). 
 
About the role of YB-1 as a RNA-binding protein, it has been reported an interesting 
study which illustrates how its structure is well suitable to different cellular 
mechanisms. The authors explain that at a comparatively low YB-1/mRNA ratio, 
typical of translated polysomal mRNPs, monomeric YB-1 interacts with RNA through 
both its CSD and CTD and causes mRNP unwinding. In these complexes, mRNA 
has its termini exposed to both translation initiation factors and ribosomes. At a high 
YB-1/mRNA ratio, typical for free untranslated mRNPs, YB-1 undergoes 
multimerization through its CTD, while its CSD remains mRNA-bound. A large YB-1 
multimeric complex composed of 15-18 molecules accommodates at its surface an 
RNA segment of about 600-700 nt.  Long mRNAs can be accommodated at several 
multimers (Skabkin, 2004; Lyabin, 2014).   
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YB-1 has also the ability to produce fibrils which may underlie formation of RNA 
granules, such as stress granules and P-bodies in the cell (Guryanov, 2012; Lyabin, 
2014). In particular, under conditions of a high ionic strength, YB-1 forms reversible 
amyloid-like fibrils (Selivanova, 2010) and its disordered terminal domains modulate 
this process: the A/P domain stimulates fibril formation, while the first part of CTD 
suppresses it at any level of ionic strength (Guryanov and Selivanova, 2012). This 
ability is presumably explained by its low stability, because its melting temperature is 
as low as 39◦C and at physiological temperature its best part remains in a non-native 
state (Guryanov, 2012).  
Finally, YB-1 was first recognized as a protein bound to promoters of the HLA-
DRgene and to Epidermal Growth Factor enhancer Didier, 1988; Sakura, 1988). 
These genomic regions are characterized by the presence of the so-called Y-box 
sequence ( 5’CTGATTGGC/TCTTAA-3’), to whom YB-1 owes its name. Later, YB-1 
was found to bind and regulate the expression of genes with or without the Y-box 
sequence in their regulative regions. A slight specificity of YB-1 to the Y-box can be 
observed in vitro, however YB-1 appears to bind strongly to single-and double-
stranded GGGG, CACC and CATC motifs (Zasedateleva, 2002). In a recent 
manuscript by Dolfini and Mantovani (Dolfini, 2013), using the ChIP-on ChIP and 
ChIP-Seq bioinformatic data, it has been reported that YB-1 has no particular 
specificity for the canonical Y-box sequence.  
 
 
1.3.2 YB-1 functions 
 
YB-1 belongs to a group of intrinsically disordered proteins that do not follow the 
classical rule “one protein-one function”.  It is an example the novel principle claiming 
that a disordered structure may suggest many functions. In fact,  YB-1 has several 
functions and it is involved in many cellular processes due to (i) its ability to interact 
with nucleic acids, (ii) its ability to form complexes with other proteins and, moreover, 
(iii) its capacity to shuttle between the nucleus and the cytoplasm under particular 
stimuli such as heat (Stein, 2001), anticancer drugs, and ultraviolet (UV) irradiation 
(Bargou, 1997; Koike, 1997; Fujita, 2005) or during G1/S phase transition (Lyabin, 
2014; Inoue, 2011 ) 
 
Proliferation 
 
Several studies have linked the expression of YB-1 with the cell proliferative activity. 
Distinct team have observed that knockout of mouse YB-1 causes abnormalities in 
neurotubule formation during the early embryonic development, fetal growth 
retardation and prenatal deaths (Lu,  2005; Uchiumi, 2006). 
Interestingly, overexpresson of YB-1 has been observed in primary melanoma 
(Schittek, 2007), prostate cancer (Giménez-Bonafé, 2004), glioblastoma (Faury, 
2007) and neuroblastoma (Wachowiak, 2010). Reduction of YB-1 expression, 
instead, causes growth inhibition or apoptosis in a broad range of cancer cells 
both in vitro and in vivo (Lasham, 2013). Targeted overexpression of YB-1 in the 
mammary gland of a transgenic mouse results in the formation of breast cancer 
(Bergmann, 2005). 
 
YB-1 appears to be involved in the control of cell proliferation through different 
mechanisms: 
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- YB-1 has the ability to control the expression of different E2F family members 
and it directly binds to the promoters of several canonical E2F1-regulated 
genes (Lasham,  2012). 
- YB-1 regulates the PI3KCA gene encoding the catalytic subunit p110α of PI3K 
enzymes. This gene is frequently amplified or mutated in cancers. The PI3K 
pathway signals through the multifunctional protein kinase Akt, which in turn 
regulates mTOR, control several oncogenic mechanisms, including 
proliferation, survival, metabolism and metastasis (Dazert, 2011).  
- YB-1 plays an integral role in the PI3K/Akt/mTOR pathway and depends on 
Akt for its nuclear translocation following phosphorylation at Ser102 in a 
number of cell lines, including basal-like breast cancer cells (Sutherland, 
2005) ovarian cancer cells (Basaki, 2007)  and melanoma cells (Sinnberg, 
2012)  
- YB-1 represses transcription of the TP53 gene (Lasham, 2003) and it can 
disable the p53 pathway by regulating its activity. In addition, it has been 
shown that YB-1 controls the expression of upstream regulators of RB, like 
cyclins D1, CDK1 and CDK2 (Lasham, 2013).  
 
 
Invasion and metastasis 
 
YB-1 regulates pathways involved in invasion and metastasis. In vitro studies have 
shown that YB-1 potentiates the invasive properties of several cancer cell lines 
(Lovett, 2010). Several mechanisms have been proposed to explain YB-1 pro-
metastatic property: 
 
- YB-1 has been shown to promote the translation of mRNAs encoding E-
cadherin-repressing factors such as Snail, Lef 1 and Twist (Evdokimova, 
2009). The cadherins are involved in maintaining cell–cell adhesion in the 
tumour mass and they are frequently inactivated during metastasis 
progression (Jamora, 2003).  
- YB-1 induces transcription of a number of matrix metalloproteinases 
(MMPs), including MMP-2, MMP-12 and MMP-13  responsible for the 
dissociation BM/ECM (basement membrane/extracellular matrix) (Samuel, 
2007). 
- YB-1 appears to regulate the translation of TGFβ1(Fraser, 2008) and to 
bind to the promoters of Wnt pathway proteins, involved also in 
angiogenesis. 
- YB-1 is a transcriptional activator of the CD44 gene (To, 2010), an 
important membrane-bound protein that plays a relevant role in metastasis. 
 
 
Chemoresistance 
 
In the presence of genotoxic agents, such as anti-cancer drugs and ultraviolet 
irradiation, YB-1 upregulates the transcription of the Multidrug Resistance 1 
(MDR1) gene, resulting in the increased expression of P-glycoprotein (Ohga, 1998). 
The P-glycoprotein, a member of the ATP-binding cassette (ABC) transporter 
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superfamily, is known to mediate the efflux of xenobiotics in the cell (Litman, 2001) 
affecting the sensitivity of the cancer cell to chemoterapic agents. 
In particular, nuclear YB-1 influences the transcription of chemoresistance genes, 
decreasing chemosensitivity of cancer cells to a wide range of anticancer drugs, such 
as cisplatin (Ohga, 1996), doxorubicin (Bargou, 1997), paclitaxel (Fujita, 2005) and 
mitomycin C (Shibahara, 2004).  Cisplatin-resistant human head and neck cancer KB 
epidermoid cancer cells and ovarian cancer cells exhibited higher nuclear expression 
of YB-1 than the drug-sensitive wild type cancer cells (Yahata, 2002). Moreover, it 
has recently shown that YB-1 is able to increase the expression 
of CD44 and CD49f genes associated with cancer stem cells (To, 2010), both genes 
induce chemoresistance in MDA-MB-231 breast cancer cells (Fillmore, 2008). CD44, 
in fact, interacts with hyaluronan and activates drug-resistant genes such 
as MDR1 (Inoue, 2011).  
 
 
Inflammation 
 
Some of the pathways and players linked to YB-1 and previously described such as  
EGFR, STAT3, MMP-2 and CD44 promote cancer cell inflammation. In addition to 
these, YB-1 has been found correlated with other inflammatory pathways: 
 
- In mesangial inflammatory cells and HK2 and HEK293 kidney epithelial cells, 
oxidative stress and cytokines like PDGF-BB, interferon-and 
lipopolysaccharide trigger YB-1 secretion. Extracellular YB-1 associates with 
outer cell membrane components and interacts with extracellular Notch-3 
receptor domains. YB-1 secretion and Notch-3 receptor expression/activation 
may amplify the inflammatory response of mesangial cells (MC) conferred by 
the Jak/STAT (signal transducers and activators of transcription) pathway 
(Rauen, 2009). 
- In a Scientific EMBO Report, Frye BC and colleagues describe that 
lipopolysaccharide induces YB-1 secretion in primary monocytic cells and that 
extracellular YB-1 exerts a potent proliferative response in different cell types 
and promotes cell migration (Frye, 2009). 
- YB-1 peptides have been found in serum of sepsis patients and urine of 
patients affected by different forms of tumors  (Hanssen, 2013). The specific 
role of these peptides is still unknown. 
 
 
1.3.3 YB-1 AS A THERAPEUTIC TARGET 
 
YB-1 is upstream of several molecular pathways involved in tumorigenesis and 
inflammatory diseases, therefore YB-1 appears to be a very attractive therapeutic 
target. In the last decade different approaches to target YB-1 have been employed, 
including targeting of YB-1 directly, interfering with the activation of YB-1 or targeting 
the regulators that activate YB-1.  
First, a molecule of nucleic acid was successfully employed in different cultured 
cancer cells as a decoy to sequester YB-1 protein, resulting in inhibition of tumour 
cell growth and p53-mediated apoptosis (Homer, 2005). The use of nucleic acids as 
therapeutics has been slowed by issues of delivery, although rapid advances are 
now being made (Seton-Rogers, 2012).  
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Another therapeutic approach to directly target YB-1 could be the use of siRNAs. 
Anti-YB-1 siRNAs have been shown to suppress tumour cell invasion, proliferation, 
insensitivity to chemotherapy and to promote apoptosis (Gao, 2009). The delivery of 
siRNAs in humans is still a challenge for chemistry and pharmacology due to their 
discussed problems of stability and bioavailability (Seton-Rogers, 2012).  
In a therapeutic strategy it is important to remind that YB- 1 functions as transcription 
factor when phosphorylated at Ser102, which stimulates nuclear translocation and 
DNA binding (Southerland, 2005). S102A YB-1 mutants exhibited reduced cell 
proliferation and an interference peptide, designed as another type of ‘molecular 
decoy’ that competes with YB-1 for phosphorylation by RSK and Akt,  has been 
found successfully inhibiting proliferation of breast and prostate cancer cells in 
culture (Law, 2010). Thus peptide-based delivery systems could be a promising 
method  to inhibit YB-1 therapeutically. 
A potential method to suppress YB-1 activity could be also the use of ‘signal 
transduction’ inhibitors. A side effect of blocking kinases such as PDK-1, Akt  and 
RSK is quenching of YB-1 phosphorylation at Ser102 and thereby reduction of its 
transactivation activity. In fact,  RSK inhibition with siRNA or small molecules, such 
as BI-D1870 and SL0101, completely suppress the activation of YB-1 (Stratford, 
2008). Likewise, the MEK inhibitor PD098059 blocks RSK and suppresses the 
nuclear localization of YB-1 (Shen, 2011) as well as  YB-1 blockade may potentially 
underlie a significant part of the activity of these inhibitors.  
Very recently, Khan and colleagues have identified Fisetin (3,7,3’,4’-
tetrahydroxyflavone) as a new potential inhibitor of YB-1 activation in PCa cells. 
Fisetin  belongs to such a flavonol subgroup of flavonoids along with quercetin, 
myricetin and kaempferol. It is present in many fruits and vegetables most notably 
strawberries, apples, persimmons, kiwis, cucumbers and onions. Computational 
docking and molecular dynamics suggested that fisetin binds to the residues from β1 
- β4 strands of CSD, hindering Akt’s interaction with YB-1. Fisetin also inhibited EGF 
induced YB-1 phosphorylation and appear to reduce the expression of EMT markers 
both in vitro and in vivo (Khan, 2014). 
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AIMS OF THE THESIS  
 
Squamous cell carcinoma (SCC) is a treatment-refractory malignancy arising 
within the epithelium of the skin, lung, esophagus, oral cavity and upper aero-
digestive tract. SCCs are frequently associated with mutational inactivation of the p53 
tumor suppressor and overexpression of Np63 oncoprotein.  
Np63 expression is known to be induced by FGFR2 (Ramsey, 2013), PI3K/Akt 
(Barbieri, 2003) and EGFR/STAT3 (Ripamonti, 2013) signaling pathways. However, 
therapeutically targeting the EGFR deregulated signaling pathway in SCC has 
proven not efficient, so far (Argiris, 2013; Martins, 2013). Even more intriguing, are 
the evidences that loss, rather than overexpression, of Np63 is associated with a 
more invasive phenotype, at least in some tissues (Rocco, 2006). For instance, 
inactivation of p63 functions was demonstrated to be critical to TGFβ-mediated 
metastatic potential, through a mechanism involving TGFβ signaling activation,  
Smad and p53 mutant proteins (Adorno, 2009). These observations imply that a 
gene-therapy based on Np63 silencing must be carefully evaluated.  
Therapeutic targeting of Np63 molecular partners is an exciting, but still relatively 
underexplored area for potential therapeutic intervention in SCC.  
By coimmunoprecipitation and mass spectrometry analysis, my research team has 
identified the Y box-binding protein 1 as a Np63 interactor (Amoresano, 2010).  
YB-1 is variably expressed in most normal human tissues and YB-1 knockout mice 
are embryonically lethal (Uchiumi, 2006). As previously described YB-1 protein is a 
stem cell marker with a well assessed oncogenic potential and it shows interesting 
features that makes it a valuable therapeutic target. Moreover, YB-1 should also be 
regarded as a useful biomarker of cancer progression. 
Studies on  targeting YB-1, using cell-permeable inhibitory peptides, YB-1 siRNAs or 
oligonucleotide decoys, are the current challenge and promise in experiments to 
therapeutically target this master regulator of cancer cell biology.  
 
Given these considerations and interest in understanding how YB-1 functions in 
association with Np63 in oncogenic pathways leading to SCC, my PhD project 
was aimed to advance in the characterization of the functional interplay between 
Np63 and Y-box binding 1 oncoproteins using in cell approaches to finally focus 
on its therapeutic implications. 
 
Starting from the mass spectrometry data about YB-1 and Np63 interaction and on 
the basis of the expertise of my research group on the role of Np63  in epithelial 
cell system, I focused my study on the following points: 
 
- Validation of the YB-1/Np63  molecular interaction in primary, immortalized  
and transformed keratinocytes. 
 
- Study of the effects of Np63  expression on YB-1 functions in cancer cells, 
in terms of localization, gene expression and cell function, in order to elucidate 
their potential cross-talk. 
 
- Study of the effects of YB-1 expression in immortalized keratinocytes and 
squamous cancer cells in terms of gene expression and cell functions.  
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2.RESULTS 
 
 
 
2.1. YB-1 interacts with Np63 in vitro and in vivo  
 
At beginning of my PhD project in the laboratory of Prof. Calabrò I was involved in a  
study aimed to gain insight into the functional cross-talk between p63 and YB-1 
proteins. In fact, Calabro’s team, using functional proteomics, had previously 
described that the Y-box binding protein 1 (YB-1, NSEP1 or YBX1) is a potential p63 
interacting partner (Amoresano, 2010).  
I first validated that endogenous YB-1 and Np63 are abundantly co-expressed in 
human squamous carcinoma cells using immunoblots and immunofluorescence 
assays, confirming that A431, SCC022 and SCC011 cell lines showed intense 
signals for both proteins (Fig. 1A and B).  
 
FIGURE 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. Np63 and YB-1 are co-expressed in squamous carcinoma cell lines. (A) Whole cell lysates 
were obtained from H1299 (non-small cell lung carcinoma), A431 (epidermoid carcinoma cell line), SCC011 
and SCC022 (keratinocytes-derived SCC) cells.  30g of total protein extracts were separated by SDS PAGE 
and subjected to immunoblot. Proteins were detected with specific antibodies, as indicated. Images were 
acquired with CHEMIDOC (BIORAD) and analyzed with the Quantity-ONE software. (B) A431, SCC011, 
SCC022 cells were seeded (2.5 x 10
5
) on 35 mm dish, grown on micro cover glasses (BDH). After 24 hours at 
seeding cells were fixed and subjected to double immunofluorescence using rabbit primary YB-1 antibody and 
Fitch-conjugated secondary antibodies (green). P63 protein was detected using mouse anti-p63 and Cy3-
conjugated secondary antibodies (red). Images of merge (yellow) show the co-expression of two proteins. 
 
 
Next, I decided to confirm the interaction between Np63 and YB-1 in non 
transformed HaCaT keratinocytes and in squamous cell carcinoma (SCC011), by co-
immunoprecipitation assay. Immunocomplexes containing Np63 and YB-1 were 
isolated from total cell lysates, using either antibodies against YB-1 or antibodies 
against p63, thus confirming the interaction inferred by mass spectrometry (Figure 
2A-2D).  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2. Np63 interacts with YB-1. (A) Extracts from HaCaT cells were immunoprecipitated with 
anti-p63 antibodies and the immunocomplexes were blotted and probed with anti-YB-1, as indicated. (B) 
Extracts from HaCaT cells were immunoprecipitated with anti-YB-1 antibodies and the immunocomplexes were 
blotted and probed with anti-p63. (C) Extracts from SCC011 cells were immunoprecipitated  with anti-YB1 
antibodies and the immunocomplexes were blotted and probed with anti-p63, as indicated. (D) Extracts from 
SCC011 cells were immunoprecipitated  with anti-p63 antibodies and the immunocomplexes were blotted and 
probed with anti-YB1. Samples with no antibody (no Ab) or irrelevant α-mouse and α-rabbit antibodies were 
included as controls. 
 
Previous data showed that the C-terminal region of Np63 isoform is involved in the 
association with YB-1 and the interaction between the two proteins requires no 
additional factors in breast cancer cell lines. To determine if YB-1 interacts 
specifically with the  isoform of Np63, I transfected p63 null H1299 cells,  with 
Np63 or Np63to perform co-immunoprecipitation assays. As shown in Fig.3, 
YB-1 associates with Np63 but not with Np63

FIGURE 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 3. Np63 but not Np63 interacts with YB-1. (A) H1299 cells were transiently transfected with 
5 g of Np63 or (B) Np63 expression vectors. Equal amounts (1 mg) of extracts were immunoprecipitated 
with anti-p63 antibodies (4A4) or unrelated-mouse IgG. The immunocomplexes were blotted and probed with 
anti-p63 and anti-YB-1 antibodies, as indicated. 
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2.2 Np63 induces YB-1 nuclear accumulation 
 
It has been reported that YB-1 is ubiquitously expressed and predominantly localized 
into the cytoplasm (Homer, 2005), while Np63is mainly expressed by basal and 
myoepithelial cells in skin and glands and is almost completely restricted to the 
nuclear compartment  (Di Como, 2002). Since I noticed some overlapping between 
the p63 and YB-1 immunofluorescence signals into the nucleus of squamous 
carcinoma cell lines, I have investigated whether Np63had an effect on YB-1 
subcellular localization. I transfected Np63 in MDA-MB-231 cells, human 
metastatic breast carcinoma cells lacking p63, but expressing high level of 
endogenous YB-1.  As shown in Fig.4, in cells with no detectable p63 signal, YB-1 
exhibited a largely prevalent cytoplasmic localization (Fig. 4A, white arrows), while 
95% of Np63 expressing cells showed a strong YB-1 nuclear staining (Fig. 4A, 
yellow arrows). 
 
FIGURE 4 
 
FIGURE 4. Endogenous YB-1 accumulates in the nucleus of breast cancer cells expressing Np63.  (A) A 
representative image of a cell expressing Np63 and showing nuclear endogenous YB-1 (yellow arrow). A 
representative image showing YB-1 cytoplasmic localization in cells bearing no detectable Np63 expression 
(white arrows). MDA-MB-231 cells were seeded at 60% confluency (2.3 x 10
5
) on  24 x 24 mm sterile 
coverglasses placed in 60 mm dishes and transiently transfected with 1 g of of Np63 expression vector. 
Cells were fixed and subjected to double indirect immunofluorescence using rabbit primary YB-1 antibody and 
Fitch-conjugated secondary antibodies (green). P63 protein was detected using mouse anti-p63 and Cy3-
conjugated secondary antibodies (red). 4’,6-Diamidino-2-phenylindole (DAPI) was used to stain nuclei (blue). 
(B) MB-MDA-231 cells were transiently transfected with a fixed amount (5 g) of an empty vector (mock), 
Np63 or Np63 expression vector in 100 mm dishes. 24h after transfection, cell lysates were fractionated to 
obtain cytoplasmic and nuclear fractions. 20g of nuclear and cytoplasmic extracts were separated by SDS 
PAGE and subjected to immunoblot. Proteins were detected with specific antibodies, as indicated. PARP and 
total AKT were used as nuclear and cytoplasmic control respectively, to check for cross-contamination. Images 
were acquired with CHEMIDOC (BIORAD) and analyzed with the Quantity-ONE software. 
 
 
I verified this observation by nuclear/cytoplasmic fractionation of MDA-MB-231 cells 
transfected with Np63 or Np63. Endogenous YB-1 protein, in MDA-MB-231 
cells, was detectable as 50 and 36 kDa immunoreactive forms.  Both forms of YB-1 
appear to accumulate in the nuclear compartment of cells transfected with Np63, 
but not Np63 (Fig. 4B).  Immunoblots with antibodies against PARP-1 (nuclear) 
and Akt (cytoplasmic) were performed to check for the quality of the fractionation. 
Interestingly, while the amount of total Akt was comparable, phosphorylated Akt, at 
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Serine 473,  was enhanced in Np63, but not Np63 transfected cells (Fig. 4B). 
This observation was in line with previous data showing the specific ability of Np63 
isoform to promote PI3K/Akt pathway activation (Barbieri,2003).  
 
I then evaluated the contribution of Np63to YB-1 subcellular distribution in 
SCC011 and in SCC022 cells expressing both proteins endogenously. To this aim, I 
analyzed YB-1 subcellular distribution, following p63 depletion, by immunoblot on 
nuclear/cytoplasmic fractions in SCC011 cells and by immunofluorescence in 
SCC022 cells. As shown in fig. 5A and B, following p63 knock-down, the YB-1 
nuclear pool was dramatically reduced. 
 
FIGURE 5 
 
 
FIGURE 5. YB-1 and p63 knockdown in SCC022 cells. (A) Immunofluorescence assay in SCC022 cells 
transfected with scrambled, YB-1 or p63 siRNA oligos. YB1 was detected using anti-YB-1 and secondary anti-
rabbit Cy5-conjugated (green) antibodies. p63 was detected using anti-p63 and secondary anti-mouse Cy3-
conjugated (red) antibodies. Hoechst was used to stain nuclei. (B) SCC011 cells were seeded at 60% confluency 
(1.5 x 10
6
) in 100mm dishes. 24h after seeding cells were transiently silenced with IBONI p63-siRNA pool 
(20nm final concentration). 48h after p63-silencing cell lysates were fractionated to obtain cytoplasmic and 
nuclear fractions. Nuclear and cytoplasmic extracts were separated by SDS PAGE and subjected to immunoblot. 
Proteins were detected with specific antibodies, as indicated. PARP and total AKT were used as nuclear and 
cytoplasmic control respectively, to check for cross-contamination. Images were acquired with CHEMIDOC 
(BIORAD) and analyzed with the Quantity-ONE software. 
 
 
 
2.3 Np63 affects YB-1 binding to Snail and YB-1 mRNAs 
 
Nuclear accumulation of YB-1 induced by Np63 causes consequently a reduction 
of its cytoplasmic pool, therefore, affecting YB-1 functions.  
Cytoplasmic localization of YB-1 was associated with binding and translational 
activation of Snail1 mRNA (Evodokimova, 2009). Snail1 protein is a transcriptional 
repressor of Np63and E-cadherin and promotes the epithelial-mesenchimal 
transition in several epithelial-derived cancer cell lines (Peirò, 2006). My group had 
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previously observed that Np63 overexpression in MB-MDA-231 caused a 
reduction of Snail1 protein level (Fig. 6A). Such reduction was not associated with a 
decrease of Snail1 mRNA level (Fig. 6B), thereby suggesting that Snail1 protein was 
down-regulated at translational level. They hypothesized that the specific association 
of Np63 with YB-1 would reduce the amount of YB-1 bound to the Snail1 
transcript. To test this hypothesis they performed RNA-Immunoprecipitation (RNA-IP) 
coupled with real time PCR to quantitate the amount of Snail1 mRNA bound to 
endogenous YB-1, in mock and Np63 transfected MDA-MB-231 cells. The 
obtained results confirm that Np63 reduces the amount of YB-1 bound to Snail1 
transcript (Fig. 6C). A similar analysis performed on YB-1 transcript  gave the same 
result (Fig. 6D).  
 
FIGURE 6 
 
FIGURE 6. Np63 affects Snail1 protein 
level and YB-1 binding to Snail1 and YB-1 
mRNAs in MDA-MB-231 cells. (A) MDA-MB-
231 cells were transfected with an empty vector 
(mock) or a fixed amount (1g in 60mm dishes) 
of Np63 or Np63 expression vector. 24 hr 
after transfection, cells were harvested and total 
extracts  were prepared. 20g of each extract 
were loaded on SDS-PAGE and subjected to 
immunoblot with the indicated antibodies. (B) 
MB-MDA-231 cells were transfected with an 
empty vector or Np63 encoding plasmid. 24hr 
after transfection total RNA was purified and 
retrotranscribed as described in Materials and 
Methods. The expression level of Np63 was 
checked by immunoblot (right panel). PCR was 
performed with primers designed to specifically 
amplify Snail1, Twist or HPRT transcripts and 
analyzed by agarose-gel electrophoresis (left 
panel). Plot showing the level of Snail1 and 
Twist transcripts was normalized respect to 
HPRT. Values are the mean of 3 independent experiments (lower panel).  
Nuclear extracts from Np63 transfected MB-MDA-231 cells were immunoprecipitated with anti-YB1 
antibody. After reverse cross-linking the YB1-bound RNA was purified, retrotranscribed and subject to qRT-
PCR analysis using oligonucleotides designed to specifically amplify Snail1 transcript (C) or YB-1 transcript 
(D). Plots represent the % of enrichment of Snail1/YB-1 transcript normalized as indicated in Materials and 
Methods. 1/50 of the input extract was loaded as control. The values are the mean + S.D. of three biological 
replicates.  
 
 
 
2.4Np63 and YB-1 binds to the PIK3CA gene promoter and cooperate in 
its transcriptional activation  
 
Given the observed YB-1 behaviour in the cytoplasm in presence of Np63 I 
focused my attention on the potential role of two proteins in the regulation of nuclear 
targets. The PIK3CA gene encodes the p110 catalytic subunit of the 
phosphatidylinositol-3-kinase (PI3K) and is a well characterized YB-1 direct 
transcriptional target (Astanehe, 2009). I speculated that Np63 should increase 
PIK3CA promoter activity because of its ability to cause YB-1 nuclear accumulation. 
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Previous  luciferase assays, shown in Fig. 7A, revealed that Np63 transfection in 
MDA-MB-231 cells caused a relevant increase of the PIK3CA promoter activity, 
consistently attenuated by YB-1 knock-down. Since my group had already observed 
that Np63was able to transactivatethe PIK3CA promoter in a dose dependent 
manner, while Np63 was completely uneffective (Fig. 7B), we deeply investigated 
the role of Np63 and YB-1 in PIK3CA promoter activation by Chromatin 
Immunoprecipitation (ChIP).  
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FIGURE 7. Np63 and YB-1 activates the PIK3CA gene promoter. (A) MB-MDA- cells were transfected 
with 1g of PIK3CA-promoter luciferase reporter plasmid. The luciferase activity upon siRNA-mediated 
knockdown of endogenous YB-1 was measured in presence or absence of Np63 expression. Values are shown 
as mean + SD of three biological replicates. The extent of YB-1 knock-down was documented by western 
blotting as shown in the lower panel. (B) MB-MDA-231 cells were seeded at 60% confluency (1.2 x 10
6
) in 
100mM dishes and transiently transfected with 1g of PIK3CA-promoter luciferase reporter plasmid and the 
indicated amounts of  Np63 or Np63 plasmid. Values are the mean + SD of three independent experimental 
points. Lower panel: immunoblotting with indicated antibodies to detect proteins in samples transfected with 
different amounts of Np63 or Np63 
 
 
We first performed ChIP assays in MDA-MB-231 cells transfected with Np63 or 
Np63 using anti-p63 antibodies and PIK3CA promoter specific primers.  As shown 
in Fig. 8A, Np63 but not  Np63binds to the genomic sequence of the PIK3CA 
promoter.  
Then, we evaluated the effect of Np63expression on the binding of YB-1 to the 
PIK3CA promoter. Flag-YB-1 was transfected, in MB-MDA-231 cells, with or without 
Np63 plasmid. Chromatin immunoprecipitations (ChIP) was carried out with anti-
Flag antibodies and coupled with quantitative real-time PCR. As show in Fig. 8B, 
Flag-YB1 efficiently binds to the PIK3CA promoter and its binding was substantially 
increased byNp63.  
Lastly, by using a sequential chromatin immunoprecipitation assay (Re-ChIP) in 
SCC011 cells, expressing endogenous  Np63 and YB-1, I found that both proteins 
are recruited to the PIK3CA proximal promoter suggesting that they cooperate in 
PIK3CA gene transactivation as a complex (Fig. 8C). 
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FIGURE 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8. Np63 increases YB-1 binding to the PIK3CA gene promoter. (A) MDA-MB-231 cells were 
seeded at 60% confluency (1.2 x 10
6
) in 100mM dishes and transiently transfected with Np63 or Np63 
plasmid (5 g). After formaldehyde cross-linking, the DNA/proteins complexes were immunoprecipitated with 
anti-p63 (4A4) antibody. Immunoprecipitated DNA was PCR amplified with PIK3CA promoter oligos and 18S 
rRNA oligos (right). The data obtained from the ChIP assay were measured by densitometry and are presented as 
signal relative to the input (left). (B) MDA-MB-231 cells were seeded at 60% confluency (1.2 x 10
6
) in 100mM 
dishes and transiently transfected with 3XFlag empty vector or 3XFlag-YB-1 (5 g) plasmid with or without 
Np63 (2.5 g) expression vector. The cells were cross-linked with formaldehyde and DNA/protein complexes 
were immunoprecipitated with anti-Flag antibody or irrelevant IgG antibody as negative control. The DNA 
immunoprecipates were analysed by qPCR using PIK3CA or GAPDH promoter oligos. qRT-PCR results were 
analized with the ΔΔCT method and expressed as fold of enrichment respect to the IgGAb control samples. 
Values are represented as the mean of three independent experiments. (C) SCC011 cells at 85% confluency were 
fixed with formaldehyde, the DNA/proteins complexes were subjected to sequential-ChIP with anti-p63 (4A4), 
anti-YB1(Ab12148) or irrelevant IgG antibody as described in experimental procedure. Immunoprecipitated 
DNA was PCR amplified with PIK3CA promoter primers and 18S rRNA primers to check the quality of the 
input chromatin and the cleaning of the other samples.  
 
 
 
2.5Np63 affects cell shape and motility  
 
So far, little attention has been focused on the effects of Np63 on epithelial cancer 
cell morphology and motility. I have unexpectedly noted a profound change in cell 
morphology when SCC011 cells were depleted of Np63 by siRNA. SCC011 cells 
are round in shape and under high-density culture conditions appear orderly 
arranged with tight cell-cell contacts. Conversely, Np63-depleted cells tend to lose 
their contacts and exhibited an unusual extended phenotype that was distinct from 
that of the control cells cultured at the same density (Fig. 9A). The unusual change in 
morphology of Np63-depleted cells indicated possible alterations in actin 
cytoskeleton organization. Therefore, I examined the status of actin stress fibers at 
the level of individual cells, in control and Np63-depleted cells, with TRITC-
phalloidin followed by fluorescence microscopy. As shown in Fig. 9B, the control cells 
exhibited a diffuse pattern of actin staining, while Np63-depleted cells displayed a 
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more substantial enhancement of actin stress fibers suggesting an inhibitory effect of 
Np63 on cancer cell motility.  
Remarkably, compared to the control cells, Np63-depleted SCC011 cells express 
higher level of N-cadherin and lower amount of E-cadherin suggesting that they were 
undergoing epithelial to mesenchimal trans-differentiation (EMT) (Fig. 9C). 
I determined the influence of Np63 on cell motility by time-lapse microscopy using 
siRNA-based silencing of endogenous Np63 in SCC011 cells.  Silencing efficiency 
was about 90% as determined by fluorescent staining for p63 protein (data not 
shown). SCC011 migration was characterized by oscillations of the cells around their 
initial adhesion site. These oscillations occurred at random directions in space, as 
reported in the windrose plots of the trajectories (Fig. 9D, inset). Conversely, Np63 
silenced cells display much wider oscillations (Fig. 9D). These observations were 
confirmed by the analysis of the migration parameters “Speed (S)” and “Persistence 
time (P)”, that are computed from cell tracks and are a measure of the frequency of 
cell steps and of the minimum time that is necessary for a cell to significantly change 
direction. According to those parameters, SCC011 exhibit lower speed (p<0.05) and 
shorter persistence time (0.26 ± 0.03 m/min and 6.5 ± 0.7 min), respect to 
Np63depleted cells (0.44 ± 0.05 m/min and 8.2 ± 2.3 min). These data indicate a 
role of Np63in affecting cell motility. In particular, the absence of Np63causes 
the cells to migrate faster with less frequent direction changes, which enables the 
cells to explore larger areas, in a fixed time interval. 
 
FIGURE 9 
 
FIGURE 9. Np63 
affects cell shape 
and motility. (A) 
SCC011 cells were 
transiently silenced 
with IBONI p63-
siRNA pool (20nm 
final concentration). 
Cell were fixed and 
subjected to double 
immunofluorescence 
48 hrs after silencing. 
(B) Protein extracts 
from control and p63 
depleted cells were 
separated by SDS 
PAGE and subjected 
to immunoblot. 
Proteins were 
detected with specific 
antibodies. (C) Actin 
staining with TRITC 
conjugated phalloidin 
of control and Np63-depleted SCC011 cells (see Materials and Methods). Cell expressing Np63 displayed 
a round morphology. Conversely, Np63-depleted cells had a polarized  morphology with more evident 
lamellipodia and trailing edge. (D) Windrose plot of trajectories described by Np63 depleted SCC011 or 
SCC011 control cells (inset) in 12 hour time lapse video. Only fifteen cell trajectories were reported in each plot 
for graphical clarity. 
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Since previous observations had shown that the absence of ΔNp63α affects cell 
motility in YB-1 dependent manner (data not shown), I have investigated on the 
potenital effect of YB-1 silencing on SCC022 motility, by time-lapse microscopy.  
siRNA-based silencing of endogenous proteins, according to our observations in 
SCC011 cells, showed that ΔNp63α silenced cells display higher speeds (p < 0.01) 
than control cells. Conversely, SCC022 cell motility was unaffected by YB-1 depletion 
(Fig. 10A and 10B). 
 
FIGURE 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10. Effect of p63 and YB-1 silencing on SCC022 cells migration speed. (A) Motility assay on 
SCC022 cells after transient silencing of p63 and YB-1 performed by time-lapse microscopy. After 24 h of 
incubation with siRNA oligos, cell migration assay was performed. Averaged cell speeds after 16 h of 
observation are reported. Horizontal lines and boxes and whiskers represent the medians, 25th/75th, and 5th/95th 
percentile, respectively. P-value < 0.01 is represented by **. Only statistically different doubles are marked. (B) 
Immunoblot analysis of Np63a and YB-1 proteins levels in SCC022 cells after 40 h of Np63 or YB-1 
silencing and used in cell migration assay. Cell extracts were blotted and probed with anti-p63 or anti-YB-1 
antibodies. GAPDH was used as a loading control. Np63 protein band was almost undetectable while YB-1 
protein was reduced to 40%, as assed by densitometric scanning. 
 
 
 
 
 
2.6 YB-1 knockdown in HaCaT cells 
 
Since I have shown that Np63 inhibits epithelial-to-mesenchimal transition and 
motility of squamous carcinoma cells, I decided to expand our knowledge on YB-1 
and Np63 functional cross-talk evaluating the role of YB-1 on survival of 
keratinocytes and squamous carcinoma cells. 
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FIGURE 11 
 
 
 
FIGURE 11. YB-1 knockdown affects HaCaT cell survival. (A) upper panel, Phase-Contrast imaging and  
Hoechst staining (lower panel) showing HaCaT keratinocyte cells transfected with scrambled, YB-1 or p63 
siRNA oligos. (B) Immunoblot analysis of HaCaT keratinocytes transfected with scrambled and YB1 (upper 
panel) or p63 (lower panel) siRNA oligos, respectively.  48 hours after silencing whole cell extracts were 
immunoblotted with YB-1, p63 and PARP antibodies. Actin was used as a loading control. A representative 
immunoblot (left panel) and densitometric analysis (right panel) are shown from four independent experiments 
(n=4). The blots were normalized to actin and the fold-change protein level expression is reported in comparison 
to control (value set at 1.0). (C) Quantitative real-time PCR analysis of HaCaT keratinocytes transfected with 
scrambled or YB-1 siRNA oligos. GADD45A mRNA level was measured as a control. (D) Quantitative Real-
time PCR analysis of HaCaT keratinocytes transfected with scrambled or p63 siRNA oligos. In both experiments 
data were analyzed according to the fold-changes compared to scrambled control (value set at 1.0) using the 2-
ΔΔCt
 method. P-value <0.05 is represented by *; P-value <0.01 is represented by **. 
 
 
 
First, I examined the effect of YB-1 silencing in mitotically active HaCaT 
keratinocytes. Interestingly, at 48 hrs of silencing I observed massive cell detachment 
(Figure 11A, upper panel) associated with a high proportion of condensed and 
fragmented nuclei (Figure 11A, lower panel). Western blot analysis showed a 
significant reduction of Np63 protein level and PARP1 proteolytic cleavage (Figure 
11B, left panel) indicating that YB-1 is critical for keratinocyte survival.  
Np63 is known to sustain survival in squamous cell carcinoma (Rocco, 2006; Hibi, 
2000) and up-regulate cell adhesion-associated genes (Carrol, 2006). To rule out the 
possibility that YB-1 silencing induces cell death by merely reducing the level of 
Np63, I knocked down Np63 expression in HaCaT cells by RNA interference. 
According to previous  studies (Barbieri, 2006), I observed neither cell detachment 
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(Figure 1A, upper panel) nor PARP1 activation (Figure 11B, right panel) clearly 
indicating that apoptosis, induced by YB-1 depletion, cannot be simply ascribed to 
the lack of Np63.  
Next, I evaluated the level of Np63 transcript following YB-1 knockdown by Real 
Time quantitative PCR (RT-qPCR) and I found that it was drastically reduced (Figure 
11C). After p63 silencing, instead, YB-1 transcript level was slightly enhanced (Figure 
11D) while the mRNA of GADD45A, a gene induced by stressful conditions and used 
as control, was enhanced in both experiments (Figure 11 C and D).  
 
2.7 YB-1 knockdown in squamous carcinoma cells 
Next, I used RNA interference to explore the function of YB-1 in squamous cell 
carcinoma (SCC). SCC022 are highly metastatic and, when subcutaneously injected 
in nude mice, form large tumors, while SCC011 cells, instead, generate only keratin 
pearls (C. Missero, personal communication).  
 
FIGURE 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 12. YB-1 knockdown in SCC011 and SCC022 squamous carcinoma cells. (A) Phase-contrast 
imaging showing SCC011 (upper panel) and SCC022 (lower panel) cells at 48 hours post-YB1 silencing. (B) 
Immunoblot analysis of SCC011 or SCC022 cells transfected with scrambled or YB-1 siRNA oligos. 48 hours 
after silencing whole cell lysates were immunoblotted with YB-1, p63 and PARP antibodies. GAPDH was used 
as a loading control. A representative immunoblot (left panel) and densitometric analysis (right panel) are 
shown from four independent experiments (n=4). The blots were normalized to GAPDH and the fold-change 
protein level expression is reported in comparison to control (value set at 1.0). (C) Quantitative Real-time PCR 
analysis of SCC011 (left panel) and SCC022 cells (right panel) transfected with scrambled or YB-1 siRNA 
oligos. Data were analyzed according to the fold-changes compared to scrambled control (value set at 1.0) using 
the 2
-ΔΔCt
 method. P-value <0.05 is represented by *; P-value <0.01 is represented by **. (D) Effect of YB1 
silencing on the viability of HaCaT and SCC cells. Cell viability was assessed by MTT assay following 48 hours 
of YB-1 silencing. Data are represented as the mean +/- SD from three independent experiments. The asterisk 
indicates P-value<0.05. 
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Similarly to what observed in HaCaT cells, YB1-depleted SCC011 cells detached 
from the plate generating abundant cellular debris (Figure 12A, upper panel) and 
exhibited a reduced level of Np63 protein (Figure 12B). PARP1 cleavage was 
barely detectable (Figure 12B).  
According to our previous observations described above (see paraghraph 2.5, Figure 
10), SCC022 cells looked healthy and tightly adherent to the plate after YB1 silencing 
(Figure 12A, lower panel). Surprisingly, as detected by immunoblot analysis, the 
expression level of Np63 protein was significantly increased (Figure 12B).  
Interestingly, Np63 transcript in SCC011 was reduced while in SCC022 it was 2.1-
fold higher than control (Figure 12C).  
 
Analysis of cell viability by the MTT assay showed that after 48 hrs of YB-1 
knockdown the percentage of viability of SCC022 cells was 70% of the control, while 
it was reduced to 10% in HaCaT and SCC011 cells (Figure 12D).  
 
2.8 YB-1 silencing hyper-activates the PI3K/AKT signaling pathway in 
SCC022 cells 
 
ΔNp63α is a target of the phosphoinositide-3-kinase (PI3K) pathway downstream of 
the Epidermal Growth Factor Receptor (Barbieri, 2003). I hypothesized an 
involvement of the PI3K/AKT pathway in the upregulation of Np63 observed in 
SCC022 cells following YB-1 silencing, and I looked for changes in the 
phosphorylation status of AKTSer473. Interestingly, unlike HaCaT and SCC011, 
SCC022 cells exhibited constitutive phosphorylation of AKTSer473 which was 
reproducibly potentiated following YB-1 depletion (Figure 13A and B), suggesting that 
YB-1 expression restrains AKT activation. To corroborate this result, I treated YB1-
silenced SCC022 cells with Ly294002, a highly selective PI3K inhibitor. Remarkably, 
Ly294002 treatment counteracted AKT hyperphosphorylation and the increase of 
Np63 protein level in response to YB-1 silencing (Figure 13B).  Moreover, it 
resulted in cell death and detachment (data not shown). Importantly, Ly294002 
treatment alone had no apparent effect on Np63 level and SCC022 cell viability 
(Figure 13B and data not shown). Quantification ofNp63 transcript in YB-1 
depleted SCC022 cells, treated or not with LY294002, showed that the increase of 
Np63 transcription was strictly dependent on the PI3K/AKT pathway (Figure 13B). 
Moreover, inhibition of the proteasome activity with MG132 did not significantly 
enhance Np63 protein level in YB1-silenced SCC022 cells, thereby confirming that 
Np63 up-regulation was almost exclusively at transcriptional level (data not 
shown).  
The PI3K/AKT signaling pathway is negatively regulated by the phosphatase and 
tensin homologue PTEN (Song, 2012). To further investigate on the ability of 
SCC022 cells to escape from death following YB-1 depletion, I compared the protein 
level of PTEN among HaCaT, SCC011 and SCC022 cell lines. Compared to HaCaT 
and SCC011 cells, the level of PTEN protein in SCC022 cells was very low, 
accounting for their high basal level of AKTSer473 phosphorylation (Figure 13D). 
Furthermore, YB-1 silencing resulted in increased levels of cytoplasmic PTEN in 
HaCaT and SCC011 cells, while no effects on PTEN protein level was observed in 
YB-1 silenced SCC022 cells (Figure 13E).  
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FIGURE 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13. YB-1 knockdown enhances pAKT
S473  
in SCC022 squamous carcinoma. (A) Immunoblot 
analysis of HaCaT, SCC011 and SCC022 cells transfected with scrambled or YB1-siRNA oligos.  48 hours 
after silencing whole cell extracts were immunoblotted with YB-1, pAKT
S473 
and AKT antibodies. Actin was 
used as a loading control. (B) SCC022 cells were transfected with scrambled or YB-1 siRNA oligos 
transfection. After 42 hrs cells were treated with LY294002 for 6 hrs. Whole cell extracts were analyzed by 
immunoblotting with YB-1, pAKT
S473
, p63 and AKT antibodies. Actin was used as loading control. (C) 
Quantitative Real-time PCR of Np63 mRNA levels. Np63 mRNA levels were analyzed according to the 
fold-changes compared to scrambled control (value set at 1.0) using the 2
-ΔΔCt
 method. P-value < 0.05 is 
represented by *; P-value < 0.01 is represented by **. DMSO was used as control (D) Immunoblot analysis 
of HaCaT, SCC011 and SCC022 cells. Whole cell extracts were immunoblotted with, PTEN,  pAKT
S47 
, and 
AKT antibodies. GAPDH was used as loading control. (E) Nuclear and cytoplasmic fractionation of extracts 
from control or YB-1 silenced HaCaT, SCC011 and SCC022 cells are shown in Figure 5A. Fractions were 
analysed by immunoblotting with PTEN antibody. GAPDH and PARP were used as cytoplasmic and nuclear 
controls, respectively. 
 
2.9 Cross-talk of Np63 and YB-1 with EGFR/STAT3 and  PI3K/AKT 
signaling pathways  
 
In pancreatic cancer cells, Np63 expression was shown to induce the Epidermal 
Growth Factor Receptor (EGFR) (Danilov, 2011). As I observed a PI3K-dependent 
increase of Np63 in SCC022 cells upon YB-1 silencing, I decided to evaluate the 
level of EGFR and its direct downstream target STAT3 in SCC022 cells upon YB-1 or 
Np63 silencing. As shown in Figure 14, along with Np63YB-1 depletion up-
regulates EGFR and STAT3 both at protein (Figure 14A) and RNA level (Figure 
14B). Real Time PCR assay in SCC022 cells clearly shows that YB-1 silencing 
results in about 2 and 3.5 fold induction of EGFR and STAT3 transcripts, respectively 
(Figure 14B). Following Np63 silencing, instead, the expression of both EGFR and 
STAT3 was switched off although the level of YB-1 protein remained unaltered 
(Figure 14A). These results suggest that Np63 is a major activator of the 
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EGFR/STAT3 axis in squamous carcinoma cells. Accordingly, in SCC011 and 
HaCaT cells where YB-1 silencing reduces Np63 EGFR and STAT3 transcription 
was also reduced (Fig. 14C and D).  
 
 
FIGURE 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14. Cross-talk of ΔNp63α and YB-1 with EGFR/STAT3 pathway. (A) Immunoblot analysis of 
SCC022 cells transfected with scramble, YB-1 or p63 siRNA oligos. Whole cell extracts were immunoblotted 
with, YB-1, p63, EGFR, STAT3 antibodies. Actin was used as a loading control. (B)  Quantitative Real-time 
PCR analysis of SCC022 cells transfected with scrambled or YB-1 siRNA oligos. YB-1, EGFR and STAT3 
mRNA levels  were analyzed according to the fold-changes compared to scrambled control (value set at 1.0) 
using the 2
-ΔΔCt
 method. P-value < 0.05 is represented by *; P-value < 0.01 is represented by **. Quantitative 
Real-time  PCR analysis of (C) SCC011 cells and (D) HaCaT cells transfected with scrambled or YB-1 siRNA 
oligos. YB-1, EGFR and STAT3 mRNA levels were analyzed according to the fold-changes compared to 
scrambled control (value set at 1.0) using the 2
-ΔΔCt
 method. P-value < 0.05 is represented by *; P-value < 0.01 is 
represented by **. 
 
  
 
 
To confirm the ability of Np63 to regulate EGFR gene expression I performed 
transient transfection and luciferase reporter assays in MDA-MB231 breast cancer 
cells expressing no detectable p63.  MDA-MB231 cells were transiently transfected 
with the EGFR promoter-luciferase vector and increasing amount of expression 
plasmid encoding wild type Np63 or its mutant form bearing  the F to L substitution 
at position 518 of the SAM domain. This mutant was previously described to be 
transactivation defective (Radoja, 2007).  
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FIGURE 15  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 15. ΔNp63α regulates EGFR expression. (A) Luciferase assay of EGFR-promoter activity in MDA-
MB231 cells. Cells were  transiently transfected with 1μg of luciferase reporter plasmid and the indicated 
amounts of ΔNp63α or ΔNp63 F518L plasmids. Luciferase assay was performed at 48 hrs post-transfection. 
Values are the mean +/- SD of three independent experimental points. (B) Representative immunoblotting 
showing the level of Np63 in transfected MDA-MB231 cell extracts used for the luciferase assay shown in 
7C. GAPDH immunodetection was used as loading control. (C) MDA-MB231 cells were transfected with empty 
vector or Np63 plasmids. At 24h post-transfection cells were harvested and whole cell extracts were analyzed 
by immunoblotting with p63, STAT3 and EGFR antibodies. Actin was used as a loading control. 
 
 
Remarkably, wild type but not mutant Np63 protein induced luciferase activity, in a 
dose-dependent manner (Figure 15A and B). Moreover, Western blot analysis of 
extracts from MDA-MB231 breast cancer cells transiently transfected with Np63 
showed induction of both EGFR and STAT3 endogenous proteins, confirming that 
EGFR and STAT3 expression are induced by Np63 (Figure 15C).  
 
 
 
  
2.10 YB-1 controls CD44 expression in keratinocytes 
 
It was previously reported that YB-1 induces the expression of CD44 in breast cancer 
cells (To, 2010). Since CD44 is a cell surface adhesion molecule involved in the 
control of keratinocyte proliferation (Tuhkanen, 1999) I decided to evaluate its 
potential involvement in YB1 dependent HaCaT cell death. I first evaluated the effect 
of YB-1 depletion on CD44 expression. As expected, YB-1 knockdown in HaCaT 
cells reduced CD44 protein level (Figure 16A). Moreover, full length CD44 transcript 
and its epithelial isoforms CD44v4 and CD44v5 were all reduced upon YB-1 silencing 
(Figure 16B). Conversely, Np63 silencing resulted in a slight increase of CD44 
protein (Figure 16C) and transcript levels (Figure 16D).  
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FIGURE 16 
 
FIGURE 16. YB-1 knockdown in HaCaT cells 
induces CD44 downregulation. (A)(C) Immunoblot 
analysis of HaCaT keratinocytes transfected with 
scrambled and YB1 (upper panel) or p63 (lower 
panel) siRNA oligos, respectively.  48 hours after 
silencing whole cell extracts were immunoblotted 
with YB-1, p63 and CD44 antibodies. Actin and 
GAPDH were used as a loading control. (B) 
Quantitative real-time PCR analysis of HaCaT 
keratinocytes transfected with scrambled or YB-1 
siRNA oligos. (D) Quantitative Real-time PCR 
analysis of HaCaT keratinocytes transfected with 
scrambled or p63 siRNA oligos. In both experiments 
data were analyzed according to the fold-changes 
compared to scrambled control (value set at 1.0) using 
the 2
-ΔΔCt
 method. P-value <0.05 is represented by *; 
P-value <0.01 is represented by **. 
 
 
 
Similarly, in SCC011 cells, that are prone to detach, CD44 transcripts were reduced 
following YB-1 depletion (Figure 17A), while in SCC022, CD44 transcripts were 
significantly enhanced (Figure 17B). As shown for Np63 expression (Figure 13B), 
LY294002 treatment of YB-1 silenced SCC022 showed that the increase of CD44 
transcription was dependent on the PI3K/AKT pathway hyper-activation (Figure  
17C).  
 
FIGURE 17 
(A)  (B) Quantitative real-time PCR analysis 
of SCC011 and SCC022 transfected with 
scrambled or YB-1 siRNA oligos, 
respectively.CD44 mRNA levels were 
analyzed according to the fold-changes 
compared to scrambled control (value set at 
1.0) using the 2
-ΔΔCt
 method. P-value < 0.05 
is represented by *; P-value < 0.01 is 
represented by **. DMSO was used as 
control (C) Quantitative Real-time PCR 
analysis of SCC022. transfected with 
scrambled or yb-1 siRNA oligos. After 42 
hrs cells were treated with LY294002 for 6 
hrs. In both experiments data were analyzed 
according to the fold-changes compared to 
scrambled control (value set at 1.0) using 
the 2
-ΔΔCt
 method. P-value <0.05 is 
represented by *; P-value <0.01 is 
represented by **. 
 
 
Finally, we simultaneously depleted Np63 and CD44 in HaCaT cells to check 
whether it was enough to mimic the effect of YB-1 silencing. However, although the 
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silencing at 48 hrs was highly efficient (Figure 18A), I observed neither cell 
detachment (Figure 18B) nor PARP1 proteolytic activation (Figure 18A). Moreover, 
as shown by the induction of cytokeratin-1 (CK1) (Figure 18A) and the change of cell 
morphology (Figure 18B), CD44 and Np63 concomitant knockdown appears to 
induce keratinocyte differentiation rather than apoptosis 
 
FIGURE 18 
 
Figure 18. p63/CD44 knockdown in HaCaT cells. (A) Immunoblotting and (B) Phase-Contrast imaging of 
HaCaT keratinocytes cells transfected with scrambled, p63 and/or CD44 siRNA oligos. Whole cell extracts were 
immunoblotted with CK-1, p63, PARP and CD44 antibodies. GAPDH was used as loading control.  
 
 
2.11 YB-1 and p63: crosstalk pathway in Melanoma 
I have spent six months (from May 13st to December 18st 2013) of my PhD’s 2nd 
year working at Blizard Institute - Queen Mary University of London to collaborate 
with Bergamaschi’s team.  
Recently, Bergamaschi’s group showed for the first time there is the stabilization of 
endogenous TA and N p63 isoforms in both nuclear and mitochondrial 
compartments of melanoma cells, in response to genotoxic stress. Moreover, 
depletion of p63 by RNA interference (RNAi) revealed that the expression of TA 
and/or N p63 isoforms confers resistance to chemotherapy in melanoma cell lines 
and provides evidence for an oncogenic role of p63 in this tumor (Matin, 2013). 
Malignant melanoma, a highly malignant tumor of the pigment-producing cells in the 
skin, is among the human cancers whose incidence has increased most rapidly in the 
last few decades. Cell for cell, probably no human cancer is as aggressive as 
melanoma. It is among a handful of cancers whose dimensions are reported in 
millimeters (Chin, 2006).  Early-stage melanoma can be cured by surgical resection, 
but late-stage melanoma is difficult to treat with current therapies. To improve 
treatment for melanoma patients, large efforts have been put into the elucidation of 
cellular and molecular mechanisms underlying this disease. So far, the initiation and 
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progression of melanoma have been associated with a number of signaling 
pathways, including Ras/Raf/MEK/ERK signaling, WNT/-catenin signaling, and 
PTEN/AKT signaling, and recently microRNAs (miRNAs) have been implicated as 
key regulators in these pathways (Gray-Schopfer, 2007; Mueller, 2009; Mueller and 
Bosserhoff, 2010; Bell and Levy, 2011). It has been also reported that YB-1 
expression results upregulated in melanoma. YB-1 protein is translocated to the 
nucleus during melanoma progression and, in addition, that it is a critical factor in 
proliferation, survival, migration, invasion and chemosensitivity of this tumor (Shittek, 
2007).   
Our collaboration was aimed to explore the possibility of p63 and YB-1 cross-talk 
pathways, involved in melanoma development as in our SCC model system. 
 
Among available melanoma cell lines I have choosen to perform my experiments in 
two metastatic cell lines, WM1158 and A375M, which express TAp63 and Np63 
isoforms, respectively. In addition, I have used MEL-224 cells, derived from a typical 
VGP melanoma tumor devoid of p63 expression.   
I have detected in all melanoma cells, for the first time, a typical pattern of YB-1 
including bands between 10 KDa and full length 50KDa. 
MG132-treatment on melanoma cells, trasfected or not with 
TAp63andNp63reaveled that the small molecular weight YB-1 bands are 
partially derived from proteasome activity and their abundance and localization 
depends on p63 expression (Figure 19A).  
 
FIGURE 19 
 
 
FIGURE 19. YB-1 Expression in MEL-224  and WM1158 melanoma cells. (A) Immunoblot analysis of 
MEL-224 cells transfected with scrambled plasmid or Np63/TAp63 treated or not with MG132 for six 
hours, after 18hrs of transfection.  Cytoplasmic and nuclear fractions were immunoblotted with YB-1 antibodies. 
GAPDH and LaminaA were used as a loading and quality control. (B) WM1158 cells were transfected with 
scrambled or YB-1 siRNA oligos transfection. After 48 hrs of silencing whole cell extracts were immunoblotted  
with YB-1, PARP, Cyclin D1 and pAKT
ser473
 
 
 
Since YB-1 silencing affects keratinocyte adhesion, I have investigated the effects of 
YB-1 knock-down on melanoma cell lines. Interestingly, I have found that, in 
WM1158 cells, expressing TAp63 isoform, YB-1 depletion induces apoptosis and 
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cell detachment (Figure 19B). Moreover, I have observed that TAp63 isoform 
induces nuclear accumulation of YB-1, as shown in figure 20A and B. 
 
FIGURE 20 
 
 
FIGURE 20. p63-dependent YB-1 localization in MEL-224 cells. (A) Immunoblot analysis of MEL-224 cells 
transfected with scrambled plasmid or Np63/TAp63.  24 after transfection cytoplasmic and nuclear fractions 
were immunoblotted with YB-1 and p63 antibodies. GAPDH was used as a loading control. (B) 
Immunofluorescence assay on MEL-224 cells transfected with scrambled plasmid or 
Np63/TAp63tagged.  At 24 hours after transfection, cells were fixed and subjected to double 
immunofluorescence using rabbit primary YB-1 antibody and Fitch-conjugated secondary antibodies (green). 
p63-HA protein was detected using mouse anti-HA and Cy3-conjugated secondary antibodies (red). Images of 
merge (yellow) show the co-expression of two proteins. 
 
Our preliminary data indicate that Np63 controls YB-1 protein integrity and nuclear 
localization both in keratinocytes, SCC cell lines and melanoma model. Moreover, I 
have observed that the cross-talk between p63 and YB-1 is expected to be 
functionally significant in proliferating keratinocytes as well as in melanoma system. 
 
MEL-224 
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3.DISCUSSION 
 
A significant proportion of the human population suffers from some form of skin 
disorder, whether it be from burn, injury or inherited skin anomalies. The ideal 
treatment would be to regrow skin tissue from autologous stem cells. Elucidating the 
molecules involved in orchestrating the production of new skin cells are important 
steps in devising more efficient methods to produce bio-epidermal substitutes. 
Np63 and YB-1 are highly expressed in the proliferating basal layer of stratified 
epithelia of skin, breast and prostate.  
During my PhD a number of evidences have been collected clearly indicating that 
Np63 and YB-1 expression must be switched off to allow skin terminal 
differentiation (di Martino, 2015 submitted). In primary keratinocytes, transient 
overexpression of Np63 causes skin hyperplasia and abnormal differentiation 
thereby predisposing to malignant transformation (Moll, 2004).  
My work contributed to a deeper knowledge of Np63-YB-1 functional crosstalk in 
highly proliferative immortalized or transformed keratinocytes (SCC011/22).  
First, I have validated Np63/YB-1 interaction in distinct cell contexts and 
demonstrated that this interaction causes accumulation of YB-1 into the nuclear 
compartment, thereby influencing its localization-dependent  functions. In fact, YB-1 
into the nucleus is expected to induce pro-proliferative genes while in the cytoplasm 
regulates translation.  
A clear evidence of Np63/YB-1 cooperation in regulation of gene expression is 
shown by my experiments on the PI3KCA gene promoter. In fact, using Chromatin IP 
and reporter assays I have demonstrated that Np63 and YB-1 are both recruited to 
the PIK3CA proximal promoter and transactivate PIK3CA gene promoter, thereby 
supporting the hypothesis that this molecular association can act as a pro-survival 
mechanism. 
Moreover, although preliminary, in melanoma cells I have shown that a potential 
interaction between TAp63 and YB-1 might exist. In fact, this p63 isoform is able to 
accumulate YB-1 in the nucleus of MEL-224 cells, as shown by immunofluorescence 
and immunoblot assays.  
 
Into the cytoplasm, YB-1 functions as a positive regulator of EMT, by enhancing 
Snail1 translation, which reduces cell-cell adhesion (Evdokimova, 2009). Accordingly, 
I have shown that Np63 enforced expression reduces the activating binding of YB-
1 to the Snail1 transcript and, remarkably, depletion of endogenous Np63 in SCCs 
results in E-cadherin repression and increased cell motility.  
Moreover, YB-1 plays, also, an important role in cytoskeleton organization by binding 
to F-actin and microtubules (Uchiumi, 2006). I have shown, by phalloidin staining, 
that Np63 depletion in SCC cells promotes morphological changes and causes a 
profound cytoskeleton reorganization. Interestingly, Np63 depleted cells had a 
polarized morphology, with more evident lamellipodia and trailing edge and exhibited 
mature stress fibers, suggesting a pro-migratory behavior. I can speculate that the 
absence of Np63 can promote F-actin polymerization by YB-1, thereby inducing 
the formation of stress fibers.  
All together, these data indicate that Np63/YB1 association into the nucleus can 
act as a pro-proliferative/survival mechanism and that, probably, the balance 
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between Np63 and YB-1 protein levels could be critical for the transition to a 
mesenchimal-like phenotype explaining, at least in part, why Np63 depletion 
promotes cancer cell invasion and spread. Moreover, the oncongenic potential of YB-
1 itself is well-assessed, but because of its multifunctional character, its specific role 
remains elusive.  
Given all these considerations, the last part of my work was aimed to extend our 
knowledge on the YB-1 and Np63 functional interplay. 
First, I studied the effects of YB-1 silencing on cancer cell vitality. Remarkably, I 
found that YB-1 depletion caused HaCaT and SCC011 cell death. Moreover, YB-1 
knockdown strongly reduced Np63 transcripts and protein levels, showing the 
existence of a reciprocal regulation between p63 and YB-1 (Yang, 1999). 
Furthermore, following YB-1 depletion I also found downregulation of CD44, the 
principal receptor for hyaluronate, that is also known to maintain the proliferative 
state of basal keratinocytes (Tuhkanen, 1999; Westfall, 2003). However, my results 
showed that Np63 knockdown is not sufficient to trigger cell death, indicating that 
YB-1, in keratinocytes, plays additional p63-independent pro-survival functions.  
Unexpectedly, in highly metastatic SCC022 cells, YB-1 silencing induced Np63  
transcription and potentiated AKT activation rather than promote cell death. This 
phenomenon suggest that YB-1 can act as a negative AKT regulator.   
Np63 induction is a consequence of AKT hyperactivation as previously described 
by Barbieri (Barbieri, 2003). But how can I explain this negative modulation of 
PI3K/AKT pathway by YB-1 from a molecular and mechanistic point of view?  
It could be useful to remind that YB-1 interacts with AKT kinase which induces its 
phosphorylation (Bader, 2008). A possible explanation might be that YB-1/AKT 
interaction impairs AKT phosphorylation. Future studies on structural aspects of YB-1 
and pAKT interaction might clarify this point. Moreover, this would allow us to create 
mutants that specifically lack this interaction to assess if it is amenable to 
pharmacological intervention. 
Remarkably, I did not observe AKT activation in YB-1 depleted  HaCaT and SCC011 
cells. How can I describe the different outcomes of the cell lines in response to YB-1 
silencing?  
I have hypotesized the involvement of PTEN (phosphatase and tensin homolog), that 
functions as tumour suppressor by negatively regulating AKT signaling pathway. On 
the other hand, Np63 is known to repress the expression of PTEN (Leonard, 
2011).  
Accordingly, in PTEN-proficient HaCaT and SCC011 cells, where YB-1 silencing 
caused a decrease of Np63a, I observed an increase of PTEN protein level. 
Instead, in SCC022 cells PTEN was defective and non-responsive to YB-1 silencing.  
These findings indicate that YB-1 not only inhibits AKT, but also controls PTEN 
levels. Moreover, the revelance of these data is also supported by interesting results 
of cytoplasmic PTEN modulation following YB-1 depletion in MDA-MB231 and A431 
cells (data not shown). In fact, YB-1 silencing down-regulates PTEN in the cytoplasm 
of A431 squamous carcinoma cells, while causes its increase in MDA-MB231 breast 
cancer cells, suggesting that YB-1/PTEN regulation is a wide and general 
mechanism in the oncogenesis. 
 
In summary, our results indicate that, being able to sustain Np63 gene expression, 
YB-1 is part of a complex molecular network linking Np63 to the PI3K/AKT/PTEN 
pathway and that establishment of a positive feedback loop coupling induction of 
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Np63 expression with PI3K/AKT activation may be a relevant step in progression 
of squamous carcinogenesis.  
An important finding of my work is the observation that Np63 controls the 
expression of the Epidermal Growth Factor Receptor switching-on the entire 
EGFR/STAT3 axis. Accordingly, in normal adult epidermis, the EGFR is 
predominantly expressed in basal keratinocytes and signaling events elicited by it are 
known to affect their proliferation and migration (Bito, 2011). Np63 therefore, 
represents an important molecular connection between YB-1, the PI3K/AKT and the 
EGFR/STAT3 signaling pathways. I can postulate that constitutive activation of 
PI3K/AKT, such as in PTEN-deficient cells, may likely cause persistence of Np63 
which can induce keratinocyte hyper-proliferation by impinging on the EGFR/STAT3 
pathway. Interestingly, in physiological conditions EGF-dependent and PI3K/AKT 
pathways are both required for efficient skin wound re-epithelialization (Chen, 2014). 
Moreover, EGFR/STAT3 inhibition was shown to be unable to induce apoptosis (Bito, 
2003), thereby providing a plausible explanation of why Np63 silencing alone was 
not sufficient to induce cell death in our experimental settings.  
In summary, I have presented clear evidences suggesting that YB-1 can play a role 
in skin carcinogenesis. However, the emerging picture is that the molecular basis of 
squamous cancerogenesis is quite heterogenous. Therefore, a careful evaluation of 
the signaling pathways activated in each particular tumour is mandatory.    
Association of YB1-targeting with drugs that inhibits the PI3K and/or EGFR pathway 
could be valuable strategies to treat squamous carcinoma. In vivo experiments will 
help to clarify this relevant point. 
 
Finally, small YB-1 derived peptides were recently isolated from human body fluids 
(urine, plasma). Such peptides have been shown to be produced and secreted by 
mesangial and tumour cells (Frye, 2009 ); in addition, they have pro-proliferative and 
pro-inflammatory functions. 
During my work, I have observed in melanoma cells small YB-1 derived peptides 
whose abundance is regulated by p63.  I can hypothesize that YB-1 secretion 
pathway is a more general mechanism involving a wide number of tumour cells. 
Further experiments are needed to shed light on this molecular mechanism. 
The most relevant aspect of this finding is its potential application as prognostic and 
diagnostic marker of cancer progression and potential therapeutic target.  
52 
 
 
SECOND PART 
 
 
4.INTRODUCTION 
 
 
Thanks to the collaboration with Prof. Piera Quesada’s team I had the opportunity to 
perform experiments aimed to investigate the role of p53 family members in the 
response of cancer cells to Topoisomerase I and poly(ADP-ribose)polymerase 
(PARP1) inhibitors.  Prof. Piera Quesada, has a long-term experience on poly(ADP-
ribose)polymerase enzymes and the role of PARP1 in the DNA damage signaling 
network.  
 
 
4.1 Poly(ADP-ribose) polymerase (PARP) - 1 
 
PARP-1 is the founding and the most fully studied members of a large family of 18 
multifunctional enzymes, encoded by different genes and displaying a conserved 
catalytic domain, that catalyze the poly(ADP-ribosyl)ation (PARylation) of target 
proteins. 
PARylation is an immediate DNA-damage-dependent post-translational modification 
of  nuclear proteins, that contributes to the survival of injured cells (Burkle, 2013). 
  
PARP-1 has four important domains:  
1) a 46-kDa N-terminal DNA binding domain (DBD), containing 2 zinc finger motifs, 
and responsible for the interactions with DNA breaks;  
2) a 54-kDa catalytic domain (CD) at the carboxyl terminus that polymerizes linear or 
branched poly-ADP ribose units;  
3) a caspase-cleaved domain, containing a bipartite nuclear localization signal (NLS) 
and a caspase-3 cleavage site;  
4) a 22-kDa central auto-modification domain, containing a BRCT (BRCA1 carboxy-
terminal) motif, involved in protein-protein interactions, which promotes the 
recruitment of DNA repair enzymes to the site of DNA damage (de Lartigue, 2013).  
PARP-1 is immediately stimulated by DNA strand breaks and it sequentially transfers 
ADP-ribose units from -NAD+ to various nuclear proteins acceptors, or itself in an 
automodification reaction, thereby synthesizing PAR, a linear or multi-branched 
polymer of ADP ribose (Davar, 2012).  
 
 
 
4.2 Role of PARP in DNA Repair 
 
DNA can be damaged as a result of constant barrage of environmental insults, toxic 
products of metabolism and erroneous DNA replication. These alterations can be 
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divided into: 1) base modifications; 2) single strand breaks (SSB); 3) double strand 
breaks (DSB); and 4) intrastrand or interstrand cross-links. Several DNA repair 
mechanisms have evolved to repair these lesions and maintain genomic integrity. 
Given the large array of potential lesions and the importance of high-fidelity repair, 
DNA repair mechanisms are generally complex, highly redundant and conserved 
across phylogenetic classes (O’Brien, 2006). 
DNA repair mechanisms include: 1) base excision repair (BER); 2) nucleotide 
excision repair (NER); 3) mismatch repair (MMR); 4) direct repair mechanisms; 5) 
homologous recombination (HR) and non-homologous end-joining (NHEJ) (Jackson, 
2009).  
PARP-1 enzyme has a critical role in the BER pathway, the predominant mechanism 
of SSB repair, in fact it binds to single-strand breaks (SSBs) in DNA, modifies 
proteins in the proximity and, ultimately, leads to the recruitment of DNA repair 
proteins to the sites of the damage. Actually, PARP-1 acts as a “molecular sensor” to 
identify DNA SSBs; it is recruited and activated by SSBs as homodimer in a fast 
reaction, which is amplified from 10 to 500-fold with formation of PAR-polymers 
within 15 to 30 seconds. Upon binding to a damaged strand via its zinc finger DNA-
binding domain, PARP-1 undergoes a conformational change, inducing the catalytic 
monomer/subunit to transfer ADP-ribose moieties from NAD+ (Nicotinamide-
Adenine-Dinucleotide) substrate to the auto-modification domain of acceptor 
monomer/subunit (Davar, 2012). 
The lengthening PAR chain builds up a large negatively charged structure at the SSB 
which recruits other DNA repairing enzymes. These include DNA ligase III (LigIII), 
DNA polymerase beta (polβ), and scaffolding proteins such as x-ray cross 
complementing gene 1 (XRCC1), that collectively form the base excision repair 
(BER) multi-protein complex.  
Furthermore, PARylated PARP-1 can modulate DNA-topoisomerase 1 by not 
covalent but specific interaction of PAR with some TOP I sites, resulting in DNA 
cleavage inhibition and stimulation of the re-ligation reaction (see also later).  
As it dissociates from DNA, PARylated PARP-1 becomes a target of the poly(ADPR) 
glycohydrolase enzyme that catalyze the degradation of PAR polymers, thereby 
assuring the restoration of its native and active form (Burkle, 2013). 
 
In response to DNA damage cell cycle checkpoint activation and growth arrest rely 
on the ATM/ATR kinases and their downstream targets, like p53 (Nguyen, 2011). It 
has been shown that p53 can be a target of PARP-1, as well as other transcription 
factors (i.e. p21)  which binds PARP-1 during base excision repair. 
Moreover, PARP-1 is one of several known cellular substrates of caspases and its 
cleavage by caspases is considered to be a hallmark of apoptosis (Daniel, 2010).  
The cleavage of PARP-1 by caspases 3 and/or 7 results in the formation of 2 specific 
fragments: a 89-kDa catalytic fragment and a 24-kDa DBD (Hunter, 2011). The 89-
kDa fragment, containing the auto-modification domain and the catalytic domain of 
the enzyme, have a greatly reduced DNA binding capacity.  
The 24-kDa cleaved fragment with 2 zinc-finger motifs is retained in the nucleus, 
irreversibly bound to nicked DNA, where it acts as a trans-dominant inhibitor of active 
PARP-1. Importantly, irreversible binding of the 24-kDa PARP-1 fragment to DNA 
strand breaks inhibits DNA repair enzymes (including PARP-1) and attenuates DNA 
repair (also preserving the cellular ATP pools) (Ferraris, 2010). 
Apoptosis, the process of programmed cell death, is an essential part of the 
maintenance of cellular homeostasis and survival of multi-cellular organisms. 
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Physiological apoptosis controls cell numbers, tissue and organ morphology and 
patterning, and removes injured or mutated cells (Audeh, 2010). Dysregulated 
apoptosis results in elevated or decreased cell death often leading to 
neurodegenerative disorders, cancer and other hyper-proliferative disorders 
(Ledermann, 2011).  
 
 
 
 
4.3 PARP Inhibitors 
 
PARP-1 knockout mice are viable, but they appear to be highly sensitive to genomic 
instability caused by DNA-alkylating agents or γ-irradiation (Sugo, 2007). This is not 
surprising given the multiple redundant DNA repair mechanisms present in 
eukaryotic cells; unrepaired SSBs can possibly be converted into DSBs at replication 
forks, allowing subsequent repair by unaffected HR mechanisms. However, if cells 
have a deficient HR repair mechanism, PARP-1 inhibition can be expected to result 
in unsalvageable DNA damage and consequent lethality (Davar, 2012). Bryant et al. 
showed that BRCA2-deficient cells - in which the homologous recombination 
mechanism is defective - were exquisitely sensitive to PARP-1 inhibition (Bryant, 
2005). Subsequently, Farmer and colleagues demonstrated that PARP-1 inhibition in 
embryonic stem cells, lacking wild-type BRCA1 and BRCA2, resulted in early cell 
death (Farmer, 2005).  
Given these considerations, an anti-tumor strategy based on this approach would 
specifically target cells with the primary defect and spare healthy cells. Hence, it 
stands to reason that PARP inhibition will be similarly effective in cells in which HR is 
deficient or impaired – i.e. cells that share a “BRCA phenotype” or “BRCAness” 
(Davar, 2012). 
 
PARP inhibitors block the activity of the PARP enzymes by mimicking the 
nicotinamide moiety of nicotinamide adenine dinucleotide (NAD) and binding to the 
PARP catalytic site, which either directly blocks PARP enzymatic activity or causes 
PARP to accumulate on DNA (known as PARP trapping).  
 
PARP inhibitors are the poster child for the therapeutic paradigm of synthetic lethality 
in cancer drug development, the theory that two defects, which alone are benign in 
cancer cells, can be lethal when combined. If SSBs are left unrepaired, they have the 
potential to develop into lethal double-strand breaks (DSBs), which would lead to cell 
death. Suppressing PARP activity prevents SSB repair via the BER pathway, but 
other DNA repair pathways such as HR and NHEJ simply take over. However, if 
PARP inhibitors are used against tumors in which there is already a DNA repair 
defect, the combination drives synthetic lethality (Davar, 2012). 
There are two routes to synthetic lethality with PARP inhibitors. They can be used as 
monotherapy in patients with known mutations in DNA repair proteins, the most 
renowned being the breast cancer type 1 and 2 susceptibility proteins (BRCA1 and 
BRCA2), or they can be used as combination therapy with DNA-damaging 
chemotherapeutic agents or radiotherapy. 
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In particular, PARP inhibitors increase the cytotoxic effects of some 
chemotherapeutic agents as camptothecin (CPT), the prototype of TOP1 (DNA 
Topoisomerase 1) inhibitors, or its derivative Topotecan (TPT). 
Top1 enzymes are the only topoisomerases that form a covalent link with the 3′-end 
of the broken DNA, while generating a 5′-hydroxyl end at the other end of the break. 
Another unique feature of the Top1 enzymes is their DNA relaxation mechanism by 
“controlled rotation” rather than by “strand passage”. In other words, Top1 enzymes 
relax DNA by letting the 5′-hydroxyl end swivel around the intact strand. This mode of 
catalysis involves an intermediate known as the cleavage complex, which comprises 
the Topoisomerase enzyme attached to the cleaved DNA by a covalent 
phosphotyrosyl bond (Alagoz,  2012). 
Camptothecin (CPT), an alkaloid plant identified from the Camptotheca acuminate,  
and its water–soluble derivative TPT act as TOP 1 inhibitors. In fact, they are able to 
stabilize the cleavage complex in the abortive complex and abolish the DNA 
relegation activity of the enzyme, generating an accumulation of SSBs to which the 
protein is covalently linked. Double strand breaks arise when replication forks collide 
with the SSBs and run off. The cytotoxic mechanism of CPT/TPT is largely S-phase-
dependent and is usually repaired by the HR pathway (Davar, 2012). 
Quesada and collaborators have demonstrated that PARylated PARP-1 counteract 
CPT through non covalent but specific interaction of PAR with some TOP 1 sites, 
which results in inhibition of DNA cleavage and stimulation of the relegation reaction 
(Malanga, 2004). Moreover, they have shown that PJ34, a PARP inhibitor, can 
positively or negatively modulate p53 and its target p21WAF depending on the cell 
genetic background or DNA damage stimulus (i.e. cisplatin or TPT) (Cimmino, 2007; 
Gambi, 2008; D’Onofrio, 2011). 
Remarkably, regulating p21WAF expression is one model whereby PARP inhibitors, 
following the activation of different checkpoint pathways, can cause cell cycle arrest. 
In addition, it has recently been reported that in breast carcinoma MCF7 cells, PJ34 
causes a p21WAF-dependent mitotic arrest and neither PARP-1 nor p53 is required 
for this mechanism (Madison, 2011). Furthermore, in triple negative breast cancer 
cell lines, PJ34 synergizes with cisplatin by reducing the levels of Np63 with a 
concomitant increase of p21WAF (Hastak, 2010).   
 
In this scenario, chemotherapy protocols based on PARP inhibitors can be useful to 
restore apoptotic cell death and they can be used as adjuvant of TOP I inhibitors. 
 
The aim of my work was to investigate the effects of PJ34 used as a single agent or 
in association with CPT or TPT in the DNA damage response of mammary breast 
cancer cells (MCF7p53wt and MDA-MB231p53mut) and squamous carcinoma cells 
(SCC022 p53null). I was particular interested at the involvement of p63 in the sensitivity 
to these agents. The other relevant point was to look at the expression levels of pro-
arrest or proapoptotic proteins implicated in the p53/p63-dependent pathway (i.e. 
p21WAF, MDM2, BAX). 
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5.RESULTS 
 
 
 
Prof. Quesada and collaborators have demonstrated that p53 proficient MCF7 cells 
show high sensitivity to PJ34 in combination with 1M CPT or 5M TPT.  p53-null 
MDA-MB231 and SCC022 squamous carcinoma cells, instead, were more resistant. 
In MCF7 cells, TPT, known to be S-phase specific, caused a G2/M cell cycle arrest 
when used at lower concentration (1 M). In addition, the TPT-dependent G2/M cell 
cycle arrest was enhanced by TPT±PJ34 combined treatment and resulted in a 
remarkable increase of cells with sub-diploid DNA, confirming a synergic cytotoxic 
effect of TOP I and PARP-1 inhibitors. Given the similarity between p53 and p63 it 
was our interest to look at the expression of p63 protein isoforms and its down-
stream target genes upon combined treatment with TOP I and PARP-1 inhibitors. 
 
 
5.1 Involvement of p63 in the cell response to TPT ± PJ34 treatment 
 
I first analyzed the response of MCF7 cells to TPT ± PJ34 treatment by looking at the 
expression level of  p53 and p63 by western blot analysis. I also monitored the 
expression of some of p53/p63 target genes, such as p21WAF and cyclin B1, known 
to be involved in the regulation of the cell cycle. 
I found that compared to TPT alone, combined treatment up-regulated p53 
expression more efficiently. On the other hand, I observed down-regulation of MDM2, 
the most important p53 negative regulator (Figure 21A).  
 
FIGURE 21 
 
FIGURE 21 PJ±PJ34 
treatment in MCF7 cells.  
(A) Western blot analysis 
of p53, p63, p21WAF and 
cyclin B1 expression in 
MCF7 cells untreated or 48 
hrs treated with the 
indicated drugs. 
 GAPDH was used as 
loading control. (B) p53 
and TAp63band 
intensities were quantified 
by densitometric scanning. 
Data expressed as Arbitrary 
Densitometric Units (ADU) 
were normalized to the 
internal control GAPDH. 
(C) Immunodetection of 
p53 and -H2AX or AIF 
and Bcl2 respectively in the 
nuclear or postnuclear 
fraction of MCF7 cells 
treated with CPT and PJ34 
alone and in combination. 
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Interestingly, p63 immunoreactive bands, corresponding to the molecular weight of 
the pro-apoptotic TAp63 and isoforms was also up-regulated by S.E.combined 
treatments. 
Densitometric analysis revealed a 19 to 20 fold induction of both p53 and p63 protein 
expression after TPT ± PJ34 20M treatment (Figure 21B).  The CDK inhibitors 
p21WAF was also increased while cyclin B1 level was reduced. These data were in 
line with the G2/M block previously observed by cytofluorimetric analyses (data not 
shown). 
To verify the subcellular localization of induced p53 and TAp63 proteins, I have 
fractionated nuclear and cytoplasmic extracts of MCF7 cells to perform immunoblot 
analysis. As shown in figure 21 C, following TPT-PJ34 20M treatment p53 and 
TAp63 accumulated in the nucleus were they functions as transcription factors. 
Nuclear H2AX expression and PARP-1 specific cleavage were also monitored as 
markers of dsDNA damage and caspase-dependent apoptosis, respectively (upper 
panel).  
Furthermore, the expression level of the pro-apoptotic BAX protein, whose gene is 
transcriptionally activated by p53 and TAp63, increased in the cytoplasmic fraction by 
either TPT alone or TPT-PJ34 combined treatment. The level of the mitochondrial 
apoptosis inducing factor AIF was unaffected (Figure 21C  lower panel). 
 
 
5.2 Analysis of the effects of TPT+/-PJ34 treatments on SCC022 
squamous carcinoma cells. 
 
SCC022 carcinoma cells are devoid of p53, but express high level of the anti-
apoptotic Np63 isoform. Interestingly, Np63 was dramatically reduced by 
CPT/TPT treatment with or without PJ34. Immunoblot analysis also showed a 
concomitant reduction of Cyclin B1 suggesting that cells were undergoing a G2/M 
cell cycle arrest. Importantly, by western blot I was unable to detect p63 isoforms 
other than Np63both in untreated and TPT ± PJ34 treated SCC022 cells, although 
the 4A4 antibody used was able to detect all p63 isoforms (data not shown).  
However, Np63depletion following CPT/TPT ± PJ34 treatments was not sufficient 
to induce apoptosis suggesting that p53 or TAp63 expression are necessary to 
induce the apoptotic response (Figure 22 A). To prove this hypothesis we transfected 
p53 and TAp63 in SCC022 cells. After 24 hours the cells were incubated with the 
drugs for further 24 hours.  
Immunoblot analysis confirmed that SCC022 cells respond to TPT+PJ34 treatment 
by reducing Np63 protein level. However, caspase-dependent cleavage of PARP-
1 was observed only in p53 or TAp63 transfected cells (Figure 22B).  
By RT-PCR analysis I measured the level of Np63 mRNA in untreated (CTR) and 
TPT+PJ34 treated SCC022 cells and I found that it was comparable thus suggesting 
that Np63 down-regulation was exclusively at protein level (Figure 22C). 
In MDA-MB231 cells, no p63 immunoreactive bands were seen in all experimental 
conditions (data not shown), thereby excluding a possible role for p63 in TPT ± PJ34 
– induced cytotoxicity in this cellular context. 
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FIGURE 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 22.  Analyses of the effects of TPT+PJ34 treatment in SCC022p53null cells p53+/-TAp63γ 
transfected. (A) Western blot analysis of p63 and Cyclin B1 expression in MCF7 cells untreated or 48 hrs 
treated with the indicated drugs. GAPDH was used as loading control. (B) Western blot analysis of p63, PARP-1 
and p53 expression in SCC022 cells p53+/- transfected. (C) Analysis by RT-PCR of mRNA levels of ΔNp63α in 
untreated and 24 hrs treated cells with the indicated drugs. (D) Immunodetection with anti-PARP-1, anti-p53, 
anti-panp63, anti-BAX antibodies. GAPDH was used as loading control. (E) Immunoblot on SCC022 extract 
treated with TPT and MG132 using YB-1 and p63 antibodies. GAPDH was used as loading control. 
 
 
Figure 22C and D show the appearance of the PARP-1 89 KDa proteolytic fragment 
(Figure 22C and D), in p53 or TAp63 expressing cells. Moreover, endogenous 
Np63 protein was further reduced after TPT+PJ34 treatment (Figure 22D). 
Immunoblot analysis with a pan-p63 antibody was used to reveal both endogenous 
Np63and transfected TAp63 proteins (Figure 22D).  
These results indicates that reduction of Np63 induced by TPT+PJ34 in SCC022 
cells, per se is not sufficient to induce apoptosis, but it seems to cooperate with 
exogenous p53 or TAp63 in the restoration of apoptosis upon TPT+PJ34 treatment. 
To test a possible involvement of the ubiquitin/proteasome pathway in Np63 
degradation we repeated the experiment in presence of the proteasome inhibitor 
MG132. As shown in Figure 22E MG132 treatment did not rescue the level of 
Np63 protein. Based on this result we can speculate that Np63 degradation 
upon TPT+PJ34 treatment might dependent on caspase activity. Further experiments 
with caspase-specific inhibitors can clarify this point. 
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5.3 Analysis of the effects of TPT+/-PJ34 treatments on p53 post-
translational modifications. 
 
Activation of p53 transcriptional function by genotoxic stimuli imposes a variety of 
p53 posttranslational modifications; one of the best characterized is phosphorylation 
at Serine 15 by ATM (Dumaz, 1999). We analyzed the effect of TPT alone and in 
combination with PJ34 on p53 protein phosphorylation by using a phospho-specific 
antibody that recognizes 15serp-p53 (Figure 23A). In MCF7 cells, after 6 hours of 
treatment with TPT+/-PJ34, the steady state level of endogenous p53 protein 
increased along with its phosphorylated form at serine 15. Densitometric analyses 
indicated a 10 to 12 fold increase of p53 amount in TPT and TPT+PJ34 samples 
starting from 6 hours of treatment (Figure 23B). Remarkably, immunoblot analysis 
showed that stabilized and phosphorylated ser15p53 was located in the nucleus where 
it can play its transcriptional functions (Figure 23C and D). 
 
FIGURE 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 23. Analyses of TPT+/-PJ34 dependent p53 phosphorylation in MCF7 cells. (A) Western blot 
analysis of MCF7 cells and (B) isolated nuclei untreated or 6 and 24 hrs treated with the indicated drugs. 
Immunodetection of ser15-p-p53 and p53 band intensities were quantified by densitometric scanning (C) (D). 
Data are the mean ± S.E.M. of three independent experiments on three biological samples, expressed as 
Arbitrary Densitometric Units (ADU) and normalized to internal controls GAPDH and Actin. 
 
 
 
5.4 Analysis of the effects of TPT+/-PJ34 treatments on mRNA levels of 
p21WAF and BAX genes. 
 
Next, using qRT-PCR, we quantified the level of p21 and BAX transcript, upon 
treatment of MCF7 cells with TPT+/-PJ34 for 6 or 24 hours. p21 and BAX are 
activated by p53 upon DNA damage. These experiments were performed on cells 
that showed comparable levels of p53 and ser15p-p53 protein (Figure 23). Total RNA 
was purified from cells treated with the indicated drugs. RNA was subjected to qRT-
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PCR assays to quantify p21WAF and BAX mRNA levels. As shown in Figure 24A, 
we found a 4.5 fold increase in p21WAF mRNA level in cells subjected to TPT 
treatment that was strongly reduced by PJ34 addition. Concerning BAX we found 
only slight differences suggesting a PJ34-dependent increase of BAX mRNA after 24 
hours of treatment ( Figure 24B). 
 
FIGURE 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Analyses of TPT+/-PJ34 dependent expression of p21WAF and BAX genes. (A)(B) Real-time-
PCR analysis of mRNA levels of p21WAFand BAX genes in MCF7 cells 6-24 hours treated with the indicated 
drugs. Data normalized respect to 18S are reported as increment’s fold of controls and represent the mean ± 
S.E.M. of three independent experiments on three biological samples. Unpaired Student’s t-test was conducted to 
determine whether mRNA level was higher in cells induced with TPT compared with TPT+PJ34 at the same 
time points. **P <0.01. 
(C)(D) ChIP experiments were performed in MCF7 cells 6-24 hours treated with the indicated drugs with p53 or 
control immunoglobulin G (IgG) antibodies and quantified by PCR on p21WAF or BAX promoter. Data 
normalized respect to control samples are reported as increment’s fold and represent the mean ± S.E.M. of three 
independent experiments on three biological samples. Unpaired Student’s t-test was conducted to determine 
whether promoter occupancy was higher in cells treated with TPT compared with TPT+PJ34 at the same time 
points. *P <0.05 and **P <0.01. 
 
 
 
5.5 Analysis of the effects of TPT+/-PJ34 treatments on p53 binding to 
promoters of p21WAF and BAX genes. 
 
Finally, we used the Chromatin Immunoprecipitation (ChIP) to measure occupancy of 
p21WAF and BAX gene promoters by p53 protein, in cells treated with TPT or 
TPT+PJ34. Since it was previously shown that standard ChIP is flawed by PAR that 
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may cause changes in promoter-occupancy dependent on artificial formation of 
polymers (Beneke, 2015), we modified the standard protocol, as described in 
Materials and Methods, to prevent artificial polymer synthesis. Interestingly, 
according to the observed increase of p21WAF transcript (Figure 24A), p53 
occupancy of p21WAF promoter was strongly increased in TPT treated cells 
compared to control cells and significantly reduced by addition of PJ34 (Figure 24C). 
Occupancy of BAX promoter by p53, instead, was significantly increased by 
TPT+PJ34 combined treatment after 6 hours of treatment, while at 24 hours of 
treatment we could not detect significant changes (Figure 24D). 
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6.DISCUSSION 
 
 
We reported that TPT+PJ34 treatment in MCF7 cells causes a remarkably increase 
of TAp63  and  protein levels. In particular, TAp63 is a potent apoptosis inducer 
and like p53 accumulates in the nucleus, where it can functionally interact with p53 in 
the control of transcription. My work describe the response of p53 proficient MCF7 
cells to TOP I or TOP I and PARP-1 inhibitors. Such treatment increases p53 level 
and its phosphorylation status at serine 15. Transcriptionally activated p53 can 
induce p53-dependent transcription leading to increase of p21WAF and BAX 
transcript and protein levels.  
In fact, in p53 proficient cells such as MCF7, as a consequence of TPT-dependent 
DNA damage, the pro-arrest p21WAF protein is rapidly up-regulated. Indeed, both 
p53 binding to p21WAF promoter and p21WAF mRNA appeared to be enhanced 
after 6 hours of TPT treatment. Concomitant PARP-1 auto-modification was 
indicative of a DNA repair attempt. 
Under more severe DNA damage conditions, the p53 binding at the p21WAF 
promoter was reduced while occupancy of BAX promoter was enhanced. However, 
the increase of BAX transcript was delayed and the protein level was clearly 
detectable only after 24 hours. Under this condition, PARP-1 undergoes caspase 
dependent cleavage. 
These observations underline the role of PAR and PARP-1 in the differential 
recruitment of p53 on its target promoters upon DNA damage. Indeed, while TPT 
treatment induces p53 recruitment on p21/WAF gene promoter with its consequent 
up-regulation, TPT+PJ34 treatment acts as a switch in the cell fate decision by 
inducing the pro-apoptotic BAX gene expression. A selective binding and control of 
pro-arrest or pro-apoptotic gene promoters by p53 occurring under specific stimuli, 
may likely reflect the severity of DNA damage. 
 
Finally, my results point to a role for p63 in the cell response to treatment with TOP I 
and PARP-1 inhibitors. In, MCF7p53WT cells the endogenously expressed 
TAp63isoform, which closely mimics p53, is up-regulated upon TPT+PJ34 
treatment. Moreover, we found that transfected TAp63is sufficient to trigger 
caspase-dependent apoptosis in apoptosis-resistant SCC022 cells by inducing BAX 
expression and degradation of the endogenous anti-apoptoticNp63protein. 
The restoration of apoptosis is considered a chemotherapic strategy that can be 
based on PARP-1 and p53 joint tumor suppressor functions. Our results indicate that 
modulation of other components of the p53 family (i.e. TAp63and/or Np63) can 
be involved and significantly contribute to the cell response to DNA damage stimuli 
thus adding further complexity to this phenomenon (Costanzo, 2014). 
Our studies highlighting the different outcome (i.e cell cycle arrest vs apoptosis) of 
PARP-1 activation/inhibition and give right of the use of PARP inhibitor as 
chemotherapic adjuvant and/or in monotherapy also in TAp63/Np63 proficient 
cancer cells .  
Finally, even if preliminary, concomitant YB-1 and Np63down-regulation in TPT 
treated SCC022 cells suggest a new potential approach to sensitize these cancer 
cells to chemotherapy. Further experiments are needed to gain insight into this 
mechanism. 
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7.MATERIALS AND METHODS 
 
 
Plasmids - PIK3CA promoter luciferase plasmid was provided by Dr Arezoo 
Astanehe (Research Institute for Children’s and Women’s Health, Vancouver, British 
Columbia, Canada).  
The 1.1 Kb EGFR promoter luciferase plasmid was provided by Dr. A.C. Johnson 
(US National Cancer Institute, Massachusetts, USA). The cDNA encoding human 
Np63 and Np63F518L were previously described (Lo Iacono, 2006). 
 
Cell lines and transfection  – Squamous carcinoma cells (SCC011 and SCC022) 
were provided by Dr. C. Missero. These cell lines were maintained in RPMI 
supplemented with 10% fetal bovine serum at 37°C and 5% CO2. A431 and H1299 
cells were obtained from ATCC and maintained in DMEM supplemented with 10% 
fetal bovine serum at 37°C and 5% CO2.  
HaCaT, MCF7 and MDA-MB231 cells were purchased from Cell Line Service (CLS, 
Germany) and cultured at 37°C and 5% CO2.  
MEL-224 and WM1158 melanoma cells were provided by Dr. D. Bergamaschi. 
HaCaT, MCF7, MEL-224 and WM1158 cells were maintained in DMEM 
supplemented with 10% FBS. MDA-MB231 cells were maintained in DMEM 
supplemented with 5% FBS.   
 
Lipofections were performed with Lipofectammine 2000 (Life Technologies, CA, 
USA), according to the manufacturer’s recommendations. 
YB1 transient silencing was carried out with IBONI YB-1siRNA pool (RIBOXX GmbH, 
Germany) and RNAiMAX reagent (Life Technologies, CA, USA), according to the 
manufacturer’s recommendations. Briefly, cells were seeded at 60% confluence (1.5 
× 106) in 100-mm dishes and transiently silenced with IBONI YB1-siRNA at 20 nM 
final concentration.  
YB-1 guide sequences:  
UUUAUCUUCUUCAUUGCCGCCCCC; 
UUAUUCUUCUUAUGGCAGCCCCC;  
UUCAACAACAUCAAACUCCCCC;  
UCAUAUUUCUUCUUGUUGGCCCCC.  

Np63 transient silencing was carried out with  IBONI p63-siRNA pool (RIBOXX 
GmbH, Germany) at 20 nM final concentration and RNAiMAX reagent (Life 
Technologies, CA, USA).  
p63 guide sequences:  
UUAAACAAUACUCAAUGCCCCC;  
UUAACAUUCAAUAUCCCACCCCC;  
AUCAAUAACACGCUCACCCCC;  
AUGAUUCCUAUUUACCCUGCCCCC. 
 
 “All Star Negative Control siRNA”, provided by Quiagen (Hilden, Germany), was 
used as negative control.  
 
Antibodies and chemical reagents - p63 (4A4) , anti-actin (1-19),  anti-cytokeratin 1 
(4D12B3), anti-GAPDH (6C5), were from Santa Cruz (Biotechnology Inc.), PARP, 
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EGFR, STAT3 AKT, pAKT (Ser473) and rabbit polyclonal YB1 antibody (Ab12148) 
were from Cell Signaling Technology (Beverly, Massachussets). Mouse monoclonal 
E-CADHERIN (ab1416) and SNAIL1 antibodies were from Abcam (Cambridge, UK). 
Mouse monoclonal N-CADHERIN (610921) was from BD Transduction Laboratories. 
Cy3-conjugated anti-mouse IgG and Cy5-conjugated anti-rabbit IgG were from 
Jackson (ImmunoResearch Laboratory, Inc, Pennsylvania). Antiphospho-p53(ser15) 
(9284), anti-BAX (D2E11) and anti-CD44 rabbit polyclonal antibodies were from Cell 
Signaling (Invitrogen, Milano, Italy). Anti-MDM2 (Ab-2) mouse monoclonal antibody 
was from Oncogene Research Products (Boston, USA). 
 
Proteasome inhibitor MG132 were purchased from Sigma-Aldrich (St Louis, MO) and 
used at 10 M final concentration in DMSO (Sigma-Aldrich, St Louis, MO).  
LY294002 was purchased from Calbiochem (CA, USA) and used at 50  final 
concentration in DMSO. TPT was from Glaxo Smith-Kline (Verona, Italy) and PJ34 
[N-(6-oxo-5,6,-dihydrophenanthridin-2- 
yl)-(N,N-dimethylamino) Acetamide] from Alexis Biochemicals (Vinci-Biochem, 
Firenze, Italy). 
The cocktail of protease inhibitors was from ROCHE-Diagnostic (Milano, Italy). 
 
Chromatin immunoprecipitation (ChIP) assay - ChIP was performed with chromatin 
from human MDA-MB-231 cells transfected with Np63, Np63 and/or FlagYB1. 
Chromatin samples were subjected to pre-clearing with 80 μl of Salmon Sperm DNA-
satured agarose A beads, 2 hrs at 4°C with rotation. The immunoprecipitation step 
was obtained with YB-1 antibodies (ab12148).   
Real Time PCR was performed with the 7500 Applied Biosystems apparatus and 
Syber Green MasterMix (Applied Biosystems) using the following oligonucleotides: 
PIK3CA-Forw CCCCCGAACTAATCTCGTTT 
PIK3CA-Rev  TGAGGGTGTTGTGTCATCCT 
Sequential Chromatin Immunoprecipitation was performed with chromatin from 
SCC011. 
Chromatin samples were subjected to pre-clearing with 80 μl of Salmon Sperm DNA-
satured agarose A beads, 2 hrs at 4°C with rotation. The first immunoprecipitation 
step was obtained with p63 antibodies (4A4). After several washes 
immunocomplexes were extracted from beads with 100 μl of TE-SDS 2% . The 
second immunoprecipitation step was obtained with YB1 (Ab12148) antibodies after 
a 30 fold dilution in DB buffer. (Tris-HCl 50 mM, EDTA  5 mM, NaCl 200 mM, NP40 
0.5%, 15 mM DTT). Samples were incubated overnight at 4°C with rotation. 
Immunocomplexes were extracted from beads as above described. 
Immunoprecipitated protein-DNA complexes  were subjected to reverse cross-linking 
and Proteinase K treatment. DNA was purified by phenol/chloroform extraction and 
resuspended in 40 μl of TE. 2 μl were used for PCR reaction performed with the 
following primers: 
PIK3CA promoter-For  
ACAAACCCCTGGAATGTGAG 
PI3KCA promoter-Rev 
TGGAAAAGCGTAGGAGCAGT 
 
Coimmunoprecipitation - To detect p63/YB-1 interaction in SCC011 cells, 5.0 ×105 
cells were plated in 60 mm dishes. For coimmuprecipitations, whole cell extracts, 
precleared with 30 μl of protein A-agarose (50% slurry; Roche, Manheim, Germany), 
67 
 
were incubated overnight at 4°C with anti-YB-1(3 μg)  or -rabbit IgG  (3 μg). The 
reciprocal experiment was performed with anti-p63 (2 μg) or -mouse IgG.  
 
Luciferase reporter assay - MDA-MB-231 cells were cotransfected with Np63, 
PIK3CA luc-promoter/EGFR-luc promoter and pRL-TK. YB-1 gene silencing was 
carried out 24 hrs before plasmid transfection. At 24h after transfection, cells were 
harvested in 1x PLB buffer (Promega) and luciferase activity was measured using 
Dual Luciferase Reporter system (Promega) using pRL-TK activity as internal control. 
FireFly-derived luciferase activity was normalized for transfection efficiency. 
Successful transfection of p63 and silencing of YB-1 was confirmed by 
immunoblotting.  
 
RNA Immunoprecipitation - 1 x 106 MDA-MB-231 cells were seeded in 100mm plates 
and transfected with pcDNA3.1 or Np63 expression plasmids. 24h after 
transfection, cells were fixed with 1% formaldehyde for 10 min and washed twice in 
ice-cold PBS. Cell extracts were prepared in RNA-immunoprecipitation buffer (0.1% 
SDS, 1% Triton, 1mM EDTA, 10mM Tris pH 7.5, 0.5mM EGTA, 150mM NaCL) 
supplemented with complete protease inhibitor mixture (Sigma Chemical Co., St. 
Louis, MO, USA) and sonication was carried out with BANDELINE SONOPULSE 
HD2200 instrument under following conditions: 8 pulses of 4 sec at 0.250% of 
intensity. Cell extracts were incubated with anti-YB-1 (3g) at 4°C overnight. The 
RNA-protein immunocomplexes were precipitated with protein A beads (Roche 
Applied Science, IN) satured with tRNA and, after reverse cross-link, subjected to 
RealTime PCR. 
 
Immunofluorescence – A431, SCC011 and SCC022 cells (2.5 x 105) were plated in 
35 mm dish, grown on micro cover glasses (BDH). At 24 hours after seeding, cells 
were washed with cold phosphate-buffered saline (PBS) and fixed with 4% 
paraformaldehyde (PFA) (Sigma-Aldrich, Germany) for 15 min at 4°C. Cells were 
permeabilized with ice-cold 0.1% Triton X-100 for 10 min and then washed with PBS. 
p63 was detected using a 1:200 dilution of the monoclonal antibody 4A4. YB-1 was 
detected using 1:100 dilution of the YB1 antibody (Ab12148).  
After extensive washing in PBS, the samples were incubated with Cy3-conjugated 
anti-mouse IgGs and Cy5-conjugated anti-rabbit IgGs at room temperature for 30 
min. After PBS washing, the cells were incubated with DAPI (4′,6′-diamidino-2-
phenylindole; 10 mg/ml (Sigma-Aldrich, Germany) for 3 min. The glasses were 
mounted with Moviol (Sigma-Aldrich, Germany) and examined under a fluorescence 
microscope (Nikon). Images were digitally acquired and processed using Adobe 
Photoshop software CS. 
 
Cytoskeleton analysis – Actin bundles were stained with TRITC conjugated 
phalloidin. Cell fixation was performed with 4% paraformaldehyde for 20 min and 
then permeabilized with 0.1% Triton X-100 (Sigma, St. Louis, MO, USA) in PBS 1x 
for 10 min. Actin staining was done by incubating sample with TRITC phalloidin 
(Sigma) in PBS for 30 min at room temperature. Images of fluorescent cells were 
collected with a fluorescent inverted microscope (IX81, Olympus, Tokyo, Japan) 
equipped with an ORCA 2.8 digital camera (Hamamatsu Photonics, Japan). 
 
Time-lapse microscopy – SCC011 cells were cultured on 35 mm dishes (Corning, 
NY) at 2x104 cells/dish density. Np63 transient silencing was performed as 
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described in the Experimental procedure. At 48 hours from the additionofNp63 
si-RNA, the culture dishes were placed in a mini-incubator connected to an 
automated stage of an optical microscope (Olympus Co., Japan). Images of selected 
positions of the cell culture were collected in brightfield (BF) every 10 minutes for 
12h. The BF images were mounted to obtain 72 frames time lapse video per each 
position. Cell trajectories were reconstructed from time lapse video using Metamorph 
software (Molecular Device, CA). Root mean square speed (S) and persistence time 
(P) were chosen as relevant parameters in order to describe the macroscopic 
features of cell migration in the different experimental conditions. These parameters 
were calculated according to the procedure reported by Dunn G.A. (Dunn, 1983) 
Briefly, mean-squared displacement (MSD) of each cell, is calculated according to 
overlapping time intervals method (Dickinson, 1993). Subsequently, S and P are 
estimated by fitting the experimental data of the MSD to a linear approximation of the 
persistent random walk model. The upper limit for the data fitting was set 
approximately at 200 min per each cell owing to the deviation from linearity that is 
observed at higher time points. The fitting procedure provided (S, P) pairs per each 
cells and Statistical significance between S and P values of the different experimental 
setups was assessed by performing a non-parametric Kruskal-Wallis test in Matlab 
(MathWorks, MA). p values < 0.05 were considered significant.  
Cell migration in H1299 cells was evaluated with a similar approach. Briefly, cells 
were cultured on 35 mm dishes (Corning, NY) at a density of 2×104 cells/dish. 
Np63 expression was induced with 2 g/ml doxycycline for 48 hr. 16 hr after 
transfection, cell dishes were placed in a mini-incubator connected to an automated 
stage of an optical microscope (Cell^R, Olympus Co., Japan). Time zero images of 
selected position were collected in fluorescence in order to localize transfected cells. 
Then, at the same positions, images were recorded in brightfield (BF) every 10 
minutes for 12 hours. Data analysis was performed as described above. 
 
Cell Viability assay - Cell viability was determined by the MTT 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide assay (Sigma-Aldrich, St Louis, MO). Briefly, 
cells were seeded in 96-well plates at 2 x 103 and transfected with scrambled or YB-1 
siRNA oligos, 48h after silencing  MTT solution (5mg/ml in PBS, 20 l/well) was 
added to cells to produce formazan crystals. MTT solution was substituted by 150 l 
DMSO 30 minutes later to solubilize the formazan crystals. The optical absorbance 
was determined at 570 nm using an iMark microplate reader (Bio-Rad, USA). The 
experiments were carried out in triplicate for each knockdown and compared to 
scrambled control. 
 
Quantitative Real Time-PCR-For PCR analysis total RNA was isolated using the RNA 
Extraction Kit  from Qiagen (Hilden, Germany) according to the manufacturer’s 
instructions. RNA (2-5µg) was treated with DNAse I (Promega, Madison USA) and 
used to generate reverse transcribed cDNA using SuperScript III (Life Technologies, 
CA, USA),  according to the manufacturer’s instructions. All samples in each 
experiment were reverse transcribed at the same time, the resulting cDNA diluted 1:5 
in nuclease-free water and stored in aliquots at –80°C until used.  
Real Time PCR with SYBR green detection was performed with a 7500 RT-PCR 
Thermo Cycler (Applied Biosystem, Foster City, USA). The thermal cycling conditions 
were composed of 50ºC for 2 min followed by an initial denaturation step at 95ºC for 
10 min, 45 cycles at 95ºC for 30s, 60ºC for 30s and 72ºC for 30s. Experiments were 
carried out in triplicate. The relative quantification in gene expression was determined 
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using the 2-ΔΔCt method (Livak and Schmittgen, 2011). Using this method, we 
obtained the fold changes in gene expression normalized to an internal control gene 
and relative to one control sample (calibrator). 18S was used as an internal control to 
normalize all data and the siCtrl was chosen as the calibrator. 
Appropriate no-RT and non-template controls were included in each 96-well PCR 
reaction and dissociation analysis was performed at the end of each run to confirm 
the specificity of the reaction.  
TWIST (F): 5’ AGAAGTCTGCGGGCTGTG 
TWIST (R):5’TCTGCAGCTCCTCGTAAGACT 
HPRT (F):5'CCTGCTGGATTACATTAAAGC 
HPRT (R) : 5' CTTCGTGGGGTCCTTTTC 
YB1 (F):5’CGCAGTGTAGGAGATGGAGAG 
YB1 (R):5’GAACACCACCAGGACCTGTAA 
Np63 (F):5’GGTTGGCAAAATCCTGGAG 
Np63 (R):5’GGTTCGTGTACTGTGGCTCA 
EGFR (F) :5’TTCCTCCCAGTGCCTGAA 
EGFR (R):5’GGGTTCAGAGGCTGATTGTG 
STAT3 (F) :5’CCTCTGCCGGAGAAACAG 
STAT3 (R):5’CTGTCACTGTAGAGCTGATGGAG 
GADD45A (F): 5’ TTTGCAATATGACTTTGGAGGA 
GADD45A (R): 5’ CATCCCCCACCTTATCCAT 
18S (F):5’TCGAGGCCCTGTAATTGGAA 
18S (R):5’CTTTAATATACGCTATTGGAGCTG 
 
Chromatin Immunoprecipitation (ChIP) assay in MCF7 cells - According with Beneke, 
2015  cells were cross-linked for 10 min at room temperature with 4% formaldehyde 
into the medium and neutralized by the addition of 1.25 M glycine/PBS for 2 min. 
After removing of the solution, plates were washed twice with PBS (2 min each). To 
yield chromatin suspension, cells were scraped in 0.5 ml SDS lysis buffer (1% SDS, 
10 mM EDTA (pH8.0), 50 mM Tris-HCl (pH 8.0) supplemented with protease 
inhibitors (ROCHE-Diagnostic) after incubation for 5 min at 4°C. Suspensions were 
sonicated using Bioruptor (Diagenode) on high setting (30 sec on and 30 sec off) for 
50 cycles. Concentration was adjusted to 1 μg/μl with lysis buffer and stored at 4°C. 
For ChIP, suspensions were brought to room temperature and 160 μl were spun 
down for 5 min at maximum speed. 150 μl supernatant was mixed with 1.35 ml ChIP 
dilution buffer (20 mM Tris-HCl (pH 8.0), 2 mM EDTA (pH 8.0), 150 mM NaCl, 1% 
Triton-X-100) supplemented with protease inhibitors (ROCHE-Diagnostic) and 
incubated with 1.5 μg of p53 (DO-1) monoclonal antibody or 1.5 μg of normal IgG 
(Santa Cruz Biotechnology). Samples were rotated overnight at 4°C. 100 μl of on 
agarose-beads immobilized Protein G (Thermo Scientific, Rockford/IL, USA) were 
resuspended in 1 ml 9:1 dilution buffer:lysis buffer mix (DB:LB) and pre-absorbed 
with 100 μg/ml BSA and 500 μg/ml sheared salmon sperm DNA overnight at 4°C on 
a rotator.  
On the next day, beads were washed twice with DB:LB and resuspended in 1 ml 
DB:LB. 50 μl of the beads suspension was added to each cell lysate and incubated 
for at least 2 h at 4°C on a rotator. 
Suspensions were spun down 10 min at 1000 x g and supernatant was aspirated. 
Beads were washed 3 times in 0.5 ml wash buffer (150 mM NaCl, 20 mM Tris-HCl 
(pH 8.0), 2 mM EDTA (pH 8.0), 1% Triton-X-100, 0.1 % SDS) supplemented with 
protease inhibitors (ROCHE-Diagnostic) and centrifuged as above; Beads were 
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washed in 0.5 ml final wash (500 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2 mM EDTA 
(pH 8.0), 1% Triton-X-100, 0.1% SDS) supplemented with protease inhibitors 
(ROCHE-Diagnostic) and immune-complexes were eluted by addition of 160 μl 
elution buffer (100 mM NaHCO3, 1% SDS) 5 min at room temperature. 500 μg/ml of 
Proteinase K and RNAse A were added to each sample and incubated for 30 min at 
37°C and for 1 h at 56°C. DNA-protein crosslinks were reversed by adding NaCl to a 
final concentration of 200 mM and incubation overnight at 65°C. DNA was isolated by 
Phenol/Chloroform procedure and subsequent ethanol precipitation. 
DNA fractions were subjected to PCR with primers specific for p21WAF and BAX 
promoter regions and with KOD Hot Start polymerase according to manufacturer’s 
instructions (Novagen/Merck, Darmstadt, Germany). 
PCR was performed in 32 cycles (20 sec 95°C/10 sec annealing temperature/5 sec 
70°C) and products were resolved by 2.5% agarose gel electrophoresis. Primer 
sequences and respective annealing temperatures are listed: 
Primer sequence fwd / rev (5’-3’);  
p21WAF GTGGCTCTGATTGGCTTTCTG/GCTAAGGTTTACCTGGGGTCTTTA  
BAX ATAACGTCCTGCCTGGAAGC/CCCCAGCGCAGAAGGAATTA  
ChIP experiments were performed as three independent biological replicates and 
each experiment was performed in triplicate. Promoter occupancy was calculated 
with the percent input method by using the Image J software. 
 
Statistics - Statistical Analysis was performed by using the Graph Pad software and 
the unpaired Student’s t test.P-value of <0.05 were considered statistically significant 
(*); P-value of <0.01 were considered extremely statistically significant (**). 
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Antonella Di Costanzo‡, Annaelena Troiano‡, Orsola di Martino‡, Andrea Cacace‡, Carlo F. Natale§,
Maurizio Ventre§, Paolo Netti§, Sergio Caserta¶, Alessandra Pollice‡, Girolama La Mantia‡, and Viola Calabrò‡1
From the ‡Department of Structural andMolecular Biology and §Center for Advanced Biomaterials for Health Care, Istituto Italiano
di Tecnologia and Interdisciplinary Research Centre on Biomaterials, University of Naples “Federico II”, Naples 80126 and the
¶Department of Chemical Engineering, University of Naples “Federico II”, Naples 80125, Italy
Background: YB-1 is a multifunctional protein that affects transcription, splicing, and translation.
Results: Np63, the main p63 protein isoform, interacts with YB-1 and affects YB-1 subcellular localization and regulation of
cell survival and motility genes.
Conclusion: Np63 and YB-1 interaction inhibits epithelial to mesenchymal transition and tumor cell motility.
Significance: This is the first demonstration of a physical and functional interaction between YB-1 and Np63 oncoproteins.
TheY-box binding protein 1 (YB-1) belongs to the cold-shock
domain protein superfamily, one of themost evolutionarily con-
served nucleic acid-binding proteins currently known. YB-1
performs a wide variety of cellular functions, including tran-
scriptional and translational regulation, DNA repair, drug
resistance, and stress responses to extracellular signals. Inas-
much as the level of YB-1 drastically increases in tumor cells,
this protein is considered to be one of themost indicativemark-
ers of malignant tumors. Here, we present evidence that
Np63, the predominant p63 protein isoform in squamous
epithelia and YB-1, can physically interact. Into the nucleus,
Np63 and YB-1 cooperate in PI3KCA gene promoter activa-
tion. Moreover, Np63 promotes YB-1 nuclear accumulation
thereby reducing the amount of YB-1 bound to its target tran-
scripts such as that encoding the SNAIL1 protein. Accordingly,
Np63 enforced expressionwas associatedwith a reduction of
the level of SNAIL1, a potent inducer of epithelial to mesenchy-
mal transition. Furthermore, Np63 depletion causes morpho-
logical change and enhanced formation of actin stress fibers in
squamous cancer cells. Mechanistic studies indicate thatNp63
affects cell movement and can reverse the increase of cell motility
induced by YB-1 overexpression. These data thus suggest that
Np63 provides inhibitory signals for cell motility. Deficiency of
Np63 gene expression promotes cell mobilization, at least par-
tially, through a YB-1-dependentmechanism.
The Y-box binding protein 1 (YB-1), also known as NSEP1,
CSBD, and MDR-NF1, is a member of the highly conserved
Y-box family of proteins that regulate gene transcription by
binding to the TAACC element (the Y-box) contained within
many eukaryotic promoters (1). Transcriptional targets of YB-1
include genes associated with cell death, cell proliferation, and
multidrug resistance (1, 2). YB-1 protein can also regulate gene
transcription by binding to other transcription factors such as
p53, AP1, and SMAD3 (2).
YB-1 is an important marker of tumorigenesis and is overex-
pressed in many malignant tissues, including breast cancer,
non-small cell lung carcinoma, ovarian adenocarcinoma,
human osteosarcomas, colorectal carcinomas, and malignant
melanomas (1). Mostly cytosolic, YB-1 protein shuttles
between the nucleus and cytoplasm. Cytoplasmic YB-1 acts as a
translation factor of oncogenic/pro-metastatic genes (3). It
binds to the mRNA cap structure and displaces the eukaryotic
translation initiation factors eIF4E and eIF4G, thereby causing
mRNA translational silencing (4). However, cytoplasmic YB-1
activates cap-independent translation of mRNA encoding
SNAIL1, a transcription factor that promotes epithelial-mesen-
chymal transition by suppressing E-cadherin (5). According to
those observations, the YB-1 protein level, in breast carcinoma,
is positively correlated to the increase of SNAIL1 protein level
and reduced expression of E-cadherin (6).
In normal conditions, YB-1 is located in the cytoplasm and
transiently translocates to the nucleus at the G1/S transition of
the cell cycle (7). Moreover, nuclear translocation of YB-1 was
shown to occur in response to DNA-damaging agents, phos-
phorylation at Ser-102 by AKT kinase, UV irradiation, TGF
stimulation, virus infection, hypothermia, and pharmacological
compounds (1, 8, 9). Under stress stimuli, YB-1 nuclear trans-
location requires a physical interaction with wild type p53 (10).
Herein, we report that YB-1 directly interacts with Np63
and accumulates in the nuclear compartment. Np63 is
encoded by the TP63 locus, a homologue of the p53 tumor
suppressor gene and themost ancientmember of the p53 family
(11). Because of the presence of two promoters, the TP63 gene
encodes twomajor classes of proteins as follows: those contain-
ing a transactivating domain homologous to the one present in
p53 (i.e. TAp63), and those lacking it (i.e. Np63) (12). In addi-
tion, alternate splicing at theC terminus generates at least three
p63 variants (, , and ) in each class. The TAp63 isoform
* This work was supported by MIUR Grant PRIN 2009KFS94X_003 (to V. C.).
1 Towhomcorrespondence shouldbe addressed: Dept. Biologia Strutturale e
Funzionale,Università Federico II, ViaCinziaMonteSAngelo, 80126Napoli,
Italy. Tel.: 39-081-679069; Fax: 39-081-679033; E-mail: vcalabro@unina.it.
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resembles most p53, whereas the -isoforms include a con-
served protein-protein interaction domain named the sterile 
motif.
Gene knock-out mice demonstrated that p63 plays a critical
role in the morphogenesis of organs/tissues developed by epi-
thelial-mesenchymal interactions such as the epidermis, teeth,
hair, and glands (13). In adults, Np63 expression occurs in
the basal cells of stratified epithelia. High expression of
Np63 is associated with the proliferative potential of epithe-
lial cells (14) and is enhanced at the early stages of squamous
cell carcinomas (SCCs)2 (15). Down-regulation of Np63 by
SNAIL transcription factor instead was found to reduce cell-
cell adhesion and increase the migratory properties of squa-
mous carcinoma cells (16).Moreover, a partial or complete loss
of Np63 expression was associated with tumor metastasis
supporting the idea thatNp63 plays a relevant role inmetas-
tasis suppression (17, 18). Here, we provide experimental evi-
dence that the YB-1 protein associates with Np63 and such
interaction plays a critical role in the control of genes involved
in cell survival and motility.
EXPERIMENTAL PROCEDURES
Plasmids—cDNAs encoding human FLAG-tagged YB-1
were provided byDr. SandraDunn (Research Institute for Chil-
dren’s and Women’s Health, Vancouver, British Columbia,
Canada). PIK3CA promoter luciferase plasmid was provided by
Dr. Arezoo Astanehe (Research Institute for Children’s and
Women’s Health, Vancouver, British Columbia, Canada).
cDNA encoding human Np63 and Np63were previously
described (19). For bacterial expression, Np63 and Np63
cDNAs were inserted in pRSETA vector in XhoI/ClaI and
XhoI/XbaI (filled) sites, respectively. GFP and YB-1-GFP vec-
tors were provided by Dr. Paul R. Mertens (University Hospital
Aachen, Germany). PET-YB-1 was fromDr. Jill Gershan (Med-
ical College of Wisconsin, Milwaukee, WI).
Cell Lines, Transfection, and Antibodies—Squamous carci-
noma cells (SCC011 and SCC022) were described previously
and provided to us by Dr. C. Missero (20).
These cell lines were maintained in RPMI medium supple-
mented with 10% fetal bovine serum at 37 °C and 5% CO2.
A431, H1299, and MDA-MB-231 cells were obtained from
ATCC andmaintained in DMEM supplemented with 10% fetal
bovine serum at 37 °C and 5% CO2. Dox-inducible Tet-On
H1299/Np63 cells were described previously (21).
Lipofections were performed with Lipofectamine (Invitro-
gen), according to the manufacturer’s recommendations. YB-1
transient silencing was carried out with ON-TARGET plus
SMART pool YB-1-siRNA (Dharmacon) and RNAiMAX rea-
gent (Invitrogen). Np63 transient silencing in SCC011 cells
was carried out with RIBOXX (IBONI p63-siRNA pool) and
RNAiMAX reagent (Invitrogen), according to the manufactur-
er’s recommendation. An si-RNA against luciferase (si-Luc)
was used as a negative control. Anti-p63 (4A4) and anti-
actin(1–19)were fromSantaCruzBiotechnology Inc., and anti-
FLAG M2 was from Sigma. PARP, AKT, pAKT (Ser-473) and
rabbit polyclonal YB-1 antibody (Ab12148) were fromCell Sig-
naling Technology (Beverly, MA). Mouse monoclonal E-cad-
herin (ab1416) and SNAIL1 antibodies were from Abcam
(Cambridge, UK). Mouse monoclonal N-cadherin (610921)
was from BDTransduction Laboratories. Cy3-conjugated anti-
mouse IgG and Cy5-conjugated anti-rabbit IgG were from
Jackson ImmunoResearch. Doxycycline was from Clontech.
Chromatin Immunoprecipitation (ChIP) Assay—ChIP was
performed with chromatin from human MDA-MB-231 cells
transfected with Np63, Np63, and/or FLAG YB-1, as
described previously (22). Real time PCR was performed with
the 7500 Applied Biosystems apparatus and SYBR Green Mas-
terMix (Applied Biosystems) using the following oligonucleo-
tides: PIK3CA-For, CCCCCGAACTAATCTCGTTT, and
PIK3CA-Rev, TGAGGGTGTTGTGTCATCCT.
Sequential ChIP was performed with chromatin from
SCC011 cells. Method of chromatin extraction and controls
used were previously described (22).
Chromatin sampleswere subjected to pre-clearingwith 80l
of salmon spermDNA-saturated agarose A beads for 2 h at 4 °C
with rotation. The first immunoprecipitation stepwas obtained
with p63 antibodies (4A4). After several washes, the immuno-
complexes were extracted from beads with 100 l of 2%
TE/SDS. The second immunoprecipitation step was obtained
with YB-1 (Ab12148) antibodies after a 30-fold dilution in DB
buffer (50mMTris-HCl, 5mM EDTA, 200mMNaCl, 0.5%Non-
idet P-40, 15 mM DTT). Samples were incubated overnight at
4 °C with rotation. Immunocomplexes were extracted from
beads as described above. Immunoprecipitated protein-DNA
complexes were subjected to reverse cross-linking and protein-
ase K treatment. DNA was purified by phenol/chloroform
extraction and resuspended in 40 l of TE. 2 l were used for
PCR performed with the following primers: PIK3CA promoter
For, ACAAACCCCTGGAATGTGAG, and PI3KCA promoter
Rev, TGGAAAAGCGTAGGAGCAGT.
Immunoblot Analyses and Co-immunoprecipitation—Im-
munoblots and co-immunoprecipitations were performed as
described previously (19). To detect p63/YB-1 interaction in
SCC011 cells, 5.0 105 cells were plated in 60-mm dishes. For
co-immunoprecipitations, whole cell extracts, precleared with
30l of proteinA-agarose (50% slurry; RocheApplied Science),
were incubated overnight at 4 °C with anti-YB-1(3 g) or
-rabbit IgG (3 g). The reciprocal experiment was performed
with anti-p63 (2 g) or -mouse IgG.
Far Western Assays—Far Western assays were conducted
according to the protocol described by Cui et al. (23). Increas-
ing amounts (0.2, 0.5, and 1.5 g) of Np63 or Np63
recombinant proteins were subjected to SDS-PAGE and trans-
ferred to PVDF membrane (IPVH00010 Immobilon Millipore,
Milan, Italy). Bovine serum albumin (0.5 and 1.5 g; BSA) was
used as control of unspecific binding and equal loading of BSA,
and recombinant YB-1 or p63 proteins in far Western blotting
was verified by Coomassie staining (data not shown).
Luciferase Reporter Assay—MDA-MB-231 cells were
co-transfected with Np63, PIK3CA luc promoter, and pRL-
TK. YB-1 gene silencing was carried out 24 h before plasmid
2 The abbreviations used are: SCC, squamous cell carcinoma; For, forward;
Rev, reverse; PARP, poly(ADP-ribose) polymerase; Dox, doxycycline; TRITC,
tetramethylrhodamine isothiocyanate; S, speed; P, persistence time; Ab,
antibody; HPRT, hypoxanthine-guanine phosphoribosyltransferase.
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transfection. At 24 h after transfection, cells were harvested in
1 PLB buffer (Promega), and luciferase activity was measured
using the Dual-Luciferase Reporter system (Promega) using
pRL-TK activity as internal control. Firefly-derived luciferase
activity was normalized for transfection efficiency. Successful
transfection of p63 and silencing of YB-1 was confirmed by
immunoblotting.
RNA Immunoprecipitation—1  106 MDA-MB-231 cells
were seeded in 100-mm plates and transfected with pcDNA3.1
or Np63 expression plasmids. 24 h after transfection, cells
were fixed with 1% formaldehyde for 10 min and washed twice
in ice-cold PBS. Cell extracts were prepared in RNA immuno-
precipitation buffer (0.1% SDS, 1% Triton, 1 mM EDTA, 10 mM
Tris, pH 7.5, 0.5 mM EGTA, 150 mM NaCl) supplemented with
complete protease inhibitor mixture (Sigma), and sonication
was carried out with BANDELINE SONOPULSE HD2200
instrument under the following conditions: 8 pulses of 4 s at
0.250% of intensity. Cell extracts were incubated with anti-
YB-1 (3 g) at 4 °C overnight. The RNA-protein immunocom-
plexes were precipitated with protein A beads (Roche Applied
Science) saturatedwith tRNA and, after reverse cross-link, sub-
jected to real time PCR.
Semi-quantitative and Real Time PCR—For PCR analysis,
total RNA was isolated using the RNA mini extraction kit
(Qiagen, GmbH, Hilden, Germany) according to the manufac-
turer’s instructions. Total RNA (1 g) was used to generate
reverse-transcribed cDNA using SuperScript III (Invitrogen).
PCR analysis was performed with the following primers: Twist
(For), 5-AGAAGTCTGCGGGCTGTG, and Twist (Rev), -
TCTGCAGCTCCTCGTAAGACT; YB (For), 5-CGCAGTG-
TAGGAGATGGAGAG, and YB (Rev), 5-GAACACCACCA-
GGACCTGTAA; and HPRT (For), 5-CCT GCT GGA TTA
CAT TAA AGC, and HPRT (Rev), 5 CTT CGT GGG GTC
CTT TTC.
SNAIL1 amplification was performed using Quantitect
Primers/Hs SNAIL1 from Qiagen (GmbH, Hilden, Germany).
The amplification sequence consisted of 30 cycles of 94 °C for 1
min, 55 °C for 1min, and 72 °C for 1 min. PCR products were
resolved by 2% agarose electrophoresis. RT-PCR amplification
results were analyzed byQuantityOne software (Bio-Rad). Real
time PCR was performed with a 7500 RT-PCR Thermo Cycler
(Applied Biosystem) as already described (22). HPRT was used
for normalization. The results were expressed with the value
relative to HPRT (set at 1) for each mRNA sample.
Immunofluorescence—A431, SCC011, and SCC022 cells
(2.5  105) were plated in 35-mm dishes and grown on micro
cover glasses (BDH). 24 h after seeding, cells were washed with
cold phosphate-buffered saline (PBS) and fixed with 4% para-
FIGURE 1. Np63 and YB-1 are co-expressed in squamous carcinoma cell lines. a, whole cell lysates were obtained from H1299 (non-small cell lung
carcinoma), A431 (epidermoid carcinoma cell line), and SCC011 and SCC022 (keratinocyte-derived SCC) cells. 30g of total protein extractswere separated by
SDS-PAGE and subjected to immunoblot (IB). Proteins were detected with specific antibodies as indicated. Images were acquired with CHEMIDOC (Bio-Rad)
and analyzedwith the Quantity-ONE software. b,A431, SCC011, and SCC022 cells were seeded (2.5 105) on a 35-mmdish and grown onmicro cover glasses
(BDH). After 24 h at seeding, cells were fixed and subjected to double immunofluorescence using rabbit primary YB-1 antibody and Fitch-conjugated
secondary antibodies (green). p63 proteinwas detected usingmouse anti-p63 andCy3-conjugated secondary antibodies (red). Images ofmerge (yellow) show
the co-expression of two proteins.
FIGURE 2. Np63 interacts with YB-1. a, extracts from SCC011 cells were
immunoprecipitated (IP) with anti-YB-1 antibodies, and the immunocom-
plexes were blotted and probed with anti-p63 as indicated. b, extracts from
SCC011 cells were immunoprecipitated with anti-p63 antibodies, and the
immunocomplexeswereblottedandprobedwith anti-YB-1. Sampleswithno
antibody (no Ab) or irrelevant -mouse and -rabbit antibodies were
included as controls. IB, immunoblot.
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formaldehyde (Sigma) for 15 min at 4 °C. Cells were permeabi-
lized with ice-cold 0.1% Triton X-100 for 10 min and then
washedwith PBS. p63was detected using a 1:200 dilution of the
monoclonal antibody 4A4.
YB-1 was detected using 1:100 dilution of the YB-1 antibody
(Ab12148). After extensive washing in PBS, the samples were
incubated with Cy3-conjugated anti-mouse IgGs and Cy5-con-
jugated anti-rabbit IgGs at room temperature for 30 min. After
PBS washing, the cells were incubated with 10 mg/ml 4,6-
diamidino-2-phenylindole (DAPI) (Sigma) for 3 min. The
glasses were mounted with Moviol (Sigma) and examined
under a fluorescencemicroscope (Nikon). Imageswere digitally
acquired and processed using Adobe Photoshop software CS.
H1299 and MDA-MB-231 cells (5.0  105) were plated in
35-mmdishes, grown onmicro cover glasses (BDH), and trans-
fectedwith 0.2g of pcDNAYB-1/GFPplasmidwith orwithout
0.6 g of Np63 or Np63 plasmid. The GFP empty vector
was used as control (data not shown). 24 h after transfection,
cells were subjected to the immunofluorescence protocol as
described above.
Cytoskeleton Analysis—Actin bundles were stained with
TRITC-conjugated phalloidin. Cell fixation was performed with
4% paraformaldehyde for 20 min and then permeabilized with
0.1% Triton X-100 (Sigma) in PBS one time for 10 min. Actin
staining was done by incubating sample with TRITC-phalloidin
(Sigma) inPBS for 30min at roomtemperature. Images of fluores-
cent cells were collected with a fluorescent inverted microscope
(IX81,Olympus,Tokyo, Japan)equippedwithanORCA2.8digital
camera (Hamamatsu Photonics, Japan).
Time-lapse Microscopy—SCC011 cells were cultured on
35-mm dishes (Corning, NY) at 2  104 cells/dish density.
Np63 transient silencing was performed as described under
“Experimental Procedures.” At 48 h from the addition of
Np63 si-RNA, the culture dishes were placed in a mini-in-
cubator connected to an automated stage of an optical micro-
scope (Olympus Co., Japan). Images of selected positions of the
cell culture were collected in bright field every 10 min for 12 h.
The bright field images were mounted to obtain 72-frame time
lapse video for each position. Cell trajectories were recon-
structed from time lapse video using Metamorph software
(Molecular Device, CA). Root mean square speed (S) and per-
sistence time (P) were chosen as relevant parameters to
describe the macroscopic features of cell migration in the dif-
ferent experimental conditions. These parameters were calcu-
lated according to the procedure reported byDunn (24). Briefly,
mean-squared displacement of each cell was calculated accord-
ing to overlapping time interval methods (25). Subsequently, S
and P were estimated by fitting the experimental data of the
mean-squared displacement to a linear approximation of the
persistent random walk model. The upper limit for the data
fitting was set at approximately 200min for each cell because of
the deviation from linearity that was observed at higher time
points. The fitting procedure provided (S, P) pairs for each cell
and the statistical significance between S and P values of the
different experimental setups was assessed by performing a
nonparametric Kruskal-Wallis test in Matlab (MathWorks,
MA). p values 0.05 were considered significant.
Cell migration in H1299 cells was evaluated with a similar
approach. Briefly, cells were cultured on 35-mm dishes (Corn-
ing, NY) at a density of 2 104 cells/dish. Np63 expression
was inducedwith 2g/ml doxycycline for 48 h. 16 h after trans-
fection, cell dishes were placed in a mini-incubator connected
to an automated stage of an optical microscope (Cell[caret]R,
Olympus Co., Japan). Time 0 images of selected position were
collected in fluorescence to localize transfected cells. Then, at
the same positions, images were recorded in bright field every 10
min for 12 h. Data analysis was performed as described above.
RESULTS
YB-1 Interacts withNp63 in Vitro and inVivo—As a result
of a comprehensive screening for Np63 interactors, using
affinity purification followed by mass spectrometry, we identi-
fied a set of proteinswithDNA/RNAbinding activity, including
YB-1 (26). We decided to confirm the interaction between
Np63 and YB-1 in SCC as in this cellular context the TP63
gene is often amplified and/or overexpressed (27). Immunob-
lots and immunofluorescence assays performed in A431,
SCC022, and SCC011 cell lines showed intense signals for both
proteins thus confirming that endogenous YB-1 and Np63
are abundantly co-expressed in human squamous carcinoma
cells (Fig. 1, a and b).
We next performed co-immunoprecipitation experiments in
SCC011 cells. Immunocomplexes containing Np63 and
FIGURE 3. Np63 but not Np63 interacts with YB-1. a, H1299 cells
were transiently transfectedwith5gofNp63 (left panel) orNp63 (right
panel) expression vectors. Equal amounts (1 mg) of extracts were immuno-
precipitated (IP) with anti-p63 antibodies (4A4) or unrelated -mouse IgG.
The immunocomplexeswereblotted andprobedwith anti-p63 andanti-YB-1
antibodies, as indicated. b, far Western analysis. Increasing amounts of puri-
fied recombinantNp63 (0.2, 0.5, and 1.5),Np63 (0.2, 0.5, and 1.5), or BSA
(0.5 and 1.5) were subjected to SDS-PAGE. After Coomassie staining to mon-
itor equal loading, the proteins were transferred to a PVDF membrane, and
the filter was incubated with purified YB-1 recombinant protein (0.8 g/ml).
After extensive washing, the membrane was subjected to immunoblotting
(IB) with YB-1 antibodies followed by ECL detection. Recombinant YB-1 pro-
tein (0.1 g) was used as positive control.m.w.,molecular weight markers.
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YB-1 were isolated from total cell lysates, using either antibod-
ies against YB-1 or antibodies against p63 thus confirming the
interaction inferred by mass spectrometry (Fig. 2, a and b). To
determine whether YB-1 interacts specifically with the -iso-
form of Np63, we transfected p63 null H1299 cells with
Np63 or Np63 to perform co-immunoprecipitation
assays. As shown in Fig. 3a, YB-1 associates with Np63 but
notNp63. This result was also confirmedby farWestern blot
analysis using Np63, Np63, and YB-1 recombinant pro-
teins purified by affinity chromatography (Fig. 3b). The
obtained results indicate that the -isoform C-terminal region
is involved in the association with YB-1, and the interaction
between the two proteins requires no additional factors.
Np63 Induces YB-1 Nuclear Accumulation—It has been
reported that YB-1 is ubiquitously expressed and predomi-
nantly localized to the cytoplasm (2), Np63 is mainly
expressed by basal and myoepithelial cells in skin and glands
and is almost completely restricted to the nuclear compartment
(29). Because we noticed some overlapping between the p63
and YB-1 immunofluorescence signals in the nucleus of squa-
mous carcinoma cell lines, we sought to determine whether
Np63 has an effect on YB-1 subcellular localization. Fusion
of YB-1 with the green fluorescent protein (YB-1-GFP) was
transfected in H1299 cells. H1299 cells are p63 null and express
moderate levels of endogenous YB-1. GFP-positive cells were
counted, and 95% showed a strong cytoplasmic signal, although
in the remaining 5%, the signal was nuclear or distributed
between the nucleus and cytoplasm (Fig. 4, a and b). A very
similar result was observed following Np63 co-transfection
(Fig. 4, b and c, lower panel). Remarkably, combined expression
of YB-1-GFP and Np63 caused a dramatic change of YB-1-
GFP subcellular localization. In fact, among the GFP-positive
cells, more than 40% showed an intense nuclear signal (Fig. 4, b
and c, upper panel); an additional 20% exhibited YB-1-GFP
almost equally distributed between the nucleus and cytoplasm,
and the remaining 40% exhibited exclusively cytoplasmic YB-1-
GFP (Fig. 4b). As expected, Np63 and Np63 immunoflu-
orescence signals were almost exclusively nuclear (Fig. 4c).
Np63 is a selective nuclear marker of human breast
myoepithelial cells. Np63 persists in benign lesions of the
breast, although it consistently disappears in invasive carcino-
mas (30). We transfected Np63 in MDA-MB-231 cells,
human metastatic breast carcinoma cells lacking p63 but
expressing high level of endogenous YB-1. As shown in Fig. 5, in
cells with no detectable p63 signal, YB-1 exhibited a largely
prevalent cytoplasmic localization (Fig. 5a, white arrows),
although 95% of Np63-expressing cells showed a strong
YB-1 nuclear staining (Fig. 5a, yellow arrows). We verified this
observation by nuclear/cytoplasmic fractionation of MDA-
MB-231 cells transfected with Np63 or Np63. Endoge-
nousYB-1 protein, inMDA-MB-231 cells, was detectable as 50-
and 36-kDa immunoreactive forms. Both forms of YB-1 appear
to accumulate in the nuclear compartment of cells transfected
with Np63 but not Np63 (Fig. 5b). Immunoblots with
antibodies against PARP-1 (nuclear) and AKT (cytoplasmic)
were performed to check for the quality of the fractionation.
Interestingly, although the amount of total AKT was compara-
ble, phosphorylated AKT, at serine 473, was enhanced in
Np63 but not Np63-transfected cells (Fig. 5b). This
observation was in line with previous data showing the specific
FIGURE 4.Np63 induces YB-1 nuclear accumulation. a,H1299 cells (2.3 105)were seeded at 60% confluency in 24 24-mmsterile coverglasses placed
in 60-mm dishes and transiently transfected with GFP-YB-1 expression vector (0.3 g). GFP-YB-1 was detected by direct immunofluorescence. b, H1299 cells
(2.3 105) were seeded as described in a and transiently transfected with GFB-YB-1 (0.3 g) along with 1 g of Np63 or Np63 expression vectors. Plot
shows the percentage of nuclear (dark gray), nucleo-cytoplasmic (gray), and cytoplasmic (white) GFP-YB-1 in cells transfected with Np63 or Np63
expressionvectors. Eachexperimental point is the averageof countsperformedon100 cells in five independent fields. Eachhistogrambar represents themean
and standard deviation of values from three biological replicates. c,H1299 cells (2.3 105) were transfected as described in b. GFP-YB-1was detected by direct
immunofluorescence (green), and p63was detected using anti-p63 antibodies and secondary anti-mouse Cy3-conjugated (red). DAPI was used to stain nuclei.
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ability of the Np63 isoform to promote PI3K/AKT pathway
activation (31).
We then evaluated the contribution ofNp63 to YB-1 sub-
cellular distribution in SCC011 cells expressing both proteins
endogenously. To this aim we analyzed YB-1 subcellular distri-
bution by immunoblot on nuclear/cytoplasmic fractions after
depletion of Np63 by siRNA. As shown in Fig. 6, a and b, fol-
lowing p63 knockdown the YB-1 nuclear pool was dramatically
reduced, and the36-kDa formofYB-1becamedetectable (Fig. 6a).
Np63 and YB-1 Bind to the PIK3CA Gene Promoter and
Cooperate in Its Transcriptional Activation—ThePIK3CA gene
encodes the p110 catalytic subunit of the PI3K and is a well
characterized YB-1 direct transcriptional target (32). We spec-
ulated thatNp63 should increase PIK3CA promoter activity
because of its ability to cause YB-1 nuclear accumulation. We
tested this hypothesis by luciferase assays. As shown in Fig. 7a,
Np63 transfection in MDA-MB-231 cells caused a relevant
increase of the PIK3CA promoter activity that was consistently
attenuated by YB-1 knockdown. In addition, we observed that
Np63 was able to transactivate the PIK3CA promoter in a
dose-dependent manner, although Np63 was completely
ineffective (Fig. 7b).
The role of Np63 and YB-1 in PIK3CA promoter activa-
tion was thoroughly investigated by chromatin immunopre-
cipitation (ChIP). We first performed ChIP assays in MDA-
MB-231 cells transfected with Np63 or Np63 using
anti-p63 (4A4) antibodies and PIK3CA promoter-specific
primers. As shown in Fig. 8a, Np63, but not Np63, binds
to the genomic sequence of the PIK3CA promoter.
Then we evaluated the effect of Np63 expression on the
binding of YB-1 to the PIK3CA promoter. FLAG-YB-1 was
transfected, in MB-MDA-231 cells, with or without Np63
plasmid. ChIP was carried out with anti-FLAG antibodies and
coupled with quantitative real time PCR. As show in Fig. 8b,
FLAG-YB-1 efficiently binds to the PIK3CA promoter, and its
binding was substantially increased by Np63. Finally, by
using a sequential chromatin immunoprecipitation assay (Re-
ChIP) in SCC011 cells, expressing endogenous Np63 and
YB-1, we found that both proteins are recruited to the PIK3CA
proximal promoter suggesting that they cooperate in PIK3CA
gene transactivation as a complex (Fig. 8c).
Np63 Affects YB-1 Binding to SNAIL and YB-1 mRNAs—
Cytoplasmic localization of YB-1 was associated with binding
and translational activation of SNAIL1mRNA (33). Snail1 pro-
tein is a transcriptional repressor of Np63 and E-cadherin
and promotes the epithelial-mesenchymal transition in several
epithelium-derived cancer cell lines (34).We first observed that
Np63 overexpression in MB-MDA-231 caused a reduction
of SNAIL1 protein level (Fig. 9a). Such a reduction was not
associated with a decrease of SNAIL1 mRNA levels (Fig. 9b)
thereby suggesting that the SNAIL1 protein was down-regu-
lated at the translational level. We hypothesized that the spe-
FIGURE 5. Endogenous YB-1 accumulates in the nucleus of breast cancer cells expressingNp63. a,MDA-MB-231 cells were seeded at 60% confluency
(2.3105) on2424-mmsterile coverglassesplaced in60-mmdishes and transiently transfectedwith1gofNp63expression vector. Cellswere fixedand
subjected to double indirect immunofluorescence using rabbit primary YB-1 antibody and Fitch-conjugated secondary antibodies (green). p63 protein was
detected using mouse anti-p63 and Cy3-conjugated secondary antibodies (red). DAPI was used to stain nuclei (blue). A representative image is given of a cell
expressing Np63 and showing nuclear endogenous YB-1 (yellow arrows). A representative image is given showing YB-1 cytoplasmic localization in cells
bearing no detectable Np63 expression (white arrows). b, MB-MDA-231 cells were transiently transfected with a fixed amount (5 g) of an empty vector
(mock) and Np63 or Np63 expression vector in 100-mm dishes. 24 h after transfection, cell lysates were fractionated to obtain cytoplasmic (cy) and
nuclear (nu) fractions. 20 g of nuclear and cytoplasmic extracts were separated by SDS-PAGE and subjected to immunoblot. Proteins were detected with
specific antibodies, as indicated. PARP and total AKT were used as nuclear and cytoplasmic controls, respectively, to check for cross-contamination. Images
were acquired with CHEMIDOC (Bio-Rad) and analyzed with the Quantity-ONE software.
FIGURE 6. Np63 depletion reduces the pool of nuclear YB-1. a, SCC011
cells were seeded at 60% confluency (1.5  106) in 100-mm dishes. 24 h after
seeding, cells were transiently silenced with IBONI p63-siRNA pool (20 nm final
concentration). 48 h after p63-silencing, cell lysates were fractionated to obtain
cytoplasmic (cy) and nuclear (nu) fractions. Nuclear and cytoplasmic extracts
were separated by SDS-PAGE and subjected to immunoblot. Proteins were
detectedwith specific antibodies, as indicated. PARP and total AKTwere used as
nuclear and cytoplasmic control respectively, to check for cross-contamination.
Imageswere acquiredwith CHEMIDOC (Bio-Rad) and analyzedwith the Quanti-
ty-ONE software. b,plots show thepercentage of YB-1 subcellular distribution in
control sample (upper panel) and in p63-silenced sample (lower panel) consider-
ing the total amount of YB-1 between the nucleus and cytoplasm as 100%.
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cific association of Np63 with YB-1 would reduce the
amount of YB-1 bound to the SNAIL1 transcript. To test this
hypothesis, we performed RNA-immunoprecipitation coupled
with real time PCR to quantitate the amount of SNAIL1mRNA
bound to endogenous YB-1, in mock and Np63-transfected
MDA-MB-231 cells. The obtained results confirm that
Np63 reduces the amount of YB-1 bound to SNAIL1 tran-
script (Fig. 9c). A similar analysis performed on the YB-1 tran-
script gave the same result (Fig. 9d).
Np63 Affects Cell Shape and Motility—So far, little atten-
tion has been focused on the effects of Np63 on epithelial
cancer cell morphology and motility. We have unexpectedly
noted a profound change in cell morphology when SCC011
cells were depleted of Np63 by siRNA. SCC011 cells are
FIGURE 7. Np63 and YB-1 activates the PIK3CA gene promoter. a, MB-MDA cells were transfected with 1 g of PIK3CA promoter luciferase reporter
plasmid. The luciferase activity upon siRNA-mediated knockdown of endogenous YB-1 was measured in the presence or absence of Np63 expression.
Values are shown as mean S.D. of three biological replicates. The extent of YB-1 knockdown was documented by Western blotting as shown in the lower
panel. b,MB-MDA-231 cells were seeded at 60% confluency (1.2 106) in 100-mmdishes and transiently transfected with 1g of PIK3CA promoter luciferase
reporter plasmid and the indicated amounts of Np63 or Np63 plasmid. Values are the mean S.D. of three independent experimental points. Lower
panel, immunoblotting (IB) with indicated antibodies to detect proteins in samples transfected with different amounts of Np63 or Np63.
FIGURE8.Np63 increasesYB-1binding to thePIK3CAgenepromoter.a,MDA-MB-231 cellswere seededat 60%confluency (1.2106) in 100-mmdishes
and transiently transfectedwithNp63orNp63plasmid (5g). After formaldehyde cross-linking, theDNA-proteins complexeswere immunoprecipitated
(IP) with anti-p63 (4A4) antibody. ImmunoprecipitatedDNAwas PCR-amplifiedwith PIK3CApromoter oligonucleotides and 18 S rRNAoligonucleotides (right).
Thedataobtained fromtheChIP assayweremeasuredbydensitometry andarepresentedas signal relative to the input (left).b,MDA-MB-231 cellswere seeded
at 60% confluency (1.2  106) in 100-mm dishes and transiently transfected with 3FLAG empty vector or 3FLAG-YB-1 (5 g) plasmid with or without
Np63 (2.5 g) expression vector. The cells were cross-linked with formaldehyde, and DNA-protein complexes were immunoprecipitated with anti-FLAG
antibody or irrelevant IgG antibody as negative control. The DNA immunoprecipitates were analyzed by quantitative PCR using PIK3CA or GAPDH promoter
oligonucleotides. Quantitative RT-PCR results were analyzed with the CT method and expressed as fold of enrichment with respect to the IgGAb control
samples. Values are represented as the mean of three independent experiments. c, SCC011 cells at 85% confluency were fixed with formaldehyde, and the
DNA-protein complexes were subjected to sequential ChIP with anti-p63 (4A4), anti-YB-1(Ab12148), or irrelevant IgG antibody as described under “Experi-
mental Procedures.” Immunoprecipitated DNA was PCR-amplified with PIK3CA promoter primers and 18 S rRNA primers to check the quality of the input
chromatin and the cleaning of the other samples.
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round in shape, and under high density culture conditions, they
appear orderly arranged with tight cell-cell contacts. Con-
versely, Np63-depleted cells tend to lose their contacts and
exhibited an unusual extended phenotype that was distinct
from that of the control cells cultured at the same density (Fig.
10a). The unusual change in morphology of Np63-depleted
cells indicated possible alterations in actin cytoskeleton organi-
zation. Therefore, we examined the status of actin stress fibers
at the level of individual cells, in control and Np63-depleted
cells, with TRITC-phalloidin followed by fluorescent micros-
copy. As shown in Fig. 10b, the control cells exhibited a diffuse
pattern of actin staining, although Np63-depleted cells dis-
played a more substantial enhancement of actin stress fibers sug-
gesting an inhibitory effect of Np63 on cancer cell motility.
Remarkably, compared with the control cells, Np63-depleted
SCC011 cells express higher levels of N-cadherin and lower
amounts of E-cadherin, suggesting that theywere undergoing epi-
thelial to mesenchymal trans-differentiation (Fig. 10c).
We determined the influence of Np63 on cell motility by
time-lapse microscopy using siRNA-based silencing of endog-
enous Np63 in SCC011 cells. Silencing efficiency was about
90% as determined by fluorescent staining for p63 protein (data
not shown). SCC011 migration was characterized by oscilla-
tions of the cells around their initial adhesion site. These oscil-
lations occurred at random directions in space, as reported in
the windrose plots of the trajectories (Fig. 10d, inset). Con-
versely, Np63 silenced cells display much wider oscillations
(Fig. 10d). These observationswere confirmed by the analysis of
themigration parameters “Speed (S)” and “persistence time (P)”
that are computed from cell tracks and are a measure of the
frequency of cell steps and of the minimum time that is neces-
sary for a cell to significantly change direction. According to
these parameters, SCC011 exhibit lower speeds (p 0.05) and
shorter persistence times (0.26  0.03 m/min and 6.5  0.7
min) with respect to Np63-depleted cells (0.44  0.05
m/min and 8.2  2.3 min). These data indicate a role for
Np63 in affecting cell motility. In particular, the absence of
Np63 causes the cells to migrate faster with less frequent
direction changes, which enables the cells to explore larger
areas in a fixed time interval.
To gain a better insight into the effects of the interaction of
Np63 and YB-1 on cell migration, we used the genetically
modified Tet-On-H1299 cells expressing Np63 upon Dox
addition (Fig. 11a). Cells were transfected with GFP or GFP-
FIGURE9.Np63affectsSNAIL1protein level andYB-1binding toSNAIL1andYB-1mRNAs inMDA-MB-231cells.a,MDA-MB-231cellswere transfected
with an empty vector (mock) or a fixed amount (1g in 60-mm dishes) ofNp63 orNp63 expression vector. 24 h after transfection, cells were harvested,
and total extractswereprepared. 20gof eachextractwere loadedonSDS-PAGEand subjected to immunoblotwith the indicated antibodies.b,MB-MDA-231
cells were transfected with an empty vector or Np63 encoding plasmid. 24 h after transfection, total RNA was purified and retrotranscribed as described
under “Experimental Procedures.” The expression level of Np63 was checked by immunoblot (right panel). WB, Western blot. PCR was performed with
primers designed to specifically amplify SNAIL1, TWIST, or HPRT transcripts and analyzed by agarose gel electrophoresis (left panel). Plot showing the level of
SNAIL1 and TWIST transcripts was normalized respect to HPRT. Values are the mean of three independent experiments (lower panel). Nuclear extracts from
Np63 transfected MB-MDA-231 cells were immunoprecipitated with anti-YB-1 antibody. After reverse cross-linking, the YB-1-bound RNA was purified,
retrotranscribed, and subjected to quantitative RT-PCR analysis using oligonucleotides designed to specifically amplify SNAIL1 transcript (c) or YB-1 transcript
(d). Plots represent the % of enrichment of SNAIL1/YB-1 transcript normalized as indicated under “Experimental Procedures.” 1:50 of the input extract was
loaded as control. The values are the means S.D. of three biological replicates.
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FIGURE 10. Np63 affects cell shape and motility. a, SCC011 cells were transiently silenced with IBONI p63-siRNA pool (20 nm final concentration). Cells
were fixedand subjected todouble immunofluorescence48hafter silencing, as alreadydescribed.b,proteinextracts fromcontrol andp63-depletedcellswere
separated by SDS-PAGE and subjected to immunoblot. Proteins were detected with specific antibodies. c, actin staining with TRITC-conjugated phalloidin of
control and Np63-depleted SCC011 cells (see “Experimental Procedures”). Cell expressing Np63 displayed a round morphology. Conversely, Np63-
depleted cells had a polarized morphology with more evident lamellipodia and trailing edge. d,windrose plot of trajectories described by Np63 depleted
SCC011or SCC011 control cells (inset) in 12-h time lapse video. Only 15 cell trajectorieswere reported in eachplot for graphical clarity. E-cad, E-cadherin;N-cad,
N-cadherin.
FIGURE 11. Effects ofNp63 and YB-1 on cell migration. a, after being subjected to themigration experiment, extracts from Tet-On H1299 cells, induced
(dox) or not (dox) with doxycycline, were prepared and subjected to immunoblot analysis to monitor Np63 induced expression. b, trajectories of
GFP/YB-1- or GFP (insets)-transfected cells. Inducible H1299/Np63 cells were transfectedwith a fixed amount of GFP-YB-1(1g) or GFP empty vector (1g).
4 h after transfection, 2g/ml doxycycline was added to induceNp63 expression, and 16 h later uninduced (Dox) and induced (Dox) cells were tracked
with optical microscopy. Plots represent data from the following number of cells (YB-1/dox 79; YB1/dox 69; control/dox 44; control/dox 49). c, bar
chart of speed (S; gray bars) and persistence ratios (P;white bars). The ratios are computed by dividing the population average values of speed and persistence
for H1299 control cells ( Dox) and Np63-expressing cells ( Dox).
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YB-1 plasmid, and unfluorescent and fluorescent cells were
tracked separately. Cells migrated describing trajectories that
are randomly distributed in plane, as depicted in plots of Fig.
10b. In Dox-free medium (Dox), GFP-YB-1-expressing cells
were characterized by a significantly higher S and lower P
(0.69 0.04 m/min and 8.4 0.5 min) than cells expressing
GFP alone (0.54  0.05 m/min and 15  2.1 min). Remark-
ably, in Dox-supplemented medium (Dox), GFP-YB-1-ex-
pressing cells exhibited S andP values (0.62 0.05m/min and
9.2  1.0 min), which were not significantly different from
those of cells transfected with GFP alone (0.68 0.05 m/min
and 8.6  0.9 min) (Fig. 10c). We also noticed that unfluores-
cent cells were characterized by the highest S values suggesting
that expression of the green fluorescent protein alters cell
migration to some extent (data not shown). However, S of
unfluorescent cells with or withoutDoxwas comparable. Over-
all, these data indicate that Np63 expression can revert the
increase of cell motility induced by YB-1-enforced expression.
DISCUSSION
In normal epithelium, Np63 protein expression is abun-
dant in basal cells and decreases with differentiation (35). Tran-
sient overexpression of Np63 was shown to enhance cell
proliferation, inhibit differentiation, and promote malignant
conversion of primary keratinocytes (36, 37). However,
enhanced and stable expression of Np63, as seen in human
squamous cell carcinomas, is believed to alter skin homeostasis
and be directly implicated in the etiology of human cutaneous
carcinomas. In normal cells, YB-1 is mainly detected in the
cytosol, particularly at the perinuclear region, with a minor
pool located in the nucleus (38). Nuclear localization of YB-1
appears to be critical for its role in promoting proliferation. In
fact, in the nucleus YB-1 may not only act as a transcription
factor of various genes that are closely associated with DNA
replication, cell proliferation, andmultidrug resistance but also
exert SOS signaling against genotoxic factors that could under-
mine the integrity of highly proliferative basal cells.
This report unveils a novel protein-protein association
involvingNp63 andYB-1. This specific association results in
the accumulation of nuclear YB-1, as shown by immunofluo-
rescence assays and nuclear-cytoplasmic fractionation. More-
over, we have demonstrated that Np63 and YB-1 cooperate
in PIK3CA gene activation with both being recruited to the
PIK3CA proximal promoter, thereby supporting the hypothesis
that this molecular association can function as a pro-survival
mechanism. It’s worth mentioning, however, that additional
mechanisms have been described to activate and translocate
YB-1 to the nucleus (8).
Into the cytoplasm, YB-1 is known to act as a positive trans-
lational regulator of SNAIL1, a potent epithelial to mesenchy-
mal transition inducer able to reduce cell-cell adhesion and
increase migratory properties of cancer cells (33). Accordingly,
we have observed that enforced expression of YB-1 in tumor
cells increases their motility and migration speed. Remarkably,
we have shown that Np63-enforced expression reduces the
activating binding of YB-1 to the SNAIL1 transcript and
restores a normal migratory behavior to YB-1-overexpressing
cells. However, depletion of endogenous Np63 in SCC cells
results in SNAIL1 up-regulation, E-cadherin repression, and
increased cell motility.
Finally, cytoplasmic YB-1 is known to bind to actin filaments
and causes actin fibers to bundle in vitro (39). It was also dem-
onstrated that YB-1 plays a relevant role in the organization of
the actin cytoskeleton by binding to F-actin and microtubules
(40, 41). In normal conditions, SCC011 cells are round in shape
and exhibit a more diffuse actin distribution, as determined by
phalloidin staining. Here, we show that Np63 depletion in
SCCcellspromotesmorphological changesandcauses aprofound
cytoskeleton reorganization. Np63-depleted cells had a polar-
izedmorphologywithmoreevident lamellipodiaand trailingedge.
They also exhibited mature stress fibers suggesting a pro-migra-
tory behavior. The alterations in cell morphology and motility of
Np63-depleted SCC cells closely resemble the process of epi-
thelial to mesenchymal transition (28). We can speculate that the
absence ofNp63 can promote F-actin polymerization by YB-1
thereby promoting the formation of stress fibers.
All together, our data indicate that Np63-YB-1 associa-
tion into the nucleus can act as a pro-proliferative/survival
mechanism, although the loss of p63 predisposes the acquisi-
tion ofmesenchymal characteristics at least in part by restoring
YB-1 cytoplasmic functions.Moreover, we suggest that the bal-
ance betweenNp63 and YB-1 protein levels could be critical
for the transition to a mesenchyme-like phenotype explaining,
at least in part, why Np63 depletion promotes cancer cell
invasion and spreading (35).
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Abstract  
Cutaneous squamous cell carcinomas (SCCs) typically lack somatic oncogene‐activating mutations 
and most of them contain p53 mutations. However, the presence of p53 mutations in skin 
premalignant lesions suggests that these represent early events during tumor progression and 
additional alterations may be required for SCC development. SCC cells frequently express high 
levels of ΔNp63α and Y‐box binding 1 (YB‐1 or YBX1) oncoproteins. Here, we show that 
knockdown of YB‐1 in spontaneously immortalized HaCaT and non‐metastatic SCC011 cells led to a 
dramatic decrease of ΔNp63α, cell detachment and death. In highly metastatic SCC022 cells, 
instead, YB‐1 silencing induces PI3K/AKT signaling hyperactivation which counteracts the effect of 
YB‐1 depletion and promotes cell survival. In summary, our results unveil a functional cross‐talk 
between YB‐1, ΔNp63α and the PI3K/AKT pathway critically governing survival of squamous 
carcinoma cells. This article is protected by copyright. All rights reserved  
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Introduction 
Squamous cell carcinoma (SCC) is a treatment-refractory malignancy arising within the epithelium 
of different organs, that is frequently associated with overexpression of ΔNp63α oncoprotein 
(Rocco et al., 2006, Hibi et al., 2000). ΔNp63α is encoded by the TP63 locus, the ancestral gene of 
the p53 gene family that gives rise to multiple isoforms that can be placed in two categories: TA 
isoforms with an acidic transactivation domain and ΔN isoforms that lack this domain. Alternative 
splicing at the carboxy-terminal (C-terminal) generates at least three p63 variants (α, β and γ) in 
each class (Rossi et al., 2006, Yang et al., 1999). ΔNp63α is essential for the maintenance of the 
proliferative capacity of epithelial cell progenitors (Senoo et al., 2004); as these cells start to 
differentiate, ΔNp63α protein level gradually drops and those that no longer express ΔNp63α, loose 
the proliferative capacity (Koster, 2010).    
In squamous carcinoma, ΔNp63α up-regulation causes skin hyperplasia and abnormal keratinocyte 
differentiation predisposing to malignant transformation (Hibi et al., 2000; Moll and Slade, 2004).  
Despite its undisputed relevance in epithelial cancer, the mechanisms through which ΔNp63α 
executes its pro-oncogenic functions are not fully understood. However, ΔNp63α expression was 
shown to be induced by activation of downstream targets of EGFR activation including STAT3 
(Ripamonti et al., 2013) and the phosphoinositide-3-kinase (PI3K) pathway (Barbieri et al., 2003).  
We have recently shown that ΔNp63α interacts with the YB-1 oncoprotein and promotes 
accumulation of YB-1 into the nuclear compartment (Di Costanzo et al., 2012; Amoresano et al., 
2010). YB-1, also named YBX1, is a member of the cold shock domain (CSD) protein family, 
which is found in the cytoplasm and nucleus of mammalian cells, being able to shuttle between the 
two compartments (Eliseeva et al., 2011). The YB-1 gene, located on chromosome 1p34 (Toh et al., 
1998), encodes a 43 kDa protein having three functional domains: a variable NH2-terminal 
Alanine/Proline rich tail domain (aa 1-51), involved in transcriptional regulation, a highly 
conserved nucleic acid binding domain (CSD, aa 51-171), and a COOH-terminal tail (B/A repeat) 
for RNA/ssDNA binding and protein dimerization (129-324). 
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YB-1 is a major downstream target of Twist (Shiota et al., 2008) and c-Myc-Max complexes by 
recruitment to the E-box consensus sites in YB-1 promoter (Uramoto et al., 2002).  YB-1 regulates 
genes promoting cancer cell growth such as EGFR, Her-2, PI3KCA and MET (To et al., 2010) as 
well as genes linked to cancer stem cells such as those encoding the hyaluronan receptor CD44, 
CD49f (integrin α6) and CD104 (β4 integrin), implying that YB-1 plays a key role as oncogene by 
transactivating genes associated with a cancer stem cell phenotype (To et al., 2010). YB-1 protein 
level drastically increases during progression of several types of tumors including squamous 
carcinoma, thereby suggesting a role for this protein in the pathogenesis of human epithelial 
malignancy (Di Costanzo et al., 2012, Kolk et al., 2011). 
To mediate gene regulation, YB-1 translocates into the nucleus and interacts with the proximal 
promoter regions of its target genes (Sutherland et al., 2005; Shiota et al., 2011). Phosphorylation of 
serine 102 in response to MAPK and PI3K/AKT signaling promotes YB-1 nuclear translocation 
(Sinnberg et al., 2012). Moreover, YB-1 translocates to the nucleus when cells are exposed to 
cytokines, anticancer agents, hyperthermia, or UV light irradiation (Schittek et al., 2007).  
Herein, we present data showing the existence of a functional cross-talk between YB-1, ΔNp63α 
and the PI3K/AKT signaling pathway critically governing survival of squamous carcinoma cells. 
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MATERIALS AND METHODS 
Plasmids 
The 1.1 Kb EGFR promoter luciferase plasmid was provided by Dr. A.C. Johnson (US National 
Cancer Institute, Massachusetts, USA). The cDNA encoding human ΔNp63α and ΔNp63α F518L 
were previously described (Lo Iacono et al., 2006).  
 
Cell lines, transfection  and antibodies  
SCC011 and SCC022 cell lines were established from cutaneous squamous carcinomas (Lefort et 
al.,  2007). SCC011 and SCC022 cells were cultured in RPMI supplemented with 10% fetal bovine 
serum at 37°C and 5% CO2. HaCaT and MDA-MB231 cells were purchased from Cell Line Service 
(CLS, Germany) and cultured at 37°C and 5% CO2. HaCaT cells were maintained in DMEM 
supplemented with 10% FBS. MDA-MB231 cells were maintained in DMEM supplemented with 
5% FBS.   
 
Transient transfection 
Lipofections were performed with Lipofectammine 2000 (Life Technologies, CA, USA), according 
to the manufacturer’s recommendations. 
YB1 transient silencing was carried out with IBONI YB-1siRNA pool (RIBOXX GmbH, Germany) 
and RNAiMAX reagent (Life Technologies, CA, USA), according to the manufacturer’s 
recommendations. Briefly, cells were seeded at 60% confluence (1.5 × 106) in 100-mm dishes and 
transiently silenced with IBONI YB1-siRNA at 20 nM final concentration.  
YB-1 guide sequences:  
UUUAUCUUCUUCAUUGCCGCCCCC; 
 UUAUUCUUCUUAUGGCAGCCCCC;  
UUCAACAACAUCAAACUCCCCC;  
UCAUAUUUCUUCUUGUUGGCCCCC.  
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ΔNp63α transient silencing was carried out with  IBONI p63-siRNA pool (RIBOXX GmbH, 
Germany) at 20 nM final concentration and RNAiMAX reagent (Life Technologies, CA, USA).  
p63 guide sequences:  
UUAAACAAUACUCAAUGCCCCC;  
UUAACAUUCAAUAUCCCACCCCC;  
AUCAAUAACACGCUCACCCCC;  
AUGAUUCCUAUUUACCCUGCCCCC. 
 “All Star Negative Control siRNA”, provided by Quiagen (Hilden, Germany), was used as negative 
control.  
Transfection efficiency of siRNA was quantified using BLOCK-iT™ Control Fluorescent Oligo 
(Life Technologies, CA, USA) at a final concentration of 20 nM using Lipofectamine RNAiMAX 
(Life Technologies, CA, USA).  Cells were stained with Hoechst and transfected cells detected by 
direct immunofluorescence. Transfection efficiency ranged between 70 and 80% .The percentage of 
transfected cells was estimated as the average of counts performed on 100 cells in five independent 
fields.  
Immunoblot analyses and coimmunoprecipitation  
Immunoblots (IB) were performed as previously described (Di Costanzo et al., 2012). Briefly, 30 
μg of whole cell extracts were separated by SDS-PAGE, subjected to immunoblot and incubated 
overnight at 4°C with antibodies.  
For nuclear-cytoplasmic fractionation 10 μg of nuclear and 30 μg of cytoplasmic extracts (1:3 rate) 
were separated by SDS-PAGE and subjected to immunoblot.  
All images were acquired with CHEMIDOC (Bio Rad, USA) and analyzed with the Quantity-ONE 
software. 
Coimmunoprecipitation was performed as previously described (Rossi et al., 2006). Briefly, whole 
HaCaT cell extracts, precleared with 30 μl of protein A-agarose (50% slurry; Roche, Manheim, 
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Germany), were incubated overnight at 4°C with anti-p63 (2 μg) or α-mouse IgG. The reciprocal 
experiment was performed with anti-YB-1(3 μg) or α-rabbit IgG (3 μg).  
 
Antibodies and chemical reagents 
Anti-p63 (4A4), anti-cytokeratin 1 (4D12B3), anti-GAPDH (6C5), and anti-actin (1-19) were 
purchased from Santa Cruz (Biotechnology Inc. CA, USA). PARP, PTEN, AKT,  pAKT S473 , 
EGFR and STAT3 antibodies were from Cell Signaling Technology (Beverly, Massachusetts). 
Rabbit polyclonal YB1 (Ab12148) antibody was purchased from Abcam (Cambridge, UK).  
Proteasome inhibitor MG132 were purchased from Sigma-Aldrich (St Louis, MO) and used at 10 
μM final concentration in DMSO (Sigma-Aldrich, St Louis, MO).  LY294002 was purchased from 
Calbiochem (CA, USA) and used at 50 μΜ final concentration in DMSO.  
Cell Viability assay 
Cell viability was determined by the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide assay (Sigma-Aldrich, St Louis, MO). Briefly, cells were seeded in 96-well plates at 2 x 
103 and transfected with scrambled or YB-1 siRNA oligos, 48h after silencing  MTT solution 
(5mg/ml in PBS, 20 μl/well) was added to cells to produce formazan crystals. MTT solution was 
substituted by 150 μl DMSO 30 minutes later to solubilize the formazan crystals. The optical 
absorbance was determined at 570 nm using an iMark microplate reader (Bio-Rad, USA). The 
experiments were carried out in triplicate for each knockdown and compared to scrambled control 
(value set at 1.0). 
 
Quantitative Real Time-PCR 
For PCR analysis total RNA was isolated using the RNA Extraction Kit  from Qiagen (Hilden, 
Germany) according to the manufacturer’s instructions. RNA (2-5µg) was treated with DNAse I 
(Promega, Madison USA) and used to generate reverse transcribed cDNA using SuperScript III 
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(Life Technologies, CA, USA),  according to the manufacturer’s instructions. All samples in each 
experiment were reverse transcribed at the same time, the resulting cDNA diluted 1:5 in nuclease-
free water and stored in aliquots at –80°C until used.  
Real Time PCR with SYBR green detection was performed with a 7500 RT-PCR Thermo Cycler 
(Applied Biosystem, Foster City, USA). The thermal cycling conditions were composed of 50ºC for 
2 min followed by an initial denaturation step at 95ºC for 10 min, 45 cycles at 95ºC for 30s, 60ºC 
for 30s and 72ºC for 30s. Experiments were carried out in triplicate. The relative quantification in 
gene expression was determined using the 2-ΔΔCt method (Livak and Schmittgen, 2011). Using this 
method, we obtained the fold changes in gene expression normalized to an internal control gene and 
relative to one control sample (calibrator). 18S was used as an internal control to normalize all data 
and the siCtrl was chosen as the calibrator. 
Appropriate no-RT and non-template controls were included in each 96-well PCR reaction and 
dissociation analysis was performed at the end of each run to confirm the specificity of the reaction.  
YB1(F):5’CGCAGTGTAGGAGATGGAGAG 
YB1(R):5’GAACACCACCAGGACCTGTAA 
ΔNp63 (F):5’GGTTGGCAAAATCCTGGAG 
ΔNp63 (R):5’GGTTCGTGTACTGTGGCTCA 
EGFR (F) :5’TTCCTCCCAGTGCCTGAA 
EGFR (R):5’GGGTTCAGAGGCTGATTGTG 
STAT3 (F) :5’CCTCTGCCGGAGAAACAG 
STAT3 (R):5’CTGTCACTGTAGAGCTGATGGAG 
GADD45A (F): 5’ TTTGCAATATGACTTTGGAGGA 
GADD45A (R): 5’ CATCCCCCACCTTATCCAT 
18S (F):5’TCGAGGCCCTGTAATTGGAA 
18S (R):5’CTTTAATATACGCTATTGGAGCTG 
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Luciferase reporter assay  
MDA-MB231 cells were co-transfected with ΔNp63α, ΔNp63α F518L and EGFR promoter-
luciferase reporter vector. Transfections were performed in triplicate in each assay. At 24h after 
transfection, cells were harvested in 1x PLB buffer (Promega, Madison, USA) and luciferase 
activity was measured using Dual Luciferase Reporter system (Promega, Madison, USA) using 
pRL-TK activity as internal control. FireFly-derived luciferase activity was normalized for 
transfection efficiency. Successful transfection of p63 was confirmed by immunoblotting. The 
average values of the tested constructs were normalized to the activity of the empty construct.  
 
Immunofluorescence and bright -field images acquisition 
HaCaT cells (2.5 x 105) were plated in 35 mm dish, grown on micro cover glasses (BDH). At 24 
hours after seeding, cells were washed with cold phosphate-buffered saline (PBS) and fixed with 
4% paraformaldehyde (PFA) (Sigma-Aldrich, St. Louis, MO) for 15 min at 4°C. Cells were 
permeabilized with ice-cold 0.1% Triton X-100 for 10 min, washed with PBS and incubated with 
Thermo Scientific Hoechst 33342 (2'-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,5'-bi-1H-
benzimidazole trihydrochloride trihydrate) for 3 min.  Images were digitally acquired at  470 nm 
using Nikon TE Eclipse 2000 microscope and processed using Adobe Photoshop software CS. 
SCC022 cells (2.5 x 105) were plated in 35 mm dish and grown on micro cover glasses (BDH). At 
24 hours after seeding, cells were transfected with scramble , YB-1 or p63 siRNA oligos. 48 hrs 
after silencing cells were washed with cold phosphate-buffered saline (PBS) and fixed with 4% 
paraformaldehyde (PFA) (Sigma-Aldrich, St. Louis, MO) for 15 min at 4°C. Cells were 
permeabilized with ice-cold 0.1% Triton X-100 for 10 min and then washed with PBS. P63 was 
detected using a 1:200 dilution of the monoclonal antibody D9 (Santa Cruz, Biotechnology Inc., 
CA, USA). YB-1 was detected using 1:100 dilution of the YB1 antibody (Ab12148). After 
extensive washing in PBS, the samples were incubated with Cy3-conjugated anti-mouse  (red) and 
Cy5-conjugated anti-rabbit IgGs (green)  at room temperature for 30 min. Cells were incubated with 
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Hoechst 33342 (2'-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,5'-bi-1H-benzimidazole 
trihydrochloride trihydrate) (Thermo Scientific) for 3 min. Images were digitally acquired and 
processed using Adobe Photoshop software CS. 
 
Cell motility assay 
SCC022 cells were cultured on 35-mm dishes (Corning, NY) at 2x104 cells/dish density. 
ΔNp63α or YB1 transient silencing were performed as described above. After 24 h from silencing 
cell migration tests were performed via an Olympus IX81 inverted microscope equipped with a 10X 
objective and an integrated stage incubator (Okolab, Italy). Images of selected positions of the cell 
culture were collected in bright field for 16 h with 5-min frame intervals. All of the collected data 
were processed with the Olympus imaging software Cell^R. To quantify the cell speed (μm/min), 
time-lapse acquisitions were processed by the dedicated software add-in (TrackIT). The average 
speed per cell was calculated from the length of the path divided by time. An average number of 60 
cells were analyzed for each condition.  
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Results 
YB-1 knockdown in HaCaT cells 
We have previously shown that ΔNp63α interacts with YB-1 in human squamous carcinoma cells 
and promotes accumulation of full length YB-1 protein (50 kDa) in the nuclear compartment (Di 
Costanzo et al., 2012). We first validated the interaction between YB-1 and ΔNp63α in non 
transformed HaCaT keratinocytes by co-immunoprecipitation assay (Supplementary Fig. 1). Then, 
we examined the effect of YB-1 silencing in mitotically active HaCaT keratinocytes. Interestingly, 
at 48 hrs of silencing we observed massive cell detachment (Figure 1A, upper panel) associated 
with a high proportion of condensed and fragmented nuclei (Figure 1A, lower panel). Western blot 
analysis showed a significant reduction of ΔNp63α protein level and PARP1 proteolytic cleavage 
(Figure 1B, left panel) indicating that YB-1 is critical for keratinocyte survival.  
ΔNp63α is known to sustain survival in squamous cell carcinoma (Rocco et al., 2006, Hibi et al., 
2000) and up-regulate cell adhesion-associated genes (Carrol et al., 2006). To rule out the 
possibility that YB-1 silencing induces cell death by merely reducing the level of ΔNp63α, we 
knocked down ΔNp63α expression in HaCaT cells by RNA interference. According to previous  
studies (Barbieri et al., 2006), we observed neither cell detachment (Figure 1A, upper panel) nor 
PARP1 activation (Figure 1B, right panel) clearly indicating that apoptosis, induced by YB-1 
depletion, cannot be simply ascribed to the lack of ΔNp63α.  
Next, we evaluated the level of ΔNp63α-specific transcript following YB-1 knockdown by Real 
Time quantitative PCR (RT-qPCR) and we found that it was drastically reduced (Figure 1C). After 
p63 silencing, instead, YB-1 transcript level was slightly enhanced (Figure 1D) while  the mRNA of 
GADD45A, a gene induced by stressful conditions and used as control, was enhanced in both 
experiments (Figure 1C and D).  
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YB-1 knockdown in squamous carcinoma cells 
Next, we used RNA interference to explore the function of YB-1 in squamous cell carcinoma 
(SCC). SCC011 and SCC022 are cell lines derived from cutaneous squamous carcinomas (Lefort et 
al., 2007). SCC022 are highly metastatic and, when subcutaneously injected in nude mice, form 
large tumors. SCC011 cells, instead, generate only keratin pearls (C. Missero, personal 
communication).  
Similarly to what observed in HaCaT cells, YB1-depleted SCC011 cells detached from the plate 
generating abundant cellular debris (Figure 2A, upper panel) and exhibited a reduced level of 
ΔNp63α protein (Figure 2B). PARP1 cleavage was barely detectable (Figure 2B). On the other 
hand, we have previously demonstrated that p63 knockdown has no apparent effect on SCC011 cell 
viability (Di Costanzo et al., 2012).  
Surprisingly, SCC022 cells looked healthy and tightly adherent to the plate after YB1 silencing 
(Figure 2A, lower panel). Moreover, as detected by immunoblot analysis, the expression level of 
ΔNp63α protein was significantly increased (Figure 2B).  Interestingly, ΔNp63α transcript in 
SCC011 was reduced while in SCC022 it was 2.1-fold higher than control (Figure 2C).  
Analysis of cell viability by the MTT assay showed that after 48 hrs of YB-1 knockdown the 
percentage of viability of SCC022 cells was 70% of the control, while it was reduced to 10% in 
HaCaT and SCC011 cells (Figure 4C).  
We have also performed p63 knockdown in SCC022 cells and, as expected, we observed 
accumulation of YB-1 in the cytoplasm without any apparent effect on cell viability 
(Supplementary Fig. 2).  
We also determined the influence of ΔNp63α or YB-1 silencing on SCC022 cell motility by time-
lapse microscopy using siRNA-based silencing of endogenous proteins. According to our previous 
observations made on SCC011 cells (Di Costanzo et al., 2012) ΔNp63α silenced cells display 
higher speeds (p < 0.01) than control cells. Conversely,  SCC022 cell motility was unaffected by 
YB-1 depletion (Supplementary Fig. 3). 
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YB-1 silencing hyper-activates the PI3K/AKT signaling pathway in SCC022 cells 
ΔNp63α is a target of the phosphoinositide-3-kinase (PI3K) pathway downstream of the Epidermal 
Growth Factor Receptor (Barbieri et al., 2003). We hypothesized an involvement of the PI3K/AKT 
pathway in the upregulation of ΔNp63α observed in SCC022 cells following YB-1 silencing, and 
we looked for changes in the phosphorylation status of AKTSer473. Interestingly, unlike HaCaT and 
SCC011, SCC022 cells exhibited constitutive phosphorylation of AKTSer473 which was reproducibly 
potentiated following YB-1 depletion (Figure 3A and B) suggesting that YB-1 expression restrains 
AKT activation. To corroborate this result, we treated YB1-silenced SCC022 cells with Ly294002, 
a highly selective PI3K inhibitor. Remarkably, Ly294002 treatment counteracted AKT 
hyperphosphorylation and the increase of ΔNp63α protein level in response to YB-1 silencing 
(Figure 3B).  Moreover, it resulted in cell death and detachment (data not shown). Importantly, 
Ly294002 treatment alone had no apparent effect on ΔNp63α level and SCC022 cell viability 
(Figure 3B and data not shown). Quantification of ΔNp63α transcript in YB-1 depleted SCC022 
cells, treated or not with LY294002, showed that the increase of ΔNp63α transcription was strictly 
dependent on the PI3K/AKT pathway (Figure 3B). Moreover, inhibition of the proteasome activity 
with MG132 did not significantly enhance ΔNp63α protein level in YB1-silenced SCC022 cells, 
thereby confirming that ΔNp63α up-regulation was almost exclusively at transcriptional level 
(Supplementary Fig. 4).  
The PI3K/AKT signaling pathway is negatively regulated by the phosphatase and tensin homologue 
PTEN (Song et al., 2012). To further investigate on the ability of SCC022 cells to escape from 
death following YB-1 depletion, we compared the protein level of PTEN among HaCaT, SCC011 
and SCC022 cell lines. Compared to HaCaT and SCC011 cells, the  level of PTEN protein in 
SCC022 cells was very low, accounting for their high basal level of AKTSer473 phosphorylation 
(Figure 3E). Furthermore, YB-1 silencing resulted in increased levels of cytoplasmic PTEN in 
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HaCaT and SCC011 cells, while no effects on PTEN protein level was observed in YB-1 silenced 
SCC022 cells (Figure 3E).  
 
Cross-talk of ΔNp63α and YB-1 with EGFR/STAT3 and  PI3K/AKT signaling pathways  
In pancreatic cancer cells, ΔNp63α expression was shown to induce the Epidermal Growth Factor 
Receptor (EGFR) (Danilov et al.,  2011). As we observed a PI3K-dependent increase of ΔNp63α in 
SCC022 cells upon YB-1 silencing, we decided to evaluate the level of EGFR and its direct 
downstream target STAT3 in SCC022 cells upon YB-1 or ΔNp63α silencing. As shown in Figure 4, 
along with ΔNp63α, YB-1 depletion up-regulates EGFR and STAT3 both at protein (Figure 4A) 
and RNA level (Figure 4B). Real Time PCR assay in SCC022 cells clearly shows that YB-1 
silencing results in about 2 and 3.5 fold induction of EGFR and STAT3 transcripts, respectively 
(Figure 4B). Following ΔNp63α silencing, instead, the expression of both EGFR and STAT3 was 
switched off although the level of YB-1 protein remained unaltered (Figure 4A). These results 
suggest that ΔNp63α is a major activator of the EGFR/STAT3 axis in squamous carcinoma cells. 
Accordingly, in SCC011 and HaCaT cells where YB-1 silencing reduces ΔNp63α, EGFR and 
STAT3 transcription was also reduced (Supplementary Fig. 5A and B).  
To confirm the ability of ΔNp63α to regulate EGFR gene expression we performed transient 
transfection and luciferase reporter assays in MDA-MB231 breast cancer cells expressing no 
detectable p63.  MDA-MB231 cells were transiently transfected with the EGFR promoter-luciferase 
vector and increasing amount of expression plasmid encoding wild type ΔNp63α  or its mutant 
form bearing  the F to L substitution at position 518 of the SAM domain. This mutant was 
previously described to be transactivation defective (Radoja et al., 2007). Remarkably, wild type 
but not mutant ΔNp63α protein induced luciferase activity, in a dose-dependent manner (Figure 4C 
and D). Moreover, Western blot analysis of extracts from MDA-MB231 breast cancer cells 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved 
 
transiently transfected with ΔNp63α showed induction of both EGFR and STAT3 endogenous 
proteins, confirming that EGFR and STAT3 expression are induced by ΔNp63α (Figure 4E).   
 
DISCUSSION 
YB-1 is a versatile protein associated with many malignancies. However, because of its 
multifunctional character, the role of YB-1 in neoplastic cell growth remains elusive (Bader et al., 
2006).  
Our previous (Di Costanzo et al., 2012) and present data show that ΔNp63α hyper-expression, as it 
occurs in squamous carcinoma cells, is associated with YB-1 nuclear localization where it is 
expected to play a pro-proliferative role. In the present manuscript we show that YB-1 depletion has 
a strong negative impact on cell survival of both immortalized HaCaT keratinocytes and non-
metastatic SCC011 squamous carcinoma cells. Interestingly, in HaCaT and SCC011 cells, YB-1 
knockdown causes a significant reduction of ΔNp63α transcription (Yang et al., 1999; Senoo et al., 
2004). However, in HaCaT and SCC cells, ΔNp63α knockdown is not sufficient to trigger cell 
death thereby indicating that YB-1, in keratinocytes, plays additional p63-independent pro-survival 
functions. 
Surprisingly, in highly metastatic SCC022 cells, YB-1 silencing does not result in cell death. 
Strikingly, in these cells, YB-1 silencing potentiates AKT activation suggesting that YB-1 can act 
as a negative regulator of the PI3K/AKT signaling pathway and its loss allows PI3K/AKT-
dependent induction of pro-survival genes, including ΔNp63α. Interestingly, the low level of 
endogenous PTEN observed in SCC022 cells can likely explain the constitutive activation of the 
PI3K/AKT pathway observed in this cell line. Remarkably, we have observed only in HaCaT and 
SCC011 cells a strong activation of PTEN in response to YB-1 depletion. In SCC022 cells, instead, 
where PI3K/AKT hyper-activation sustains ΔNp63α protein level, we did not observe any increase 
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of PTEN after YB-1 depletion. However, at this stage, we can hypothesize that, in this cell line, 
PTEN cannot be up-regulated because of epigenetic or other inactivating mechanisms.  
The evidence that PI3K/AKT hyperactivation in SCC022 cells is responsible for ΔNp63α 
transcriptional induction is in line with previous studies showing that ΔNp63α is positively 
regulated by the PI3K pathway (Barbieri et al., 2003). However, it is important to remind that 
ΔNp63α has been shown to repress the expression of PTEN (Leonard et al., 2011). Accordingly, in 
PTEN-proficient HaCaT and SCC011 cells, where YB-1 silencing causes a decrease of ΔNp63α, 
we observed an increase in the level of PTEN protein which is expected to restrain signaling by the 
PI3K pathway. 
In summary, our results indicate that, being able to sustain ΔNp63α gene expression, YB-1 is part 
of a complex molecular network linking ΔNp63α to the PI3K/AKT/PTEN pathway and that 
establishment of a positive feedback loop coupling induction of ΔNp63α expression with 
PI3K/AKT activation may be a relevant step in progression of squamous carcinogenesis.  
An important finding of our work is the observation that ΔNp63α controls the expression of the 
Epidermal Growth Factor Receptor switching-on the entire EGFR/STAT3 axis. Accordingly, in 
normal adult epidermis, the EGFR is predominantly expressed in basal keratinocytes and signaling 
events elicited by it are known to affect their proliferation and migration (Bito et al., 2011). 
ΔNp63α, therefore, represents an important molecular connection between YB-1, the PI3K/AKT 
and the EGFR/STAT3 signaling pathways. We can postulate that constitutive activation of 
PI3K/AKT, such as in PTEN-deficient cells, may likely cause persistence of ΔNp63α which can 
induce keratinocyte hyper-proliferation by impinging on the EGFR/STAT3 pathway. Interestingly, 
in physiological conditions EGF-dependent and PI3K/AKT pathways are both required for efficient 
skin wound re-epithelialization (Haase et al., 2003). Moreover, EGFR/STAT3 inhibition was shown 
to be unable to induce apoptosis (Bito et al., 2003) thereby providing a plausible explanation of why 
ΔNp63α silencing alone was not sufficient to induce cell death in our experimental settings.  
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In summary, we have presented clear evidences to suggest that YB-1 can play a role in skin 
carcinogenesis. However, the molecular basis of cancer can widely vary and the ability of YB-1 to 
control multiple and overlapping pathways raises concerns about the consideration of YB-1 as an 
attractive target for therapy against metastatic squamous cancer. In particular, our results indicate 
that YB-1 knockdown in cells whose oncogenic transformation depends on PI3K/AKT constitutive 
activation is expected to enhance rather than arrest metastatic progression. Association of YB1-
targeted therapy with drugs that target the PI3K and/or EGFR pathway should be evaluated as a 
valuable strategy to treat squamous carcinoma. In vivo experiments will help to clarify this relevant 
point.  
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Figures Legend 
 
Figure 1. YB-1 knockdown affects HaCaT cell survival. (A) upper panel, Phase-Contrast 
imaging and  Hoechst staining (lower panel) showing HaCaT keratinocyte cells transfected with 
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scrambled, YB-1 or p63 siRNA oligos. (B) Representative immunoblot analyses of HaCaT 
keratinocytes transfected with YB1 (upper panel), p63 (lower panel) or scrambled (siCtrl) 
siRNA oligos, respectively.  48 hours after silencing whole cell extracts were immunoblotted 
with YB-1, p63 and PARP antibodies. Actin was used as a loading control. Bar graphs are 
quantitative densitometric analyses of four indipendent Western blots. The blots were 
normalized to actin and the fold-changes of protein levels are reported in comparison to control 
(value set at 1.0). P-value <0.05 is represented by *; P-value <0.01 is represented by **. (C) 
Quantitative real-time PCR analysis of HaCaT keratinocytes transfected with scrambled or YB-1 
siRNA oligos. GADD45A mRNA level was measured as a control. (D) Quantitative Real-time 
PCR analysis of HaCaT keratinocytes transfected with scrambled or p63 siRNA oligos. In both 
experiments data were analyzed according to the fold-changes compared to scrambled control 
(value set at 1.0) using the 2-ΔΔCt method. P-value <0.05 is represented by *; P-value <0.01 is 
represented by **. 
 
Figure 2. YB-1 knockdown in SCC011 and SCC022 squamous carcinoma cells. (A) Phase-
contrast imaging showing SCC011 (upper panel) and SCC022 (lower panel) cells at 48 hours 
post-YB1 silencing.  (B) Representative immunoblot analysis of SCC011 or SCC022 cells 
transfected with scrambled or YB-1 siRNA oligos. 48 hours after silencing whole cell lysates 
were immunoblotted with YB-1, p63 and PARP antibodies. GAPDH was used as a loading 
control. Bar graph is a quantitative densitometric analysis of four indipendent Western blots. The 
blots were normalized to GAPDH and the fold-changes of protein levels are reported in 
comparison to control (value set at 1.0). P-value <0.05 is represented by *; P-value <0.01 is 
represented by **. (C) Quantitative Real-time PCR analysis of SCC011 (left panel) and SCC022 
cells (right panel) transfected with scrambled or YB-1 siRNA oligos. Data were analyzed 
according to the fold-changes compared to scrambled control (value set at 1.0) using the 2-ΔΔCt 
method. P-value <0.05 is represented by *; P-value <0.01 is represented by **. (D) Effect of 
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YB1 silencing on the viability of HaCaT and SCC cells. Cell viability was assessed by MTT 
assay following 48 hours of YB-1 silencing. Data are represented as the mean +/- SD from three 
independent experiments. The asterisk indicates P-value<0.05. 
 
Figure 3. YB-1 knockdown enhances pAKTS473  in SCC022 squamous carcinoma. (A) 
Immunoblot analysis of HaCaT, SCC011 and SCC022 cells transfected with scrambled or YB1-
siRNA oligos.  48 hours after silencing whole cell extracts were immunoblotted with YB-1, 
pAKTS473 and AKT antibodies. Actin was used as a loading control. (B) SCC022 cells were 
transfected with scrambled or YB-1 siRNA oligos transfection. After 42 hrs cells were treated 
with LY294002 for 6 hrs. Whole cell extracts were analyzed by immunoblotting with YB-1, 
pAKTS473, p63 and AKT antibodies. Actin was used as loading control. (C) Quantitative Real-
time PCR of ΔNp63 mRNA levels. ΔNp63 mRNA levels were analyzed according to the fold-
changes compared to scrambled control (value set at 1.0) using the 2-ΔΔCt method. P-value < 0.05 
is represented by *; P-value < 0.01 is represented by **. DMSO was used as control (D) 
Immunoblot analysis of HaCaT, SCC011 and SCC022 cells. Whole cell extracts were 
immunoblotted with, PTEN,  pAKTS47 , and AKT antibodies. GAPDH was used as loading 
control. (E) Nuclear and cytoplasmic fractionation of extracts from control or YB-1 silenced 
HaCaT, SCC011 and SCC022 cells are shown in Figure 5A. Fractions were analysed by 
immunoblotting with PTEN antibody. GAPDH and PARP were used as cytoplasmic and nuclear 
controls, respectively. 
 
Figure 4. Cross-talk of ΔNp63α and YB-1 with EGFR/STAT3 pathway. (A) Immunoblot 
analysis of SCC022 cells transfected with scramble, YB-1 or p63 siRNA oligos. Whole cell 
extracts were immunoblotted with, YB-1, p63, EGFR, STAT3 antibodies. Actin was used as a 
loading control. (B)  Quantitative Real-time PCR analysis of SCC022 cells transfected with 
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scrambled or YB-1 siRNA oligos. YB-1, EGFR and STAT3 mRNA levels  were analyzed 
according to the fold-changes compared to scrambled control (value set at 1.0) using the 2-ΔΔCt 
method. P-value < 0.05 is represented by *; P-value < 0.01 is represented by **. (C) Luciferase 
assay of EGFR-promoter activity in MDA-MB231 cells. Cells were  transiently transfected with 
1μg of luciferase reporter plasmid and the indicated amounts of ΔNp63α or ΔNp63α F518L 
plasmids. Luciferase assay was performed at 48 hrs post-transfection. Values are the mean +/- 
SD of three independent experimental points. (D) Representative immunoblotting showing the 
level of ΔNp63α in transfected MDA-MB231 cell extracts used for the luciferase assay shown in 
7C. GAPDH immunodetection was used as loading control. (E) MDA-MB231 cells were 
transfected with empty vector or ΔNp63α plasmids. At 24h post-transfection cells were 
harvested and whole cell extracts were analyzed by immunoblotting with p63, STAT3 and 
EGFR antibodies. Actin was used as a loading control. 
 
Supplementary Figures 
S1. YB-1 and ΔNp63α coimmunoprecipitation in HaCaT cells. (A) Extracts from HaCaT 
cells were immunoprecipitated with anti-p63 antibodies and the immunocomplexes were blotted 
and probed with anti-YB-1, as indicated. (B) Extracts from HaCaT cells were 
immunoprecipitated with anti-YB-1 antibodies and the immunocomplexes were blotted and 
probed with anti-p63. Samples with no antibody (no Ab) or irrelevant α-mouse and α-rabbit 
antibodies were included as controls. (C) Immunoblot analysis of YB-1 level in HaCaT cells 
treated with proteasome inhibitor MG132 for 6h (5μM final concentration). 36kDa and 43kDa 
YB-1 forms are reduced with concomitant accumulation of full-length YB-1 50kDa band 
showing the identity of YB-1 bands. 
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S2. YB-1 and p63 knockdown in SCC022 cells. (A) Immunofluorescence assay in SCC022 
cells transfected with scrambled, YB-1 or p63 siRNA oligos. YB1 was detected using anti-YB-1 
and secondary anti-rabbit Cy5-conjugated (green) antibodies. p63 was detected using anti-p63 
and secondary anti-mouse Cy3-conjugated (red) antibodies. Hoechst was used to stain nuclei. (B) 
(upper panel) SCC022 cells were incubated with normal mouse serum and secondary anti-mouse 
Cy3-conjugated (red) antibodies; (lower panel) SCC022 cells were incubated with normal rabbit 
serum and secondary anti-rabbit Cy5-conjugated (green) antibodies. 
 
S3. Effect of p63 and YB-1 silencing on SCC022 cells migration speed. (A) Motility assay on 
SCC022 cells after transient silencing of p63 and YB-1 performed by time-lapse microscopy. 
fter 24 h of incubation with siRNA oligos, cell migration assay was performed. Averaged cell 
speeds after 16 h of observation are reported. Horizontal lines and boxes and whiskers represent 
the medians, 25th/75th, and 5th/95th percentile, respectively. P-value < 0.01 is represented by 
**. Only statistically different doubles are marked. (B) Immunoblot analysis of ΔNp63α and 
YB-1 protein levels in SCC022 cells after 40 h of ΔNp63α or YB-1 silencing and used in cell 
migration assay. Cell extracts were blotted and probed with anti-p63 or anti-YB-1 antibodies. 
GAPDH was used as a loading control. ΔNp63α protein band was almost undetectable while 
YB-1 protein was reduced to 40%, as assed by densitometric scanning.  
 
S4. Proteasome activity is not involved in ΔNp63α up-regulation upon YB-1 silencing. 
Immunoblot analysis of SCC022 cells transfected with scrambled or YB1-siRNA oligos and 
treated with MG132 (6 hrs) after 42 hours of YB-1 silencing cells. Whole cell extracts were 
immunoblotted with YB-1 and p63 antibodies. Actin was used as loading control.  
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S5. Effect of YB-1 silencing on EGFR/STAT3 mRNA levels in SCC011 and HaCaT cells. 
Quantitative Real-time  PCR analysis of (A) SCC011 cells and (B) HaCaT cells transfected with 
scrambled or YB-1 siRNA oligos. YB-1, EGFR and STAT3 mRNA levels were analyzed 
according to the fold-changes compared to scrambled control (value set at 1.0) using the 2-ΔΔCt 
method. P-value < 0.05 is represented by *; P-value < 0.01 is represented by **. 
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A B S T R A C T
Poly(ADP-ribose)polymerase 1 (PARP-1) inhibitors are thought as breakthrough for cancer treatment in
solid tumors such as breast cancer through their effects on PARP’s enzymatic activity. Our previous
ﬁndings showed that the hydrophilic PARP inhibitor PJ34 enhances the sensitivity of p53 proﬁcient
MCF7 breast carcinoma cells to topotecan, a DNA Topoisomerase I (TOP 1) inhibitor.
In the present study, we combine the classical TOP 1 poison camptothecin or its water-soluble
derivative topotecan with PJ34 to investigate the potentiation of chemotherapeutic efﬁciency in MCF7
(p53WT), MDA-MB231 (p53mut) breast carcinoma cells and SCC022 (p53null) squamous carcinoma cells.
We show that, following TPT-PJ34 combined treatment, MCF7 cells exhibit apoptotic death while
MDA-MB231 and SCC022 cells are more resistant to these agents. Speciﬁcally, in MCF7, (i) PJ34 in
combination with TPT causes a G2/M cell cycle arrest followed by massive apoptosis; (ii) PJ34 addition
reverts TPT-dependent PARP-1 automodiﬁcation and triggers caspase-dependent PARP-1 proteolysis;
(iii) TPT, used as a single agent, stimulates p53 expression while in combination with PJ34 increases p53,
TAp63a and TAp63g protein levels with a concomitant reduction of MDM2 protein.
The identiﬁcation of p63 proteins as new players involved in the cancer cell response to TPT-PJ34 is
relevant for a better understanding of the PARP1-dependent signaling of DNA damage. Furthermore, our
data indicate that, in response to TPT-PJ34 combined chemotherapy, a functional cooperation between
p53 and TAp63 proteins may occur and be essential to trigger apoptotic cell death.
 2013 Elsevier Inc. All rights reserved.
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/b io c hem p har m1. Introduction
Poly(ADP-ribose)polymerase (PARP) inhibitors are touted as a
breakthrough for cancer treatment in solid tumors such as triple
negative breast cancer and ovarian cancer through their effects on
PARP-1’s enzymatic ADP ribosylation activity [1]; however, less
characterized PARP-1 additional functions have also been
reported and they can be critical for successful anticancer
therapies.
PARPs are involved in the regulation of many cellular processes
such as DNA repair, cell cycle progression and cell death [2]. PARP-
1 and PARP-2 are constitutive factors of the DNA damage
surveillance network, acting as DNA break sensor [3] and several
observations indicate that poly(ADP-ribosyl)ation plays an early
role in DSB signaling and repair pathways [4,5]. PARP-1 and 2 are
highly activated upon binding to DNA strand interruptions and
synthesize, within few seconds, large amounts of ADP-ribose
polymer (PAR) on several nuclear proteins including themselves,
histones, DNA-Topoisomerase 1 (TOP 1) and DNA-dependent* Corresponding author. Tel.: +39 081 679165; fax: +39 081 679233.
E-mail address: quesada@unina.it (P. Quesada).
0006-2952/$ – see front matter  2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.bcp.2013.01.019protein kinase (DNA-PK) [6,7]. Furthermore, in response to DNA
damage, PARP-1 interacts with both ATR and ATM kinases
suggesting another susceptible pathway for PARP inhibitors
induced apoptosis. [8].
Cell cycle checkpoint activation and growth arrest in response
to DNA damage rely on the ATM/ATR kinases and their
downstream targets like p53 [9–11]. p53 activates p21WAF which
binds PARP-1 during base excision repair [12].
Certain PARP inhibitors including PJ34 induce a G2/M arrest
when used in conjunction with methylating agents [13] cisplatin
[14] and TOP I poisons such as camptothecin (CPT) or its water-
soluble derivative topotecan (TPT) [15], highlighting the existence
of potentially different outcomes from PARP inhibition whose
molecular mechanisms have not yet been conclusively deter-
mined.
In brief, TOP I inhibitors reversibly abolish the DNA religation
activity of TOP I generating single strand breaks (SSBs) to which
the protein is covalently linked. Double strand breaks (DSBs)
arise when replication forks collide with the SSBs and run off.
Thus, CPT/TPT-induced DSBs are replication dependent or S
phase speciﬁc and are usually repaired by the HR pathway
[16,17]. According with previous ﬁndings poly(ADP-ribos)ylated
PARP-1 and PARP-2 counteract CPT through non covalent but
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inhibition of DNA cleavage and stimulation of the religation
reaction [6].
We have previously shown that PJ34 can positively or
negatively modulate p53 and its target p21WAF depending of
the cell genetic background or DNA damage stimulus (i.e. cisplatin
or TPT) [18–20]. Indeed, regulating p21WAF expression is one
model whereby PARP inhibitors, following the activation of
different checkpoint pathways, can cause cell cycle arrest. It has
recently been reported that in breast carcinoma MCF7 cells, PJ34
causes a p21WAF-dependent mitotic arrest and that neither PARP-
1 nor p53 is required for this mechanism [21]. Furthermore, in
triple negative breast cancer cell lines, PJ34 synergizes with
cisplatin by reducing the levels of DNp63a with a concurrent
increase of p21WAF [22].
DNp63a is a member of the p53 protein family highly
expressed in squamous cell carcinoma and invasive ductal breast
carcinoma [23,24]. DNp63a and p53 have been shown to inversely
regulate target genes such as p21WAF in the context of DNA
damage [22,25]. Owing to the presence of two promoters, the p63
gene encodes two major classes of proteins: those containing a
transactivating (TA) domain homologous to the one present in p53
(i.e. TAp63) and those lacking it (i.e. DNp63) [24]. In addition,
alternate splicing at the carboxy-terminal (C-terminal) generates
at least three p63 variants (a, b and g) in each class. The TAp63g
isoform resembles most p53, whereas the a isoforms include a
conserved protein–protein interaction domain named Sterile
Alpha Motif (SAM). TAp63 proteins mimic p53 function including
transactivating many p53 target genes and inducing apoptosis,
whereas the DNp63a protein, has been shown to repress p53-
target genes acting as an oncogene [24,26].
On the light of all these evidences, the use of chemical inhibitors
of PARP in combination with TOP I inhibitors CPT or TPT appears to
be a promising approach to enhance the antitumour activity of
these compounds.
Here, we have investigated the effect of PJ34 used as a single
agent or in association with CPT or TPT in the DNA damage
response of mammary breast cancer cells (MCF7p53wt and MDA-
MB231p53mut) and squamous carcinoma cells (SCC022p53null)
showing an active involvement of p63 in the cellular response
to these agents. We postulate that the sensitivity to combined
treatments is mediated by sustained DNA damage/inefﬁcient DNA
repair triggering p53 and p63-mediated apoptosis.
2. Materials and methods
2.1. Drugs, media, antibodies and chemicals
CPT and TPT was from Glaxo Smith-Kline (Verona, Italy) and
PJ34 [N-(6-oxo-5,6,-dihydrophenanthridin-2-yl)-(N,N-dimethyla-
mino) Acetamide] from Alexis Biochemicals (Vinci-Biochem,
Firenze, Italy). The cocktail of protease inhibitors was from
ROCHE-Diagnostic (Milano, Italy).
MCF7, MDA-MB231 and SCC022 cells were from CLS Cell Lines
Service (Eppelheim, Germany) Dulbecco’s modiﬁed Eagle’s medi-
um (DMEM), heat-inactivated foetal bovine serum (FBS) and
Roswell Park Memorial Institute (RPMI) medium were from
Invitrogen (GIBCO, Milano, Italy); penicillin, streptomycin and L-
glutamine were from LONZA (Milano, Italy).
Nicotinamide adenine [adenylate-32P] dinucleotide-[32P]-NAD+
(1000 Ci/mmole, 10 mCi/ml) was supplied by GE Healthcare
(Milano, Italy).
PVDF (poly-vinylidene-ﬂuoride) membrane was from MILLI-
PORE S.p.A. (Milano, Italy). Not-fat-milk power was from EURO-
CLONE (Milano, Italy). Anti-DNA TOP I (Scl-70) human antibody
from Topogen (ABCAM, Cambridge, UK). Anti-PARP1 mousemonoclonal antibody (C2-10), anti-p63 (4A4), anti-p53 (DO-1),
anti-p21WAF (F-5), anti-cyclin B1 (V152), anti AIF (E-1) and anti-
GAPDH (6C5) mouse monoclonal antibodies and anti-actin (H-
196) rabbit polyclonal antibody were from Santa-Cruz Biotechnol-
ogy (DBA, Milano, Italy). Anti-gH2AX (ser139, 2577) and anti-Bax
(D2E11) rabbit polyclonal antibodies were from Cell Signaling
(Invitrogen, Milano, Italy). Anti-MDM2 (Ab-2) mouse monoclonal
antibody was from Oncogene Research Products (Boston, USA).
Anti-PAR (10H) mouse monoclonal antibody was from Alexis
Biochemicals (Vinci-Biochem, Firenze, Italy). Goat anti-mouse and
goat anti-rabbit IgG HRP-conjugated antibodies were from Sigma–
Aldrich (Milano, Italy).
All other chemicals analytical grade were of the highest quality
commercially available.
2.2. Cell cultures
Breast cancer-derived MCF7p53wt and MDA-MB231p53mut cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 10% (v/v) heat-inactivated foetal bovine serum (FBS),
while squamous SCC022p53 null carcinoma cells were maintained in
Roswell Park Memorial Institute (RPMI) medium containing 10%
(v/v) FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 5 mM L-
glutamine and incubated at 37 8C in a humidiﬁed atmosphere, plus
5% CO2.
2.3. Cell treatments
Cells were seeded at 1  106 cells in 10 ml and 24 h after
seeding, treated with 1 mM CPT (stock solution 1 mM DMSO) or
5 m; TPT,10 concentration inhibiting cellular growth by 50%
(IC50) [27]. 10 mM or 20 mM PJ34 alone and in combination, for
48 h in fresh medium. Culture medium was removed and, after PBS
wash, cells were recovered 6  106 cells/ml in 50 mM Tris–HCl pH
7.5, 150 mM NaCl, 5 mM EDTA, 1% NP40 (Lysis Buffer) plus 2 mM
PMSF and 1:25 dilution of protease inhibitors cocktail solution.
After 40 min of incubation on ice, cellular suspensions were
scraped and centrifuged at 16,000  g for 20 min at 4 8C.
Cell growth inhibition was assessed by cell counting at different
time points (0–24 48 h) or by the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay using 1  104 48 h
treated cells. The experiments were performed in triplicate.
2.4. Isolation of nuclear and post-nuclear fractions
To isolate sub-cellular fractions, 3  106 cells were suspended
in 200 ml of 30 mM Tris–HCl pH 7.5 buffer, containing, 1.5 mM
MgCl2, 10 mM KCl, 1% (v/v) Triton X-100, 20% glycerol, 2 mM PMSF
and 1:25 dilution of protease inhibitors cocktail solution. After
30 min of incubation on ice, cellular suspensions were centrifuged
at 960  g for 90 s at 4 8C and the nuclear fractions recovered in the
pellet. The supernatant represents the cytoplasmic fraction.
Nuclear fractions were resuspended in 50 ml of 20 mM HEPES
pH 7.9 buffer, containing 20 mM KCl, 0.2 mM EDTA, 1.5 mM MgCl2,
25% glycerol and the protease inhibitors cocktail solution. Protein
concentration was determined using the Bradford protein assay
reagent (BIO-RAD Milano, Italy) with bovine serum albumin as a
standard.
2.5. Cytoﬂuorimetric analysis
Control and treated cells were ﬁxed in 70% ethanol and stored at
20 8C until analysis. After a washing in PBS w/o Ca2+/Mg2+, cells
were stained in 2 ml of propidium iodide (PI) staining solution
[50 mg/ml of PI, 1 mg/ml of RNAse A in PBS w/o Ca2+/Mg2+, pH 7.4]
overnight at 4 8C and DNA ﬂow cytometry was performed in
Fig. 1. Cell growth inhibition in MCF7, MDA-MB231 and SCC022 cells treated with CPT/TPT and PJ34 as single agents or in combination. Cells (104 cells/plate) were treated
48 h with CPT 1 m; or TPT 5 m; and 10 or 20 m; PJ34 alone or in combination: (A) MCF7 cell growth was measured by cell counting at different time points. Data refer to at
least three experiments giving similar results. (B) 48 h treated MCF7, MDA-MB231 and SCC022 cells were used for determination of cell growth inhibition by MTT assay. Each
plot represents the media of triplicates from three independent experiments.
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Lakes, NJ, USA) coupled with a CICERO work station (Cytomation).
Cell cycle analysis was performed by the ModFit LT software
(Verity Software House Inc., Topsham, ME, USA). FL2 area versus
FL2 width gating was done to exclude doublets from the G2/M
region. For each sample 15,000 events were stored in list mode ﬁle.
2.6. Analysis of [32P]-PAR synthesis
Following treatment with CPT/TPT  PJ34 of intact cell
(5  104cells/plate), [32P]-PAR synthesis was determined by substi-
tuting the culture medium with 1 ml of 50 mM HEPES pH 7.5 buffer,
containing 28 mM KCl, 28 mM NaCl, 2 mM MgCl2, 0.01% digitonin,
0.1 mM PMSF, 1:25 dilution of a cocktail of protease inhibitors,
0.125 mM NAD+ and 5 mCi [32P]-NAD+ (1000 Ci/mmole). After
incubation at 37 8C for 15 mins, cells were scraped, transferred to
eppendorf tubes and mixed with TCA at 20% (w:v) ﬁnal concentration.
After 90 min standing on ice, samples were collected by centrifuga-
tion at 12000 rpm for 15 min, washed twice with 5% TCA and three
times with ethanol. [32P]-PAR incorporated in the TCA-insoluble
fraction was measured by Cerenkov counting using a LS8100 liquid
scintillation spectrometer (Beckman Coulter S.p.A. Milano, Italy).
Finally, TCA protein pellets were resuspended in Laemmli buffer;
proteins were separated by 10% SDS-PAGE and after electroblotting
on PVDF membrane, [32P]-PAR acceptors were visualized by
autoradiographic analysis by the PhosphorImager (BIO-RAD). Immu-
nodetection of speciﬁc proteins was accomplished on the same blots
after autoradiography.
2.7. Immunological analyses
Aliquots of 10 ml of cellular proteins (approx 50–100 mg) were
separated by 10% SDS-PAGE and transferred onto a PVDF
membrane using an electroblotting apparatus (BIO-RAD). The
membrane was subjected to immunodetection after blocking
with 5% non-fat milk in TBST 1 h, with anti-PARP1 (C2-10; diluted
1:2500), anti-TOP I (Scl-70; diluted 1:1000), anti-PAR (10H;
diluted 1:500), anti-p63 (4A4; diluted 1:2000), anti-p53 (DO-1;
diluted 1:5000), anti-p21WAF (F-5; diluted 1:1000), anti-MDM2
(Ab-2; diluted 1:1000), anti-cyclin B1 (V152; diluted 1:1000),
anti-gH2AX (2577; diluted 1:1000), anti-Bax (D2E11; diluted
1:1000), anti AIF (E1; diluted 1:2000), anti-GAPDH (6C5;
diluted 1:5000), anti-actin (H-196; diluted 1:2000) overnight at
room temperature.
As secondary antibodies goat-anti-mouse or goat-anti-rabbit
IgG HRP-conjugate (diluted 1:5000–1:10,000) in 3% (w/v) non-fatmilk in TBST were used. Peroxidase activity was detected using the
ECL Advance Western Blot Kit of GE Healthcare (Milano, Italy) and
quantiﬁed using the Immuno-Star Chemiluminescent detection
system GS710 (BIO-RAD) and the Arbitrary Densitometric Units
normalised on those of the GAPDH loading control.
3. Results
3.1. Effect of PJ34 on TPT/CPT-induced growth inhibition in human
carcinoma cells
The concentrations of the agents and the time points used in
this study were chosen on the basis of previously published data
[20,27]. Preliminary experiments, in breast carcinoma MCF7p53wt
cells, showed that 1 mM CPT inhibits cell growth similarly to 5 mM
TPT (Fig. 1A). To potentiate the CPT/TPT cytostatic effect, PJ34
concentrations were used in a sub-lethal range (10–20 mM). A 48-
h of exposure, corresponding approximately to two rounds of
MCF7p53wt cell replication, was used according to the administra-
tion procedure during anticancer therapy. As shown in Fig. 1A, at
24 h CPT/TPT treatment has a cytostatic effect, while PJ34 induces
growth retardation in a dose-dependent way, whereupon cells
start to recover but the rate of recovery was signiﬁcantly affected
by CPT-PJ34 combined treatment (Fig. 1A).
We next investigated the impact of CPT on MDA-MB231 and
SCC022 cell survival. MDA-MB231 express a mutant p53
(p53R280 K) while SCC022 cells are p53 null. Cells were plated,
treated with CPT for 48 h and subjected to the MTT assay to
compare viability of treated and untreated cells. As shown in
Fig. 1B, CPT signiﬁcantly reduces cell viability of all cell lines tested
(around 50% of control). Moreover, treatment with PJ34 alone
affects MCF7 and MDA-MB231 cell viability, in a dose-dependent
way, whereas SCC022 cells remain almost unaffected. Interesting-
ly, compared with single drug treatments, combination of PJ34
with CPT results in a signiﬁcant enhancement of cytotoxicity in
MCF7 cells (37–33% of cell survival) while in MDA-MB231 and
SCC022 cells addition of PJ34 to CPT has a lower impact on cell
survival (Fig. 1B). Similar results are observed when PJ34 is added
to TPT (data not shown).
We have previously reported that TPT at concentrations higher
than 1 mM promptly arrested the cells in S phase while
concentrations equal or lower than 1 mM cause a G2/M arrest
[20]. To gain insight into the molecular mechanism of TPT-PJ34
interactive cytotoxicity we analysed the cell cycle distribution of
MCF7 cells treated with 10 or 20 mM PJ34 alone or in combination
with 1 mM TPT. As shown in Fig. 2, after 48 h treatment, 1 mM TPT
Fig. 2. Cell cycle analysis of MCF7 cells subjected to TPT and PJ34 single and combined treatments. MCF7 cells were treated 48 h with TPT 1 m; and 10 or 20 m; PJ34 alone or
in combination. Control and treated cells (1  106) were ﬁxed in 70% ethanol and used for ﬂow cytometric analysis (see Section 2). Determination of DNA content after PI
staining is shown and cells in G1, S and G2 phase are indicated as percentage (excluded sub-G1 cells). The table reports sub-G1 cells as the percentage of the entire population
of cells. Data refer to one of three experiments giving similar results.
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phase and the cell cycle distribution is less affected by treatment
with PJ34 (10 or 20 mM) than TPT used as single agents.
Furthermore, addition of 10 or 20 mM PJ34 to 1 mM TPT causes
a signiﬁcant increase of G2/M cells, while S-phase cells are
drastically reduced. Fig. 2 (table) also shows that single treatments
cause an increase of cells with a sub-G1 DNA content (from 6 to
19%), probably due to induction of apoptotic cell death. Remark-
ably, an increase up to 55% of sub-G1 cells is observed with TPT
1 mM + PJ34 20 mM combined treatment, showing a 2 potentia-
tion factor of PJ34 on TPT cytotoxicity.Fig. 3. Western blot analysis of TOP I soluble fraction in carcinoma cells untreated or 48
100 mg of proteins) were subjected to 10% SDS-PAGE, electroblotted on PVDF and incu
Immunodetection in MCF7 (A), MDA-MB231 (B) and SCC022 (C) cells is shown. 0.1% DM
control.3.2. Analysis of CPT- or TPT-dependent TOP I inactivation
It is already known that CPT and TPT abolish the religation
activity of TOP I generating an abortive complex to which the
enzyme is covalently linked [16]. Therefore, we determined the
efﬁcacy of TOP I inhibitors by looking at their capacity of trapping the
enzyme in the abortive complex. This was detected, by looking at the
disappearance of the immunoreactive band of the TOP I soluble
fraction by western blot analysis. After 48 h of treatment, both 1 mM
CPT and 5 mM TPT are able to block, almost completely, the TOP I
enzyme in the abortive complex, in all cell lines tested (Fig. 3). h treated with the indicated drugs. Untreated and treated whole cell extracts (50–
bated with the anti-TOP I antibody.
SO treated cells were analysed as CPT internal control. GAPDH was used as loading
Fig. 4. Analysis of TPT-dependent PARP-1 activation or PJ34-dependent PARP-1 inhibition in carcinoma cells untreated or 48 h treated with the indicated drugs. Whole cell
extract (50–100 mg of proteins) after 10% SDS-PAGE and electroblotting on PVDF were either analysed by autoradiography or incubated with the different antibodies. (A)
Autoradiographic analysis, of whole cell protein extract from untreated and treated MCF7 cells incubated with 0.125 mM [32P]-NAD+ (see Section 2); (B) immunodetection of
PARP-1 on the blot shown in (A); (C) immunodetection of PARP-1 in whole cell protein extract from untreated and treated MDA-MB231cells; (D) immunodetection of PARP-1
in whole cell protein extract from untreated and treated SCC022 cells; (E) immunodetection of PAR on the blot shown in (D)
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enzyme trapping when used in combination with CPT or TPT.
3.3. Analysis of PAR synthesis in carcinoma cells after treatment with
TPT  PJ34
PJ34 efﬁcacy as PARP inhibitor was assessed by looking at its
effect on PARP-1 automodiﬁcation. Proliferating MCF7 cells were
exposed to the drugs and PAR synthesis was measured in situ by
incubation in the presence of 0.01% digitonin with 0.125 mM [32P]-
NAD+. Samples were then analysed by SDS-PAGE followed by
autoradiography. As shown in Fig. 4A, a smear of the signal above
the PARP-1 molecular weight (113 kDa) is strongly increased in
TPT treated cells compared to the untreated sample (Fig. 4A, lane
4). As previously reported [2] such a behaviour indicates
automodiﬁcation of PARP-1 by long and branched ADP-ribose
polymers (up to 200 residues in chain) on several sites (up to 25) of
the automodiﬁcation domain. This process gives raise to higher
molecular weight PARP-1 forms that do not enter the polyacryl-
amide gel matrix. The identity of the PAR modiﬁed protein was
conﬁrmed by western blotting using a PARP-1 antibody showing a
mobility shift of the immunoreactive band at the top of the gel
(Fig. 4B, lane 4). According to our observation, the autoradio-
graphic signals are absent in cells treated with the PARP-1 inhibitor
alone (Fig. 4A, lanes 2 and 3) or in combination with TPT (Fig. 4A,
lanes 5 and 6). Interestingly, TPT–PJ34 co-treatment in MCF7 cells
induced apoptosis as demonstrated by the appearance of the
85 kDa fragment generated by the caspase-dependent cleavage of
PARP-1 (Fig. 4B, lanes 5 and 6).
Immunoblot analysis with PARP-1 antibody was also
performed in MDA-MB231 cells subjected to the same treat-
ments. As shown in Fig. 4C, in TPT-treated cells PARP-1 is
automodiﬁed to a lower extent (lane 4) and there are no signs of
apoptosis induction after TPT-PJ34 combined treatment (Fig. 4C,
lanes 5 and 6).Furthermore, we analysed the response of SCC022 squamous
carcinoma cells to PJ34 and TPT treatment. Immunoblot with the
PARP-1 speciﬁc antibody reveals that PARP-1 is modiﬁed since the
unmodiﬁed 113 kDa band is strongly reduced (Fig. 4D, lanes 4 and
5). Accordingly, immunoblot using a PAR antibody shows a
smeared signal of long and branched polymers above the PARP-1
molecular weight (Fig. 4E, lanes 4 and 5). PJ34 co-treatment
drastically reduces TPT/CPT-induced PARP 1 automodiﬁcation thus
leading to the accumulation of the 113 kDa band of PARP-1.
However, we did not observe PARP-1 speciﬁc cleavage, thereby
suggesting that cells were not undergoing apoptosis albeit up to
50 mM PJ34 was used (Fig. 4D, lanes 6 and 7). All together, our
results suggest that, compared to MCF7, MDA-MB231 and SCC022
cells are less sensitive to the drugs combination and do not respond
immediately with apoptosis to TOP I and PARP-1 inhibitors co-
treatment.
3.4. Involvement of p63 in the cell response to TPT  PJ34 treatment
To get insight into the molecular mechanism underlying the
response of MCF7 cells to TPT  PJ34 treatment, we analysed the
expression of p53, p63 and other cell cycle markers such as p21WAF,
MDM2 and cyclin B1. In MCF7 cells we found that PJ34 addition to TPT
strongly enhances the TPT-dependent stimulation of p53 expression.
Remarkably, the p53 negative regulator MDM2 was down-regulated
only upon combined treatment (Fig. 5A). Furthermore, using the 4A4
monoclonal antibody which recognizes all p63 isoforms, we only
detected bands corresponding to the pro-apoptotic TAp63 a and g
isoforms; both isoforms are up-regulated by TPT–PJ34 co-treatments
(Fig. 5A). Quantitation of proteins by densitometric scanning, reveals
a 19–20-fold increase of the expression level for both p53 and p63
proteins after TPT–PJ34 20 mM treatment (Fig. 5B). The increase of
p21WAF expression level was concomitant to a decrease of cyclin B1
thereby supporting the G2/M cell cycle arrest observed by
cytoﬂuorimetric analyses.
Fig. 5. Western blot analysis of p53, p63, p21WAF, MDM2 and cyclin B1 expression in MCF7 cells untreated or 48 h treated with the indicated drugs.
Whole cell extract (50–100 mg of proteins) after 10% SDS-PAGE and electroblotting on PVDF were incubated with the different antibodies. (A) Immunodetection of p53, p63,
p21WAF, MDM2, cyclin B1.GAPDH was used as loading control; (B) p53 and TAp63 a and g band intensities were quantiﬁed by densitometric scanning. Data expressed as
Arbitrary Densitometric Units (ADU) were normalized to the internal control GAPDH. Shown are the mean of three different experiments  S.E.
Fig. 6. Western blot analysis of protein extract from nuclear and cytoplasmic fraction of MCF7 cells and from SCC02 cells untreated or 48 h treated with the indicated drugs.
Whole extract (50–100 mg of proteins) after SDS-PAGE and electroblotting on PVDF were incubated with the different antibodies. (A) Immunodetection of p53, p63, PARP-1,
gH2AX, BAX, AIF in nuclear (upper panel) and cytoplasmic (lower panel) fractions from MCF7 cells. Actin and GAPDH were used as loading controls, respectively; (B)
immunodetection of p63 and cyclin B1 in SCC022 cell extract. GAPDH was used as loading control.
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cytoplasmic fractions. Fig. 6A shows that following TPT  PJ34
treatment both p53 and TAp63g accumulate in the nuclear
compartment. Nuclear gH2AX expression and PARP-1 speciﬁc
cleavage were monitored as markers of dsDNA damage and
caspase-dependent apoptosis, respectively (Fig. 6A, upper panel).
Furthermore, the expression level of the pro-apoptotic BAX protein,
whose gene is transcriptionally activated by p53 and TAp63, increases
in the cytoplasmic fraction by either TPT alone or TPT–PJ34 combined
treatment, while the level of the mitochondrial apoptosis inducing
factor AIF is unaffected (Fig. 6A, lower panel).
Finally, as shown in Fig. 6B, in p53 null SCC022 cells, the
DNp63a anti-apoptotic isoform is dramatically down-regulated
by CPT/TPT treatment with or without PJ34. Cyclin B1 appears to be
concomitantly reduced suggesting a G2/M cell cycle arrest.
Importantly, using the 4A4 antibody, we were unable to detect
p63 isoforms other than DNp63a both in untreated and TPT  PJ34
treated SCC022 cells (data not shown). It has previously been
demonstrated that DNp63a is required for the survival of SCC cells
[27]. Interestingly, as shown in Fig. 4D, CPT/TPT  PJ34 treatments
was not sufﬁcient to induce apoptosis in these cells thereby
suggesting the existence of an alternative anti-apoptotic pathway
able to overcome DNp63a depletion. In MDA-MB231 cells, no p63
immunoreactive bands were seen in all experimental conditions
(data not shown) thereby excluding a possible role for p63 in
TPT  PJ34-induced cytotoxycity in this cellular context.
4. Discussion
The efﬁcacy of PARP inhibitors as chemosensitizers has led to
the development of a multitude of such molecules with different
bioavailability and pharmacokinetic properties that are currently
under investigation in clinical trials [1]. However, a clear
understanding of how PARP inhibitors potentiate the activity of
antineoplastic agents is still lacking.
The hydrophilic PARP inhibitor PJ34 has already been reported
to synergize with cisplatin- and TPT-dependent apoptotic induc-
tion in triple-negative breast cancer and human carcinoma cells
expressing wild type p53 [19–22]. We have already shown that
PJ34, at a concentration of 5 mM, inhibits PARP-1 activity without
cytotoxic effects. Furthermore, in HeLa and MCF7 cells we found
that TPT toxicity was higher when PAR synthesis was reduced by
either PARP-1 silencing or PJ34 administration [20].
In the present study, we compared the response of MCF7p53wt,
MDA-MB231p53mut and SCC022p53null cells to treatment with
higher concentration of PJ34 (up to 20 mM) in combination with
1 mM CPT or 5 mM TPT. According to the previously reported
speciﬁcity of PARP inhibitors for breast cancer [1,29], we observed
a higher sensitivity to PJ34 in MCF7p53wt cells. In such cells we
conﬁrmed that TPT, which is known to be S-phase speciﬁc [30],
causes a G2/M cell cycle arrest when used at a lower concentration
(1 mM). In addition, the TPT-dependent G2/M cell cycle arrest was
enhanced by TPT + PJ34 combined treatment and resulted in a
remarkable increase of cells with sub-diploid DNA, conﬁrming a
synergic cytotoxic effect of TOP I and PARP-1 inhibitors.
Consistent with the idea that poly(ADP-ribosyl)ation plays a
role in the response to CPT/TPT-induced DNA damage we observed
the disappearance of a TOP I soluble/active fraction and the PARP-1
automodiﬁcation in MCF7, MB-MDA231 and SCC022 cells thereby
indicating that the response to DNA damage, induced by TOP I
inhibitors, in skin squamous carcinoma cells is similar to that
observed in breast carcinoma cells [31].
On the other hand, we found that prevention of PARP-1
automodiﬁcation by PJ34 induces PARP-1 proteolysis only in
MCF7p53wt implying that apoptosis induced by inhibition of PAR
synthesis requires the p53 wild type activity. Given the similaritybetween p53 and p63 it was of interest to look at the effect of TOP
I + PARP-1 inhibitors on p63 protein isoforms. Interestingly,
TPT + PJ34 treatment in MCF7 cells causes a remarkable increase
of TAp63 a and g protein levels. TAp63g in particular, was reported
to be a potent apoptosis inducer [32]. Both p53 and TAp63g
accumulated in the nuclear fraction where the proteins can
functionally interact in the control of transcription. Consistently,
TPT + PJ34 combined treatment caused a dramatic reduction of
MDM2, a negative regulator of p53 transcriptional activity and
protein level.
Remarkably, this is the ﬁrst evidence of a PJ34-inducible pro-
apoptotic response involving both p53 and p63 family members in
breast carcinoma cells. Furthermore, in SCC022p53null cells we
show that CPT/TPT single or combined treatments suppressed the
endogenously expressed DNp63a anti-apoptotic isoform together
with cyclin B1. It has previously been demonstrated that DNp63a
is required for the survival of SCC cells by virtue of its ability to
suppress p73-dependent apoptosis [28]. However, CPT/TPT  PJ34
treatments is not sufﬁcient to induce apoptosis in these cells thereby
suggesting either the presence of a non-functional p73 or the
existence of an alternative anti-apoptotic pathway able to overcome
DNp63a depletion. Similarly, it has been reported that in MDA-
MB468 cells expressing high level of DNp63a, PJ34 reduced DNp63a
level, with a concomitant increase of p73. However, in that
manuscript, apoptosis induction was not evaluated [22].
Therefore, it can be postulated that carcinoma cells, depending
on their genetic background (p53/p63 null versus p53/p63
proﬁcient), can trigger a p53-dependent pathway to induce cell
cycle arrest and apoptosis, as a results of concomitant inhibition of
PARP-1 and TOP I. To this respect, the particular p63 isoform
expressed may sustain (TAp63a and g) or inhibit (DNp63a) the
execution of the apoptotic program.
Recently, it has been shown that PARP activity is required for
TOP I poisoning-mediated replication fork slowing [33] and
reversal [34]. In fact, PARP-1 is able to slow replication fork
progression in response to CPT-dependent HR DNA repair.
Furthermore, these data identify fork reversal as a means to
prevent chromosome breakage upon exogenous replication stress
and implicate still undeﬁned proteins involved in fork reversal or
restart as factors modulating the cytotoxicity of replication stress-
inducing chemotherapeutics.
We have identiﬁed p63 as a new player of the PARP1-dependent
signalling of DNA damage. Interestingly, in the p63 DNA binding
domain, both the PAR binding motif and the glutamic acid residues
showed to act as covalent PAR acceptor sites are conserved [35,36].
Our ﬁndings contribute to the understanding of the molecular
events triggered by TOP I and PARP-1 inhibitor-dependent
genomic damage and provide a rationale for the development of
new approaches to sensitize cancer cells to chemotherapy.
Acknowledgements
This work is dedicated to the memory of Dr Maria Malanga who
died in November 2011, her good spirit, her ideas, her friendship
and her energy are greatly missed by all her colleagues. We
acknowledge Dr. Daria Maria Monti and Dr. Angela Arciello for
their help with cell cultures.
References
[1] Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition:
PARP1 and beyond. Nat Rev Cancer 2010;10:293–301.
[2] Burkle A. Poly(ADP-ribosyl)ation. LANDES Biosci 2005.
[3] .Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage
signaling network. Biochem Cell Biol 2005;83(3):354–64.
[4] Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADPribose): novel function
for an old molecule. Nat Rev Mol Cell Biol 2006;7:517–28.
D. Montariello et al. / Biochemical Pharmacology 85 (2013) 999–10061006[5] Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K. .PARP1 ensures
regulation of replication fork progression by homologous recombination on
damaged DNA. J Cell Biol 2008;183:1203–12.
[6] Malanga M, Althaus FR. Poly(ADP-ribose) reactivates stalled DNA topoisomerase
I and induces DNA strand break resealing. J Biol Chem 2004;279(7):5244–8.
[7] Mitchell J, Smith GC, Curtin NJ. Poly(ADP-Ribose) polymerase-1 and DNA-
dependent protein kinase have equivalent roles in double strand break repair
following ionizing radiation. Int J Radiat Oncol Biol Phys 2009;75(5):1520–7.
[8] Haince JF, Kozlov S, Dawson VL, Dawson TM, Hendzel MJ, Lavin MF, et al. Ataxia
telangiectasia mutated (ATM) signaling network is modulated by a novel
poly(ADPribose)-dependent pathway in the early response to DNA-damaging
agents. J Biol Chem 2007;282:16441–53.
[9] Yoon JH, Ahn SG, Lee BH, Jung SH, Oh SH. Role of autophagy in chemoresis-
tance: regulation of the ATM-mediated DNA-damage signaling pathway
through activation of DNA-PKcs and PARP1. Biochem Pharmacol
2012;83(6):747–57.
[10] Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S,
et al. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -
independent DNA damage responses induced by DNA damaging agent. Cell
Cycle 2011;10(23):4074–82.
[11] Wieler S, Gagne’ JP, Vaziri H, Poirier GG, Benchimol S. Poly(ADP-ribose)
Polymerase-1 is a positive regulator of the p53-mediated G1 arrest response
following ionizing radiation. J Biol Chem 2003;278:18914–21.
[12] Cazzalini O, Dona` F, Savio M, Tillhon M, Maccario C, Perucca P, et al.
p21CDKN1A participates in base excision repair by regulating the activity
of poly(ADP-ribose) polymerase. DNA Repair 2010;9(6):627–35.
[13] Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy.
Pharmacol Res 2005;52:25–33.
[14] Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in
cancer treatment: a clinical perspective. Eur J Cancer 2010;46(1):9–20.
[15] Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-Ribose)
polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons
by increasing the persistence of DNA strand breaks. Clin Cancer Res
2005;11:8449–57.
[16] Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev
Cancer 2006;6:789–802.
[17] Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with
replication forks are predominantly repaired by homologous recombination
involving an exchange mechanism in mammalian cells. J Mol Biol
2001;307:1235–45.
[18] Cimmino G, Pepe S, Laus G, Chianese M, Prece D, Penitente R, et al. Poly(-
ADPR)polymerase-1 signaling of the DNA damage induced by DNA topoisom-
erase I poison in D54(p53 wt) and U251(p53mut) glioblastoma cell lines.
Pharmacol Res 2007;55(1):49–56.
[19] Gambi N, Tramontano F, Quesada P. Poly(ADPR)polymerase inhibition and
apoptosis induction in cDDP-treated human carcinoma cell lines. Biochem
Pharmacol 2008;75(12):2356–63.
[20] D‘Onofrio G, Tramontano F, Dorio AS, Muzi A, Maselli V, Fulgione D, et al.
Poly(ADP-Ribose) Polymerase signaling of topoisomerase 1-dependent DNA
damage in carcinoma cells. Biochem Pharmacol 2011;81:194–202.[21] Madison DL, Stauffer D, Lundblad JR. The PARP inhibitor PJ34 causes a PARP1-
independent, p21 dependent mitotic arrest. DNA Repair (Amst)
2011;10(10):1003–13.
[22] Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast
cancer cell lines to PARP inhibition, gemcitabine and cisplatin. Cancer Res
2010;70(20):7970–80.
[23] Di Costanzo A, Troiano A, di Martino O, Cacace A, Natale CF, Ventre M, et al. The
p63 Protein Isoform {Delta}Np63a Modulates Y-box Binding Protein 1 in Its
Subcellular Distribution and Regulation of Cell Survival and Motility Genes. J
Biol Chem 2012;287(36):30170–80.
[24] Di Costanzo A, Festa L, Roscigno G, Vivo M, Pollice A, Morasso M, et al. A
dominant mutation etiologic for human Tricho-Dento-Osseus syndrome
impairs the ability of DLX3 to downregulate DNp63a. J Cell Physiol
2011;226(8):2189–97.
[25] Schavolt KL, Pietenpol JA. p53 and Delta Np63 alpha differentially bind and
regulate target genes involved in cell cycle arrest, DNA repair and apoptosis.
Oncogene 2007;26:6125–32.
[26] Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Do¨tsch V, et al. p63, a p53
homolog at 3q27–29, encodes multiple products with transactivating, death-
inducing, and dominant-negative activities. Mol Cell 1998;2(3):305–16.
[27] Devy J, Wargnier R, Pluot M, Nabiev I, Sukhanova A. Topotecan-induced
alterations in the amount and stability of human DNA topoisomerase I in
solid tumor cell lines. Anticancer Res 2004;24(3a):1745–51.
[28] Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates
survival in squamous cell carcinoma by suppression of p73-dependent apo-
ptosis Cancer Cell 2006;9(1):45–56.
[29] Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Speciﬁc
killing of BRCA2-deﬁcient tumours with inhibitors of poly(ADP-ribose) poly-
merase. Nature 2005;434(7035):913.
[30] Feeney GP, Errington RJ, Wiltshire M, Marquez N, Chappell SC, Smith PJ.
Tracking the cell cycle origins for escape from topotecan action by breast
cancer cells. Br J Cancer 2003;88(8):1310–7.
[31] Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Complex response
of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res J
1998;18(4C):2919–32.
[32] Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Do¨tsch V, et al. p63. a p53
homolog at 3q27–29 encodes multiple products with transactivating death-
inducing and dominant-negative activities Mol Cell 1998;2(3):305–16.
[33] Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K. PARP-1 ensures
regulation of replication fork progression by homologous recombination on
damaged DNA. J Cell Biol 2008;183:1203–12.
[34] .Chaudhuri AR, Hashimoto Y, Herradori R, Neelsen KJ, Fachinetti D, Bermejo R,
et al. Topoisomerase I poisoning results in PARP-mediated replication fork
reversal. Nat Struct Mol Biol 2012;19(4):417–24.
[35] Malanga M, Pleschke JM, Kleczkowska HE, Althaus FR. Poly(ADP-ribose) binds
to speciﬁc domains of p53 and alters its DNA binding functions. J Biol Chem
2000;275:40974–80.
[36] Kanai M, Hanashiro K, Kim So H, Hanai S, Boulares HA, Miwa M, et al. Inhibition
of Crm1–p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation.
Nat Cell Biol 2007;9(10):1175–83.
Biochemical Pharmacology 94 (2015) 212–219Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I
inhibitors on the p53/p63-dependent survival of carcinoma cells
Daniela Montariello a, Annaelena Troiano a, Daniela Di Girolamo a, Sascha Beneke b,
Viola Calabro` a, Piera Quesada a,*
aDepartment of Biology, University of Naples ‘‘Federico II’’, Naples, Italy
b Institute of Pharmacology and Toxicology, University of Zurich-Vetsuisse, Zurich, Switzerland
A R T I C L E I N F O
Article history:
Received 5 December 2014
Accepted 21 January 2015
Available online 7 February 2015
Keywords:
Apoptosis
Carcinoma cells
p53/p63 targets
PJ34
Topotecan
A B S T R A C T
Depending on their genetic background (p53wt versus p53null), carcinoma cells are more or less sensitive
to drug-induced cell cycle arrest and/or apoptosis. Among the members of the p53 family, p63 is
characterized by two N-terminal isoforms, TAp63 and DNp63. TAp63 isoform has p53-like functions,
while DNp63 acts as a dominant negative inhibitor of p53. We have previously published that TAp63 is
involved in poly(ADP-ribose)polymerase-1 (PARP-1) signaling of DNA damage deriving from DNA
topoisomerase I (TOP I) inhibition in carcinoma cells.
In the present study, we treated MCF7 breast carcinoma cells (p53+/DNp63) or SCC022 (p53/DNp63+)
squamous carcinoma cells with the TOP I inhibitor topotecan (TPT) and the PJ34 PARP inhibitor, to compare
their effects in the two different cell contexts.
In MCF7 cells, we found that PJ34 addition reverts TPT-dependent PARP-1 auto-modiﬁcation and
triggers caspase-dependent PARP-1 proteolysis. Moreover, TPT as single agent stimulates p53ser15
phosphorylation, p53 PARylation and occupancy of the p21WAF promoter by p53 resulting in an
increase of p21WAF expression. Interestingly, PJ34 in combination with TPT enhances p53 occupancy at
the BAX promoter and is associated with increased BAX protein level.
In SCC022 cells, instead, TPT + PJ34 combined treatment reduces the level of the anti-apoptotic
DNp63a protein without inducing apoptosis. Remarkably, in such cells, either exogenous p53 or TAp63
can rescue the apoptotic program in response to the treatment.
All together our results suggest that in cancer cells PARP inhibitor(s) can operate in the choice
between growth arrest and apoptosis by modulating p53 family-dependent signal
 2015 Elsevier Inc. All rights reserved.
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Poly(ADP-ribose)polymerases (PARPs) and p53 play relevant
roles in fundamental biological processes such as replication,
transcription, cell cycle progression and apoptosis. Because of their
protective role against oxidative and DNA damage stress, PARP and
p53 are both named ‘‘guardians of genome stability’’ [1].
PARP enzymes catalyse the synthesis of poly(ADP-ribose) chain
(PAR) whose concentration in the nucleus increases 500 fold after
DNA damage [2]. The highly abundant PARP-1 is responsible for
production of most of the cellular PAR, leading to poly-
ADPribosylation (PARylation) of chromatin-associated proteins.* Corresponding author.
E-mail address: quesada@unina.it (P. Quesada).
http://dx.doi.org/10.1016/j.bcp.2015.01.012
0006-2952/ 2015 Elsevier Inc. All rights reserved.Moreover, PARP-1 auto-modiﬁcation, as well as covalent and non-
covalent binding of PAR to several nuclear proteins, including DEK,
XPA, ATM and p53, has emerged as a key mechanism to control a
wide array of cellular processes [3].
As ﬁrst suggested by Malanga and Althaus [4] PARP-associated
polymers may recruit proteins to sites of DNA damage and regulate
their functions. Remarkably, the p53 protein is able to strongly
interact with PAR by means of three polymer binding motifs [5];
Fahrer et al. [6] deﬁned the PAR binding afﬁnity of several proteins
as a function of chain length.
On the other hand, as reported by Kanai et al. [7] in response to
DNA damage, covalent p53 PARylation is able to promote
accumulation of p53 in the nucleus, where it exerts its
transactivation function.
The p53 signaling pathway is one of the most relevant pathways
in cancer biology. In the past, research has mainly be focused on
D. Montariello et al. / Biochemical Pharmacology 94 (2015) 212–219 213the mechanism of p53-dependent regulation of apoptotic cell
death [8]. It has been asserted that p53 post-translational
modiﬁcations and transcriptional induction, allow p53 to increase
its safeguard function against cancer [9]. Indeed, in response to
cellular stressors such as DNA damage, p53 is phosphorylated,
accumulates in the nucleus and up-regulates the expression of pro-
apoptotic factors (i.e. BAX), by directly binding to the p53 response
elements within the promoters of its target genes. However, p53
was also shown to have cytoplasmic functions: for instance it can
directly activate BAX at the mitochondrial membrane [10].
It is relevant to remind that the p53 protein belongs to a gene
family including p63 and p73. However, although p63 and p73 are
structurally related to p53 and have been shown to cooperate in
p53-dependent apoptosis, they have not been directly linked to
tumor suppression [11]. Moreover, the molecular network through
which p53 interacts with its family members to execute their
cellular function is far to be completely understood. Importantly,
the p63 protein is expressed as three isoforms (TAp63a, b and g)
which differ in their C-termini. All three isoforms can be
alternatively transcribed from a cryptic promoter located within
intron 3, producing DNp63a, b and g. However, while TAp63
proteins appear to promote p53-dependent apoptosis, DNp63a,
mainly expressed in epithelial, inhibits the endogenous p53
transcriptional functions required for inducing apoptosis via a
dominant negative effect [12–14].
It is now generally accepted that p53 functions are regulated by
PARP-1. It seems that the functional consequences of p53-PARP-1
interaction largely depend on the severity of the cellular stress. For
instance, during DNA repair, p53 PARylation occurs to activate
p53-transcriptional targets that control cell cycle arrest and
eventually apoptosis. Under extreme genotoxic conditions, in-
stead, p53 itself, can stimulate PARP-1 activity, leading to NAD
depletion and necrosis [15,16]. In this scenario, chemotherapy
protocols based on PARP inhibitors can be useful to restore the
apoptotic cell death.
DNA topoisomerase I (TOP I) is another example of protein
whose functions can be reprogrammed by PARP-1. In brief, TOP I is
involved in the control of DNA supercoiling, allowing topological
changes that are necessary for DNA transactions [17]. TOP I
inhibitors, like the water-soluble campothecin derivative Topote-
can (TPT), have been approved as chemotherapic agents since they
reversibly abolish the DNA re-ligation activity of TOP I generating
single strand breaks (SSBs) to which the protein is covalently
linked. Double strand breaks (DSBs) arise when the replication
forks collide with the SSBs and run off [18,19].
According with previous ﬁndings PARylated PARP-1 counter-
acts TPT through non-covalent but speciﬁc interaction of PAR with
some TOP I sites resulting in DNA cleavage inhibition and
stimulation of the re-ligation reaction [20]. Therefore, PARP
inhibitors can be used as adjuvant of TOP I inhibitors.
The water soluble PARP inhibitor PJ34 has already been
reported to synergize with cisplatin in triple-negative breast
cancer cells: mechanistic investigations revealed that PJ34 reduced
the levels of DNp63a with a concurrent increase of its downstream
target p21WAF [21]. More recently it has been published that PJ34
has cytotoxic effects in six non small cell lung cancer cell lines:
PJ34 treatment likely induces apoptosis through an intrinsic
pathway as suggested by its effects on protein expression level
[22].
By cell cycle analysis, in HeLa and MCF7 carcinoma cells, we have
already shown, that inhibition of PAR synthesis by either PARP-1
silencing or PJ34 inhibition potentiates TPT toxicity, in terms of
G2/M cell’s accumulation and DSBs level [23]. Furthermore, in
MCF7p53WT, MDA-MB231p53mut and SCC022p53null carcinoma cells,
we observed changes of p53 and DNp63/TAp63 expression levels
associated to TPT + PJ34 combined treatments [24].Here, using MCF7 (p53+/DNp63) and SCC022 (p53/DNp63+)
cells subjected to the same agents, we looked at p53 post-
translational modiﬁcations and levels of pro-arrest or pro-
apoptotic proteins implicated in the p53/p63-dependent pathway
(i.e. p21WAF, MDM2, BAX).
2. Materials and methods
2.1. Drugs, media, antibodies and chemicals
TPT was from Glaxo Smith-Kline (Verona, Italy) and PJ34 [N-(6-
oxo-5,6,-dihydrophenanthridin-2-yl)-(N,N-dimethylamino) Acet-
amide] from Alexis Biochemicals (Vinci-Biochem, Firenze, Italy).
The cocktail of protease inhibitors was from ROCHE-Diagnostic
(Milano, Italy).
MCF7 cells were from CLS Cell Lines Service (Eppelheim,
Germany), SCC022 cells were provided by C.Missero. Dulbecco’s
modiﬁed Eagle’s medium (DMEM), heat-inactivated fetal bovine
serum (FBS), Roswell Park Memorial Institute (RPMI) medium and
Lipofectamine 2000 were from Invitrogen (GIBCO, Milano, Italy);
penicillin, streptomycin and L-glutamine were from LONZA,
(Milano, Italy).
PVDF (poly-vinylidene-ﬂuoride) membrane was from MILLI-
PORE S.p.A. (Milano, Italy). Non-fat-milk powder was from
EUROCLONE (Milano, Italy).
Anti-DNA TOP I (Scl-70) human antibody was from Topogen
(ABCAM, Cambridge, UK). Anti-PARP-1 (C2-10), anti-pan-p63
(D-9), anti-p53 (DO-1), anti-p21WAF (F-5), anti-GAPDH (6C5)
mouse monoclonal antibodies, anti-p53 (FL-393), anti-actin
(H196) rabbit polyclonal antibody and protein A/G PLUS Agarose
were from Santa-Cruz Biotechnology (DBA, Milano, Italy). Anti-
phospho-p53(ser15) (9284), anti-PARP-1 (9542), anti-BAX
(D2E11) rabbit polyclonal antibodies were from Cell Signaling
(Invitrogen, Milano, Italy). Anti-MDM2 (Ab-2) mouse monoclonal
antibody was from Oncogene Research Products (Boston, USA).
Anti-PAR (4335) mouse monoclonal antibody was supplied by
TREVIGEN (TEMA Ricerca, Bologna, Italy). Goat anti-mouse and
goat anti-rabbit IgG HRP-conjugated antibodies were from Sigma-
Aldrich (Milano, Italy). All other chemicals analytical grade were of
the highest quality commercially available.
2.2. Cell cultures and transfections
Breast cancer-derived MCF7p53wt cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% (v/v)
heat-inactivated fetal bovine serum (FBS), while squamous
SCC022p53 null carcinoma cells were maintained in Roswell Park
Memorial Institute (RPMI) medium containing 10% (v/v) FBS,
100 U/ml penicillin, 100 g/ml streptomycin, 5 mM L-glutamine and
incubated at 37 8C in a humidiﬁed atmosphere, plus 5% CO2. Cell
transfection was performed using Lipofectamine 2000 (Invitrogen,
Milano, Italy) following the manufacturers’ protocols.
2.3. Cell treatments
TPT and PJ34 were dissolved in Milli-Q water, stored as per the
manufacturers’ recommendations and diluted into cell culture
media at the indicated concentrations. Cells were seeded at 1  106
cells in 10 ml and 24 h after seeding, treated with 5 mM TPT, 10
concentration inhibiting cellular growth by 50% (IC50) [17], and
10 mM PJ34 alone and in combination for 6 or 24 h in fresh
medium. Cell culture medium was removed and, after PBS wash,
cells were recovered 6  106 cells/ml in 50 mM Tris–HCl pH 7.5,
150 mM NaCl, 5 mM EDTA, 1% NP40 (Lysis Buffer) plus 2 mM PMSF
and 1:25 dilution of protease inhibitors cocktail solution. After
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at 16,000  g for 20 min at 4 8C.
2.4. Isolation of nuclear fractions
To isolate sub-cellular fractions, 3  106 cells were suspended
in 200 ml of 30 mM Tris–HCl pH 7.5 buffer, containing, 1.5 mM
MgCl2, 10 mM KCl, 1% (v/v) Triton X-100, 20% glycerol, 2 mM PMSF
and 1:25 dilution of protease inhibitors cocktail solution. After
30 min of incubation on ice, cellular suspensions were centrifuged
at 960  g for 90 s at 4 8C and the nuclear fractions recovered in the
pellet. The supernatant represents the cytoplasmic fraction.
Nuclear fractions were resuspended in 50 ml of 20 mM HEPES
pH 7.9 buffer, containing 20 mM KCl, 0.2 mM EDTA, 1.5 mM MgCl2,
25% glycerol and the protease inhibitors cocktail solution. Protein
concentration was determined using the Bradford protein assay
reagent (BIO-RAD Milano, Italy) with bovine serum albumin as a
standard.
2.5. Immunological analyses
Aliquots of 10 ml of cellular or nuclear proteins (approx 100 mg)
were separated by 10% SDS-PAGE and transferred onto a PVDF
membrane using an electroblotting apparatus (BIO-RAD). The
membrane was subjected to immunodetection after blocking with
5% non-fat milk in TBST 1 h, with anti-PARP-1 (C2-10; diluted
1:2500), anti-TOP 1 (Scl-70; diluted 1:1000), anti-pan-p63 (D-9;
diluted 1:200), anti-p53 (DO-1; diluted 1:5000), anti-p21WAF
(F-5; diluted 1:1000), anti-MDM2 (Ab-2; diluted 1:1000), anti-BAX
(D2E11; diluted 1:1000), anti-GAPDH (6C5; diluted 1:5000) and
anti-actin (H196; diluted 1:2000) overnight at 4 8C.
As secondary antibodies goat-anti-mouse or goat-anti-rabbit
IgG HRP-conjugate (diluted 1:5000–1:10,000) in 3% (w/v) non-fat
milk in TBST were used. Peroxidase activity was detected using the
ECL Lite Ablot TURBO (Euroclone, Milano, Italy) and quantiﬁed
using the Immuno-Star Chemiluminescent detection system
GS710 (BIO-RAD) and the Arbitrary Densitometric Units normal-
ized with those of the GAPDH or actin loading controls.
2.6. Co-immunoprecipitation
Samples of MCF-7 cells (1–2  106) 24-h treated with 5 mM TPT
alone or in combination with 10 mM PJ34 were resuspended in
50 mM Tris–HCl buffer pH 7.5, containing 150 mM NaCl, 5 mM
EDTA, 0.5% NP40, 10% glycerol, 1 mM PMSF and 1:25 dilution of the
cocktail of protease inhibitors. Protein A/G plus Agarose was
equilibrated in the same buffer by 3 washes and centrifugations at
960  g 5 min at 4 8C: 40 ml aliquots were incubated with 1 mg of
protein extract in 1 ml ﬁnal volume, by buffer addition. Anti-p53
(DO-1), anti PARP-1 (C2–10) or anti-PAR (4335) monoclonal
antibodies were added (3 ml) and the suspensions were incubated
overnight at 4 8C on a rotator.
Co-immunoprecipitated samples were washed 3 times with the
same buffer, mixed 1:1 with 4 Laemmli Buffer and, together with
total protein extracts (30 mg), were subjected to 10% SDS PAGE,
transferred onto a PVDF membrane using an electroblotting
apparatus (BIO-RAD) and subjected to immunodetection, after
blocking with 5% non-fat milk in TBST for 1 h, with anti-PARP-1
(9542; diluted 1:1000), anti-p53 (FL-393; diluted 1:5000) and
anti PAR (4335 diluted 1:1000) antibodies. As secondary
antibodies goat-anti-mouse or goat-anti-rabbit IgG HRP-conjugate
(diluted 1:5000–1:10,000)  in 3% (w/v) non-fat milk in TBST were
used. Peroxidase activity was detected using the ECL Advance
Western Blot Kit of GE Healthcare (Milano, Italy) and using
the Immuno-Star Chemiluminescent detection system GS710
(BIO-RAD).2.7. RNA extraction and real-time PCR
Total RNA was isolated using PureLink RNA Mini Kit (Ambion,
Monza, Italy). 5 mg RNA each sample was reverse transcribed using
SuperScript III Reverse Transcriptase (Invitrogen, Milano, Italy)
according to manufacturer’s protocol. Real-Time PCR was per-
formed with Power SYBR Green PCR Master Mix (Applied
Biosystems, Monza, Italy) using 100 ng cDNA in a 20 ml reaction
mixture. The relative amounts of ampliﬁed transcripts (2DCT)
were estimated by the comparative CT (DCT) method and
normalized to an endogenous reference (18S) relative to a
calibrator. RT-PCR data were obtained from three independent
experiments (biological replicates); each experiment was per-
formed in triplicate. Primers are described in the following table.
Primer sequence forward/reverse (50–30)
p63 GGTTGGCAAAATCCTGGAG/GGTTCGTGTACTGTGGCTCA
p21WAF TCACTGTCTTGTACCCTTGTGC/GGCGTTTGGAGTG
GTAGAAA
BAX CCGCCGTGGACACAGAC/CAGAAAACATGTCAGCTGCCA
2.8. Chromatin immunoprecipitation (ChIP) assay
According to Beneke [25] cells were cross-linked for 10 min at
room temperature with 4% formaldehyde into the medium and
neutralized by the addition of 1.25 M glycine/PBS for 2 min. Then
the solution was removed and plates were washed twice with PBS
(2 min each). To yield chromatin suspension, cells were collected
after incubation for 5 min at 4 8C in 0.5 ml of lysis buffer 50 mM
Tris–HCl pH 8.0, 10 mM EDTA, 1% SDS (LB) supplemented with
protease inhibitors. Suspensions were sonicated on ice using
Bioruptor Diagenode (Lie`ge, Belgium) on high setting (30 s on
and 30 s off) for 50 cycles. Protein concentration was adjusted to
1 mg/ml with lysis buffer and stored at 4 8C.
For ChIP, suspensions were brought to room temperature and
160 ml were spun down for 5 min at maximum speed. 150 ml
supernatant was mixed with 1.35 ml of dilution buffer 20 mM
Tris–HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton-X-100 (DB)
supplemented with protease inhibitors, incubated with 1.5 mg of
p53 (DO-1) monoclonal antibody or 1.5 mg of irrelevant IgG and
rotated overnight at 4 8C.
100 ml of G Protein immobilized on agarose-beads (Thermo-
Scientiﬁc, Rockford/IL, USA) were, resuspended in 1 ml 9:1 dilution
buffer:lysis buffer mix (DB:LB) and pre-absorbed with 100 mg/ml
BSA and 500 mg/ml sheared salmon sperm DNA overnight at 4 8C
on a rotator. Beads were washed twice with DB:LB and
resuspended in 1 ml DB:LB.
50 ml of the beads suspension was added to each cell lysate and
incubated for at least 2 h at 4 8C on a rotator. Suspensions were
spun down 10 min at 1000  g and supernatant was aspirated.
Beads were washed 3 times in 0.5 ml wash buffer (150 mM NaCl,
20 mM Tris–HCl (pH 8.0), 2 mM EDTA, 1% Triton-X-100, 0.1% SDS)
supplemented with protease inhibitors and centrifuged as above;
Beads were washed in 0.5 ml of 20 mM Tris–HCl pH 8.0, 500 mM
NaCl, 2 mM EDTA, 1% Triton-X-100, 0.1% SDS, supplemented with
protease inhibitors and immune-complexes were eluted by
addition of 160 ml elution buffer, 100 mM NaHCO3, 1% SDS,
5 min at room temperature. 500 mg/ml of Proteinase K and RNAse
A were added to each sample and incubated for 30 min at 37 8C and
for 1 h at 56 8C. DNA–protein crosslinks were reversed by NaCl
addition to a ﬁnal concentration of 200 mM and incubation
overnight at 65 8C. DNA was isolated by Phenol/Chloroform
procedure and subsequent ethanol precipitation.
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p21WAF and BAX promoter regions and with KOD Hot Start
polymerase (Novagen/Merck, Darmstadt, Germany) according to
manufacturer’s instructions.
PCR was performed in 32 cycles (20 s 95 8C/10 s annealing
temperature/5 s 70 8C) and products were resolved by 2.5% agarose
gel electrophoresis. Primer sequences and respective annealing
temperatures are listed in the following table:
Primer sequence fwd/rev (50–30); Annealing (8C)
p21WAF GTGGCTCTGATTGGCTTTCTG/
GCTAAGGTTTACCTGGGGTCTTTA
55
BAX ATAACGTCCTGCCTGGAAGC/
CCCCAGCGCAGAAGGAATTA
59
ChIP experiments were performed as three independent
biological replicates and each experiment was performed in
triplicate. Promoter occupancy was calculated with the percent
input method by using the Image J software.
2.9. Statistics
Statistical Analysis was performed by using the Graph Pad
software and the unpaired Student’s t-test. P-value of <0.05 were
considered statistically signiﬁcant (*); P-value of <0.01 were
considered extremely statistically signiﬁcant (**).
3. Results
3.1. Analysis of TOP I and PARP-1 inhibition following TPT, PJ34 and
TPT + PJ34 treatments
We ﬁrst conﬁrmed by western blot the efﬁcacy of TPT in
trapping the TOP I enzyme in the abortive complex by looking atFig. 1. Analysis of TPT-dependent TOP I inhibition and PJ34-dependent PARP-1 inhibition a
untreated or 6 and 24-h treated with the indicated drugs were subjected to 10% S
Immunodetection of TOP I and PARP-1; (B) immunodetection of p21WAF, MDM2, BAX. 
were quantiﬁed by densitometric scanning. Data expressed as Arbitrary Densitometric Un
mean  S.E.M. of three independent experiments on three biological replicates. Unpaired S
induced with TPT compared with TPT + PJ34 at the same time points. ** P < 0.01.the disappearance of the TOP I band corresponding to the
soluble fraction of the enzyme. As shown in Fig. 1A, 6–24 h
treatment of MCF7 cells with 5 mM TPT signiﬁcantly decreased
the amount of soluble TOP I thereby indicating that the majority
of the TOP I enzyme was already blocked into the abortive
complex.
Next, we assessed the efﬁcacy of PJ34 as PARP inhibitor by
looking at its effect on PARP-1 auto-modiﬁcation. We have
previously reported that 10 mM PJ34 has not citotoxic effect per
se, indeed it does not alter p53 protein level and cell cycle kinetics
[23,24].
We performed immunoblot analysis of TPT and TPT + PJ34
treated MCF7 cell lysates using PARP-1 antibodies. As shown in
Fig. 1A, after 6 h of 5 mM TPT treatment a band (PAR-PARP-1) was
evident at the top of the gel. Such behavior indicates auto-
modiﬁcation of PARP-1 by long and branched PAR molecules (up to
200 residues in chain) on several sites (up to 25), that gives raise to
higher molecular weight PARP-1 forms (up to 250 kDa) that do not
enter the polyacrylamide gel matrix [4]. At the same time of
incubation, TPT + PJ34 treatment, instead, was able to induce
apoptosis as demonstrated by the appearance of the 89 kDa
fragment generated by the caspase-dependent cleavage of PARP-1.
After 24 h of TPT treatment the PARP-1 proteolytic cleavage was
detectable and it was more pronounced after TPT + PJ34 treatment
clearly indicating that cells were undergoing massive apoptosis
(Fig. 1A).
3.2. Analysis of the effects of TPT, PJ34 and TPT + PJ34 treatments on
pro-arrest or pro-apoptotic p53 target proteins
We have previously shown that TPT treatment leads to p53 up-
regulation [23,24], therefore we looked, by immunoblot analysis,
at the expression level of relevant p53-target proteins, as MDM2,
p21WAF and BAX, in MCF7 cells (p53+) treated with TPT, PJ34 and
TPT + PJ34. BAX is considered a pro-apoptotic protein, p21WAF is and their effects on endogenous levels of p53 target proteins. Total MCF7 cell extracts
DS-PAGE, electroblotted on PVDF and incubated with different antibodies. (A)
GAPDH was used as loading control; (C) p21WAF, MDM2 and BAX band intensities
its (ADU) were normalized to the internal control GAPDH. Data are presented as the
tudent’s t-test was conducted to determine whether protein’s level was higher in cells
D. Montariello et al. / Biochemical Pharmacology 94 (2015) 212–219216well known cell cycle inhibitor while MDM2 is the major negative
regulator of p53 [8].
As shown in Fig. 1B, TPT and TPT + PJ34 treatments up-
regulated p21WAF both at 6 and 24 h. Moreover, according to the
appearance of a distinctive PARP cleavage signature, the pro-
apoptotic BAX protein appeared signiﬁcantly increased mainly
upon TPT + PJ34 treatment. Densitometric analysis of three
independent experiments indicates a signiﬁcant (2 to 4 fold)
increase of BAX protein level at 6 and 24 h (Fig. 1C). Unexpectedly,
we did not detect any signiﬁcant alteration of the MDM2 protein
levels (Fig. 1B and C).
Next, we tested the ability of TPT + PJ34 to induce apoptosis in
p53 null SCC022 squamous carcinoma cells following 24 h of
incubation with the drugs. Such experiment was performed in p53
and/or TAp63g transfected cells.
Immunoblot analysis showed that SCC022 cells responded
to TPT + PJ34 treatment by reducing DNp63a protein level
(Fig. 2A). By RT-PCR analysis we measured the level of DNp63a
mRNA in untreated (CTR) and TPT + PJ34 treated SCC022 cells
and we found that it was comparable thus suggesting that
DNp63a down-regulation was exclusively at protein level
(Fig. 2B).
Furthermore, as demonstrated by the appearance of the PARP-1
89 kDa proteolytic fragment (Fig. 2A and C), p53 and TAp63g are
able to induce the caspase-dependent cleavage of PARP-1 and
caused a further decrease of endogenous DNp63a protein after
TPT + PJ34 treatment. Immunoblot analysis with a pan-p63
antibody was used to reveal both endogenous DNp63a and
transfected TAp63g proteins (Fig. 2C). This result indicates that
reduction of DNp63a in SCC022 cells per se is not sufﬁcient to
induce apoptosis but it seems to cooperate with exogenous p53 or
TAp63g in the restoration of apoptosis upon TPT + PJ34 treatment.
However, as DNp63a levels are reduced upon by p53 or TAp63g
expression the individual contribution of these proteins on
apoptosis is difﬁcult to assess.
Furthermore, apoptosis induction was sustained by a strong
BAX up-regulation (Fig. 2C).Fig. 2. Analysis of the effects of TPT + PJ34 treatment in SCC022p53null cells p53+/TAp63g tran
BAX antibodies. GAPDH was used as loading control. (B) Quantitative RT-PCR analysis of 
mean  S.E.M. of three independent experiments on three biological replicates.3.3. Analysis of the effects of TPT, PJ34 and TPT + PJ34 treatments on
p53 post-translational modiﬁcations
Activation of p53 transcriptional function by genotoxic stimuli
imposes a variety of p53 post-translational modiﬁcations; one of
the best characterized is phosphorylation at Serine 15 by ATM
[26]. We analyzed the effect of TPT and TPT + PJ34 on p53 protein
phosphorylation by using a phospho-speciﬁc antibody that
recognizes 15serp-p53 (Fig. 3A).
As estimated by densitometric analysis, TPT treatment caused a
10 fold increase of the steady state level of endogenous p53 protein
and its phosphorylated form at serine 15. Interestingly, a further
increase was observed after TPT + PJ34 treatment form (12 folds
compared to untreated) (Fig. 3A). Immunoblot analysis showed
that phosphorylated ser15p53 was located in the nucleus (Fig. 3B).
It was previously demonstrated that p53 exhibits a high afﬁnity
for auto-modiﬁed PARP-1 [5]. However, whether p53 undergoes
‘‘in vivo’’ covalent or non-covalent post-translational modiﬁcation
by PARP-1 (PARylation) is still a matter of debate.
To look at the TPT-dependent p53 PARylation we performed co-
immunoprecipitation experiments in MCF7 cells treated with TPT
and TPT + PJ34 for 24 h. Same aliquots of total cell extracts were
immunoprecipitated with p53, PARP-1 or PAR antibodies (Fig. 4).
Protein immunocomplexes were then analyzed by western blot
and revealed with the same antibodies.
The p53 immunoprecipitated sample from TPT treated cells,
revealed with PARP-1 antibodies (Fig. 4A panel 1), shows a slow
migrating broad band can be ascribed to auto-modiﬁed PARP-1
(PAR-PARP-1) since it was also detectable in the input sample
together with two bands corresponding to the native enzyme
(113 kDa) and the PARP-1 apoptotic fragment (89 kDa). The same
bands were detected by immunoblot of PARP-1 immunoprecipi-
tate using PARP-1 antibody (Fig. 4A panel 2). Fig. 4B panel
1 conﬁrms the presence of p53 protein in p53-immunocomplexes.
Furthermore, after anti-PAR immunoprecipitation, immunode-
tection with PAR antibodies shows a sharp band corresponding to
PAR polymers of different length linked to PARP-1 (Fig. 4A, panelsfected. (A) and (C) Immunodetection with anti-PARP-1, anti-p53, anti-pan p63, anti-
DNp63a mRNA levels in untreated and 24-h treated cells. Data are presented as the
Fig. 3. Analysis of TPT+/PJ34 dependent p53 phosphorylation in MCF7 cells. (A) Western blot analysis of MCF7 cells (A) and isolated nuclei (B), untreated or 6 and 24-h treated
with the indicated drugs. Immunodetection of ser15-p-p53 and p53 band intensities were quantiﬁed by densitometric scanning. Data expressed as Arbitrary Densitometric
Units (ADU) were normalized to GAPDH and Actin internal controls. Data are presented as the mean  S.E.M. of three independent experiments on three biological replicates.
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such protein in PAR immuno-complexes (Fig. 4B panel 3).
Moreover, lysates from MCF7 cells treated with TPT + PJ34 for
24 h were immunoprecipitated with p53 antibodies and analyzed by
immunoblot with PARP-1 and p53 antibodies. As shown in Fig. 4C,
upper panel, immunoreactive bands corresponding to the native
PARP-1 and its apoptotic fragment were present in the input sample
but not in p53 immunoprecipitates, thereby conﬁrming that, as a
consequence of PAR synthesis inhibition, interaction between p53
and PARP-1 does not occur (lane 2). Fig. 4C lower panel shows p53
bands in the input and immunoprecipitated samples.
3.4. Analysis of p53-dependent p21WAF and BAX genes expression
following TPT and TPT + PJ34 treatment
Next, we quantiﬁed the level of p21 and BAX transcript on TPT
and TPT + PJ34 treated cells that showed comparable levels of p53
and ser15p-p53 protein (Fig. 3).Fig. 4. Analysis of TPT+/ PJ34 dependent p53-PAR interaction by co-immunoprecipitation. (
PARP-1 or PAR antibodies and immunodetected with PARP-1 or PAR antibodies. (B) Tota
antibodies and immunodetected with p53 antibodies. (C) Total extract from TPT +
immunodetected with PARP-1 antibodies (upper) or p53.antibodies (lower). ImmunodTotal RNA was puriﬁed from cells treated for 6 or 24 h with the
indicated drugs and subjected to qRT-PCR assays. As shown, we
found a 4.5 fold increase in p21WAF mRNA level in cells subjected
to TPT treatment that was strongly reduced by PJ34 addition
(Fig. 5A). Concerning BAX mRNA level the increase of BAX mRNA
was detectable only after 24 h of treatment with TPT + PJ34
(Fig. 5B).
Then we analyzed the effects of TPT and TPT + PJ34 treatments
on p53 binding to promoters of p21WAF and BAX genes, by using
the Chromatin Immunoprecipitation (ChIP) approach. Since it was
previously shown that standard ChIP is ﬂawed by PAR that may
cause changes in promoter-occupancy dependent on artiﬁcial
formation of polymers [25] we modiﬁed the standard protocol, as
described in Section 2, to prevent artiﬁcial polymer synthesis.
Interestingly, according to the observed increase of p21WAF
transcript (Fig. 5A), p53 occupancy of p21WAF promoter was
strongly increased in TPT treated cells compared to control cells
and signiﬁcantly reduced by addition of PJ34 (Fig. 5C). OccupancyA) Total extract from TPT treated MCF7 cells (Input) immunoprecipitated with p53,
l extract from TPT treated MCF7 cells (Input) immunoprecipitated with p53 or PAR
 PJ34 treated MCF7 cells (Input) immunoprecipitated with p53 antibodies and
etections of irrelevant IgG immunoprecipitated samples are also shown.
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Fig. 5. Analysis of p53-dependent p21WAF and BAX genes expression following TPT and TPT + PJ34 treatment. Real-time-PCR analysis of mRNA levels of p21WAF (A) and BAX (B)
genes in MCF7 cells 6 and 24-h treated with the indicated drugs. Data normalized with respect to 18S are reported as increment’s fold of controls and represent the
mean  S.E.M. of three independent experiments on three biological replicates. Unpaired Student’s t-test was conducted to determine whether mRNA level was higher in cells
induced with TPT compared with TPT + PJ34 at the same time points. ** P < 0.01. Chromatin Immunoprecipitation in MCF7 cells 6 and 24-h treated with the indicated drugs.
Chromatin was immunoprecipitated with p53 or irrelevant immunoglobulin G (IgG) antibodies and quantiﬁed by PCR on p21WAF (C) or BAX (D) promoter. Data normalized with
respect to control samples are reported as folds of increment and represent the mean  S.E.M. of three independent experiments on three biological replicates. Unpaired Student’s
t-test was conducted to determine whether promoter occupancy was higher in cells treated with TPT compared with TPT + PJ34 at the same time points. * P < 0.05 and ** P < 0.01.
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TPT + PJ34 after 6 h of treatment, while at 24 h of treatment we
could not detect signiﬁcant changes (Fig. 5D).
4. Discussion
In the present study we investigate the PARP-1/p53(p63)
functional relationship as apoptosis inducers by looking at the
transcriptional regulation of their target genes.
It is known that one mechanism that affects the outcome of p53
activation is the abundance of the protein itself [27]: according to
the proposed afﬁnity model, at low levels p53 preferentially binds
to high-afﬁnity p53 response elements (RE) in promoters of pro-
arrest genes, whereas high levels are necessary for p53 to bind low
afﬁnity p53 RE in pro-apoptotic promoters [28].
Our ﬁndings agree with such a model since MCF7 cells respond
to TOP I or TOP I and PARP-1 combined inhibition by p53 increase,
phosphorylation at serine 15 and transcriptional activation.
Conversely, PARP-1 inhibition by treatment with PJ34 alone has
no effect on p53 level, and transcriptional activation compared to
control cells.
Moreover, in p53 proﬁcient cells such as MCF7, as a conse-
quence of TPT-dependent DNA damage, the pro-arrest p21WAF
protein is rapidly up-regulated. Indeed, both p53 binding to
p21WAF promoter and p21WAF mRNA appeared to be enhanced
after 6 h of TPT treatment. Concomitant PARP-1 auto-modiﬁcation
is indicative of a DNA repair attempt.
Under more severe DNA damage conditions induced by 6 h of
TPT + PJ34 treatment, the p53 binding to the p21WAF promoterwas reduced while occupancy of BAX promoter was enhanced.
However, the increase of BAX transcript was delayed and the
protein level was clearly detectable only after 24 h. Under this
condition, PARP-1 undergoes caspase-dependent cleavage.
These data indicate a selective binding and control of pro-arrest
or pro apoptotic gene promoters by p53 occurring under speciﬁc
stimuli which may reﬂect the severity of DNA damage.
Our previous results point to a role for p63 in the cell response
to treatment with TOP I and PARP-1 inhibitors. In MCF7p53WT cells
the endogenously expressed TAp63g isoform, which closely
mimics p53, is up-regulated upon TPT + PJ34 treatment [24]. Here-
in we show that transfection of TAp63g or wild-type p53 is
necessary to trigger caspase-dependent apoptosis in apoptosis-
resistant SCC022 cells by inducing BAX expression and degradation
of the endogenous anti-apoptotic DNp63a protein.
Remarkably, the decrease of DNp63a protein was enhanced
by expression of wild type p53 and TAp63g suggesting that they
can cooperate in the mechanism of TPT + PJ34 mediated p63
degradation.
We also present evidences that p53 interacts with PAR linked to
PARP-1 and that p53 PARylation can be induced by TPT-dependent
DNA damage. Our ﬁnding contributes to the debate on covalent or
non-covalent p53 PARylation using an in cell approach and
endogenous proteins. So far, most of the previous evidences were
obtained in vitro, or as for Kanai et al. [7] by the use of mutants.
Intriguingly, the three PAR binding motifs present in the DNA
binding domain of p53 [5] are conserved in the TAp63g sequence
[29], thereby suggesting that, like p53, also this p63 isoform can be
subjected to PARylation.
D. Montariello et al. / Biochemical Pharmacology 94 (2015) 212–219 219In conclusion, we contribute to the literature describing the role
of p53 in mediating cellular sensitivity to apoptosis, along with
directly regulating numerous critical components of the extrinsic
and intrinsic pathways. In particular, we provide further evidences
that in response to TPT-dependent DNA damage, PARylation can be
added to post-translational modiﬁcations that modulate p53
action on its target promoters.
Moreover, our ﬁndings underline the role of PAR and PARP-1 in
the differential recruitment of p53 on its target promoters upon DNA
damage. Indeed, while TPT treatment induces p53 recruitment on
p21/WAF gene promoter with its consequent up-regulation,
TPT + PJ34 combined treatment acts as a switch in the cell fate
decision by inducing the pro-apoptotic BAX gene expression.
While the regulation of p53 by PARP-1 activity has been widely
described, the regulation of PARP-1 activity by p53 reported by
Montero et al. [10] is novel and related to a non-apoptotic cell
death induction.
It has been shown that PARP-1 and p53 reciprocal regulation acts
in different mechanisms of cell death (i.e. autophagy, necrosis,
apotoptosis) [16]. Indeed, a balance exists between apoptotic and
necrotic signaling pathways in response to cellular stress and these
pathways likely regulate each other to ensure death of damaged cells.
Moreover, the restoration of apoptosis is considered a
chemotherapic strategy that can be based on PARP-1 and p53
joint tumor suppressor function. Our results indicate that
modulation of other components of the p53 family (i.e. TAp63g
and/or DNp63a) can be involved and signiﬁcantly contribute to
the cell response to DNA damage stimuli thus adding further
complexity to this phenomenon [29].
Our studies highlighting the different outcome (i.e. cell cycle
arrest vs apoptosis) of PARP-1 activation/inhibition, give right of
the use of PARP inhibitor as chemotherapic adjuvant and/or in
monotherapy even in TAp63/DNp63a proﬁcient cancer cells.
Interestingly, it has been recently published that PARP
inhibitors actualize the biological concept of synthetic lethality
in the clinical practice, yielding a paradigmatic example of
translational medicine [30].
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 26 
ABSTRACT  27 
  28 
Stearoyl-Coenzyme A desaturase 1 (SCD1) belongs to the fatty acid family of desaturases.  In 29 
lactating ruminants, the SCD1 protein is highly expressed in the mammary gland and is 30 
relevant for the fatty acid composition of milk and dairy products. Bovine mammary epithelial 31 
cells (BME-UV1), cultured in vitro, have been proposed as a model to reproduce the biology of 32 
the mammary gland. The present study was designed to investigate the responsiveness of 33 
bovine SCD1 promoter to serum, insulin, oleic acid and NFY transcription factor in BME-UV1 34 
cells. A luciferase-based reporter assay was used to monitor the transcriptional activity of the 35 
SCD1 promoter region in BME-UV1 cells treated or not with insulin and/or oleic acid. The 36 
level of endogenous SCD1 mRNA was valuated by Real time PCR. Insulin (20 ng/mL) 37 
induced a 2.0 to 2.5-fold increase of SCD1 promoter activity. Additionally, the effect of insulin 38 
was inhibited by oleic acid, serum components, and NFY enforced expression. Serum and NFY 39 
showed no synergistic or additive effect on  SCD1 promoter activity suggesting that they 40 
repress SCD1 transcription through the same responsive element. 41 
 42 
Key words: stearoyl coenzyme A desaturase; regulation of gene expression; bovine mammary 43 
cells; fatty acids; insulin. 44 
45 
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46 
INTRODUCTION  47 
Understanding the basis of lipid homeostasis is fundamental for developing new 48 
strategies to combat obesity, diabetes and other diseases of abnormal lipid 49 
metabolism. Stearoyl CoA desaturase 1 (SCD1, also called ∆
9
-desaturase) (EC 50 
1.14.99.5) is a short-lived endoplasmic reticulum-bound enzyme that catalyzes the 51 
∆
9
-cis desaturation of saturated fatty acyl-CoA substrates (SFAs) to 52 
monounsaturated fatty acids (MUFAs), primarily palmitoyl-CoA and stearoyl-CoA 53 
into palmitoleoleyl-CoA and oleyl-CoA, respectively (1). Oleic acid, the main 54 
product of SCD1 reaction, is the predominant fatty acid of human adipose tissue 55 
triacylglycerols, associating SCD1 with the development of obesity and metabolic 56 
syndrome. Moreover, as the SFA/MUFA ratio affects membrane phospholipid 57 
composition and fluidity; it has been implicated in obesity, diabetes, neurological 58 
disease, skin disorders and cancer (2). Stearoyl CoA desaturase 1 gene homologs 59 
have been identified in a range of species, many of which express multiple isoforms, 60 
with SCD1 being the most abundant isoform in lipogenic tissues (3; 4). The SCD1 61 
gene plays an important role in converting trans-11 C18:1 vaccenic acid into cis-9, 62 
trans-11 C18:2 CLA (5) and is highly expressed in the mammary gland of lactating 63 
ruminant (6). Early after parturition, the SCD1 activity in adipose tissue decreases 64 
while increasing in mammary gland (7).  65 
Activity and expression of SCD1 have been reported to be regulated by fatty acids, 66 
although the responses appear to vary among the species. For instance, oleic acid was 67 
shown to reduce rat and bovine SCD1 promoter activity (8; 9) but had no effect on 68 
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human SCD1 mRNA synthesis (10). Promoter elements that are responsible for the 69 
PUFA repression localize with the promoter elements for SREBP-mediated 70 
regulation of the SCD gene (11). In Bos Taurus, the PUFA response region (PUFA-71 
RE, 60 bp) is essential for the control of SCD1 expression by PUFA (12). This 72 
region encompasses the binding sites for Sp1 and NFY transcription factors and the 73 
Sterol Response Element (SRE) which is the binding site for the SREBP1 protein. 74 
Recently, it has been demonstrated that SREBP1 cooperates extensively with NFY in 75 
the control of genes involved in lipid metabolism. Moreover, promoters of genes 76 
involved in lipid metabolism were preferentially occupied by the combination of 77 
SREBP1 and NFY factors while genes involved in carbohydrate metabolism were 78 
enriched among targets of SREBP1 alone (13). In the present study, we have 79 
explored the ability of oleic acid and serum to repress SCD1 promoter activity in 80 
control and insulin-stimulated BME-UV1 immortalized cells that can mimic the in 81 
vivo response of bovine mammary cells. Moreover, since oleic acid was reported to 82 
have no effect on human SCD1 mRNA synthesis (10) we performed similar 83 
experiments in MCF7 cells, a  human breast cancer cell line previously defined as a 84 
model for the study of insulin action on mammalian cell metabolism (14).  85 
86 
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 87 
MATERIALS AND METHODS 88 
Cell Culture 89 
The BME-UV1 cell line was established from primary bovine mammary epithelial 90 
cells by stable transfection with a plasmid, carrying the sequence of the simian virus 91 
40 early region mutant tsA58, encoding the thermolabile large T antigen (15). BME-92 
UV1 cells were provided to us by the Laboratory of Cell Culture-Department of 93 
Veterinary Science and Technologies for Food safety at the Veterinary Medicine 94 
Faculty (University of Milan) and cultured according to Cheli et al., 1999. Human 95 
breast cancer MCF7 cells were purchased from Cell Line Service (CLS, Germany). 96 
MCF7 cells were routinely grown into 100 cm
2
 plates (Corning Life Science, 97 
Corning, NY, USA) as a monolayer culture in Dulbecco’s modified Eagle’s medium 98 
(DMEM) (EuroClone, Pero, MI) supplemented with 10% (v/v) fetal bovine serum 99 
(FBS) (EuroClone), in humidified incubator with 5% CO2 at 37° C.   100 
Construction of SCD1_PGL3 reporter plasmid containing the bovine SCD1 101 
promoter 102 
A 600 bp genomic fragment containing the SCD1 proximal promoter region, -590 103 
from the transcription start site (+1) was amplified by PCR. The amplified region is 104 
shown in Figure 1A and contains the SP1, SRE and NFY binding sites (Figure 1A 105 
and B). Whole genomic DNA was isolated from leucocytes of cow peripheral blood 106 
and used as template for PCR using bovine SCD1-promoter specific primers: 107 
Forward 5’GCATGGTACCCCAGTGCCCATC and Reverse 108 
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5’GGTACCGCGCTGCACGGTGC. The primers included a 8 extra-bases (indicated by 109 
small caps) to generate protected XhoI or KpnI restriction sites. The PCR conditions 110 
are given as follows: 94°C for 30 s, 40 cycles of 57°C for 1 min and a final extension 111 
step at 72°C for 1 min. The PCR fragment was gel purified and appropriately 112 
digested with XhoI or KpnI restriction enzyme (Roche diagnostics, MI, Italy) to 113 
produce cohesive ends. After a step of purification, the digested DNA insert was 114 
directionally cloned into the promoter-less luciferase reporter vector, pGL3-Basic 115 
(Promega, Madison USA), using XhoI and KpnI cloning sites. Ligation reaction was 116 
set up at a vector to insert ratio of 1:5, using 50 ng of pGL3-Basic vector. T4 DNA 117 
ligase and 1X ligase buffer were used according to manufacturer’s instructions. 118 
Positive clones were first selected for the presence of the XhoI and KpnI 600 bp 119 
restriction fragment, by agarose gel electrophoresis, and then sequenced.   120 
The 2.4 Kb fragment containing the p21WAF promoter was retrieved from the 121 
p21WAF-CAT plasmid (16) and ligated into the HindIII site of pGL3-basic Vector 122 
(Promega) to obtain the p21WAF-Luciferase reporter construct. 123 
cDNAs encoding human NFYA, NFYB and NFYC proteins cloned in pBK-CMV  124 
expression vector (Stratagene) were provided to us by Dr. Maria Morasso (NIH, 125 
Bethesda). 126 
Transient transfections and luciferase assay  127 
MCF-7 or BME-UV1 cells were counted and seeded in 6-well plates at a density of 128 
2.5X10
5
 cells/well in 4 mL of complete medium. For luciferase assay, each 129 
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experimental point was transfected with 1 µg of PGL plasmid (SCD1_PGL3, 130 
p21WAF_PGL3 or PGL3 basic vector). Briefly plasmid DNA was diluted in 250 µl 131 
of DMEM serum free and mixed with 2,5 µl of Lipofectamine 2000 (Life 132 
Technologies, CA, USA) in 250 µl DMEM serum free. Transfection master mixtures 133 
were incubated at room-temperature for 20 min, prior to drop-wise addition to 134 
MCF7/BME-UV1 cells. Complexes were added to the cells containing 1 mL of 135 
DMEM and 0, 5 or 10% FBS/FCS). After 24 h transfection, the medium was 136 
removed, cells were washed twice with PBS and then lysed using the Lysis Buffer 137 
(Promega) according to manufacturer’s instructions. Firefly luciferase activity in cell 138 
lysates was measured using Dual Luciferase Assay kit (Promega), according to the 139 
manufacturer’s instructions. Results were normalized against protein concentration 140 
(Bradford Assay, Biorad).  141 
To evaluate the effect of NFY transcription factor, MCF7 cells were co-transfected 142 
with 0.5 γ of SCD1_PGL3 basic construct and 0.5 γ of each NFY subunit (NFY-A, 143 
NFY-B, NFY-C). Four hours after transfection, the cells were incubated with 0%, 144 
5% or 10% FBS, for 24 h. The promoter activity was evaluated by Luciferase assay. 145 
To evaluate the effect of insulin on SCD1 promoter activity, insulin was added to 146 
MCF7 and BME-UV1 cells, at a concentration of 20 ng/mL (3.4 10
-9
 M), 4 h after 147 
transfection. Physiologic concentrations of insulin range between 10
-8
 and 10
-11
 (14) 148 
therefore treatment with 3.4 10
-9
 M  insulin is expected to induce a physiological 149 
response in mammalian cells. 150 
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  Cells were then incubated for 24 hours. To evaluate the promoter response to 151 
MUFA, oleic acid (> 99% purity, Calbiochem) was added to a concentration of 30 152 
and 50 µM according to a previously published manuscript (17).  153 
 Immunoblot 154 
Immunoblots (IB) was performed as previously described (18). NF-YA (G2, sc-155 
17753) and NF-YB (FL207, sc13045) antibodies (Santa Cruz Biotechnology Inc.)  156 
were used to specifically detect expression of NFYA or B subunits and used at 1:200 157 
dilution. The anti-GAPDH (6C5) was purchased from Santa Cruz (Biotechnology 158 
Inc.). 159 
mRNA quantification by qPCR 160 
SCD1 specific transcript was amplified by quantitative PCR. The primers designed 161 
for qPCR reaction are: Forward TCCGACCTAAGAGCCGAGAA and Reverse 162 
AGCACAACAACAGGACACCA (NCBI Reference Sequence: NM_173959.4, from 163 
751 to 823, amplified fragment 72 bp). Total RNA was extracted from BME-UV1 164 
cells maintained in culture with FCS 0% or 10%, with or without insulin (20 ng/mL) 165 
(Sigma-Aldrich, St. Louis, MO) using Cells to Ct
TM
 kit (Ambion, Life 166 
Technologies), according to the manufacturer’s instructions. To evaluate the 167 
response of SCD1 endogenous gene in BME-UV1 cells to MUFA, oleic acid > 99% 168 
purity (Calbiochem, Millipore, Germany) was added to a concentration of 30 and 50 169 
µM. 170 
For PCR analysis total RNA was isolated using the RNA Extraction Kit  from 171 
Qiagen (Hilden, Germany) according to the manufacturer’s instructions. RNA (2-172 
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5µg) was treated with DNAse I (Promega, Madison USA) and used to generate 173 
reverse transcribed cDNA using SuperScript III (Life Technologies, CA, USA) and 174 
random examers in 20 µl of total reaction volume. All samples in each experiment 175 
were reverse transcribed at the same time and the resulting cDNA diluted 1:5 in 176 
nuclease-free water and stored in aliquots at –80°C until used.  177 
Real Time PCR with SYBR green detection was performed with a 7500 RT-PCR 178 
Thermo Cycler (Applied Biosystem, Foster City, USA). The thermal cycling 179 
conditions were composed of 50ºC for 2 min followed by an initial denaturation step 180 
at 95ºC for 10 min, 45 cycles at 95ºC for 30s, 60ºC for 30s and 72ºC for 30s. For the 181 
qPCR the relative quantification in gene expression was determined using the 2
-∆∆Ct
 182 
method (19). As previously suggested, Eukaryotic translation initiation factor 3 183 
subunit K (EIF3K) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 184 
used as an internal controls to normalize all data (20). After normalization, the data 185 
were presented as fold change relative to the control sample. Appropriate no-RT and 186 
non-template controls were included in each 96-well PCR reaction and dissociation 187 
analysis was performed at the end of each run to confirm the specificity of the 188 
reaction.  189 
Statistical analysis 190 
All experiments were performed in triplicate and repeated at least two times. 191 
Quantitative data were presented as mean ± standard deviation (SD). Comparison 192 
between data was analyzed using t-tests. Significant differences were accepted 193 
when P values is less than 0.05 194 
195 
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RESULTS  196 
 197 
The effect of Fetal Bovine Serum and Insulin on SCD1 promoter activity  198 
The sequence of full length SCD1 promoter in Bos Taurus (1880 base pairs) is 199 
annotated in the (EMBL BANK) with the accession number AY241932 while a 200 
partial promoter region of Bubalus bubalis SCD1 is included in the ENA database 201 
(EMBL gene BANK) with the accession number FM876222. Comparison of the 202 
SCD1 proximal promoter region of several mammalian species, using the TFBIND 203 
and the TRANSFAC (ver.3.4) software, reveals high homology. The SCD1 proximal 204 
promoter sequences of Bos Taurus and Bubalus bubalis share 97% of identity. Figure 205 
1a shows the PUFA-responsive SCD1 promoter region encompassing the perfectly 206 
conserved binding sites for Sp1, the SREBP-1c and NF-Y transcription factors, as 207 
previously described (8).   208 
To evaluate bovine SCD1 promoter activity we generated the SCD1_PGL3 209 
luciferase reporter construct. The bovine SCD1 promoter region including the 210 
PUFA-RE was PCR amplified from genomic cow DNA and appropriate primers (see 211 
Materials and Methods). The 600 bp amplified fragment was cloned upstream of the 212 
luciferase gene in the PGL3 promoter-less vector (Promega) to generate the 213 
SCD1_PGL3 reporter construct. 214 
Cell culture conditions can have a profound impact on intracellular signaling cascade 215 
and may be a fondamental source of variability accounting, at least in part, for the 216 
conflicting results in the SCD1 litterature. For instance, oleic acid was reported to 217 
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reduce rat and bovine SCD1 promoter activity (8; 9) while having no effect on 218 
human SCD1 mRNA synthesis (10). To determine the extent to which serum affects 219 
SCD1 promoter activity, MCF7 cells were grown in serum-free or serum-220 
supplemented medium (5-10% FBS) and transiently transfected with the 221 
SCD1_PGL3 construct or the p21WAF_PGL3 plasmid, containing a serum-222 
independent promoter (our previous observations). The promoter-less pGL3 basic 223 
vector was used to evaluate the background signal. At 24 hrs after transfection, cells 224 
were collected, whole cell extracts were prepared and subjected to luciferase assay. 225 
As shown in Fig. 2a, in presence of serum, the p21WAF promoter activity was 226 
unaffected while the SCD1 promoter activity was significantly reduced (p< 0.02). In 227 
10% FBS the SCD1 promoter activity was about 4.3 folds lower than in serum-free 228 
medium, with a residual activity ranging between 15 and 25 %. The background 229 
activity of pGL3 basic construct was negligible in both serum conditions (4.3 +/- 1.5 230 
RLU, arbitrary units of luciferase activity).  231 
Next, we monitored the effect of insulin on SCD1 promoter activity. The 232 
experiments were performed in serum-free condition or 10% serum as this is the 233 
most commonly used condition for the growth of mammalian cell lines. Insulin was 234 
added to the medium at the concentration of 20 ng/mL. In serum-free medium, 235 
insulin treatment caused a 2.5-fold induction of the SCD1 promoter reporter (Fig. 236 
2b). After FBS-supplementation, the SCD1 promoter basal activity was reduced and 237 
insulin treatment was unable to evoke any response (Fig. 2b). The results 238 
demonstrate that serum components exert a strong repression on the SCD1 promoter 239 
and that insulin appears to be unable to overcome this repression.  240 
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Role of NFY transcription factor in the regulation of SCD1 promoter activity. 241 
NFY factor has been suggested to be a PUFA-specific transcription factor for SCD1 242 
gene repression (11). The transcription factor NFY is a hetero-trimeric protein, 243 
composed of three subunits NFY-A, NFY-B and NFY-C. NF-YB and NF-YC must 244 
interact and dimerize for association with NF-YA and consequent binding to 245 
CCAAT motifs in the promoter regions of a variety of genes. NFY interacts with the 246 
Sterol Regulatory Element-Binding Proteins (SREBPs). SREBPs, indeed, are weak 247 
transcriptional activators on their own and interact with their target promoters in 248 
cooperation with additional regulators, most commonly including one or both NFY 249 
and SP1 transcription factors.  To investigate the effect of NFY enforced expression 250 
on SCD1 promoter activity, we transiently transfected the SCD1_PGL3 reporter 251 
construct into MCF7 cells along with an equal amount of each plasmid encoding 252 
NFY subunit A, B or C. Four hours after transfection, the culture medium was 253 
replaced and cells were maintained in serum-free, 5% or 10% FBS-supplemented 254 
medium for 24 h.  The expression of transfected NFY subunit A and B was 255 
monitored by immunoblot analysis using NFY specific antibodies (Figure 3A). The 256 
SCD1_PGL3 activity was then evaluated by Luciferase assay.  As expected, in 257 
serum-supplemented media the basal activity of SCD1 promoter was lower than in 258 
serum-free medium  (Fig. 3A). However, both in absence and 5% serum NFY 259 
expression causes a significant decline of luciferase activity (p< 0.02) indicating that 260 
NFY is a transcriptional repressor of SCD1 gene. However, in 10% serum the 261 
residual activity of SCD1 promoter was 50% of the control and NFY caused only a 262 
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15 % reduction thereby suggesting that serum and NFY compromise SCD1 promoter 263 
activity by acting at the same regulatory element.  264 
 265 
Regulation of SCD1 promoter activity in bovine mammalian cells  266 
The regulation of SCD1 expression in bovine mammary cells affects milk yield and 267 
fatty acid profile (21). SCD1 is induced by insulin (22). It was interesting to study 268 
the effect of insulin on SCD1 gene expression in BME-UV1 cells, immortalized, but 269 
not transformed, bovine mammary cells that closely mimic the in vivo mammary 270 
epithelial cells. The promoter reporter construct was transiently transfected into 271 
BME-UV1 grown in serum-free, 5% or 10% FCS with or without insulin (20 272 
ng/mL). BME-UV1 cells were transiently transfected with SCD1_PGL3 construct 273 
and after 24 hours whole cell extracts were prepared and subjected to the luciferase 274 
assay. According to what observed in MCF7 cells, serum-addition repressed SCD1 275 
activity in bovine mammary cells (Fig. 4A). Again, we observed a 2.5 fold promoter 276 
activation by insulin only in serum-starved cells showing that the repressive activity 277 
of serum is dominant over the inductive effect of insulin. To corroborate these data, 278 
we decided to examine the level of SCD1 endogenous mRNA in BME-UV1 cells by 279 
quantitative Real Time PCR. Cells were grown in serum-free or 10% FCS medium 280 
and treated or not with insulin (20 ng/mL), for 24 hours. Total RNA was isolated and 281 
subjected to quantitative PCR using primers to specifically amplify bovine SCD1 282 
mRNA. The level of SCD1 specific transcript was normalized against the 18S 283 
ribosomal RNA and expressed as relative amount respect to the sample obtained in 284 
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serum and insulin-free medium. As shown in Fig. 4B, we confirmed that insulin 285 
treatment enhanced SCD1 mRNA expression level only in serum-deprived cells.  286 
Regulation of SCD1 promoter by oleic acid is still controversial. Oleic acids 287 
concentrations up to 100 µM were previously demonstrated do not affect MCF7 cell 288 
proliferation and viability (23). However, we performed preliminary test by treating 289 
MCF7 and BME-UV1 with increasing amount of oleic acid (15, 30, 50, 80 and 100 290 
µM) for 24 and 48 hours. In each experimental point the cells behave healthy. 291 
Moreover, cells lysates were analyzed by immunoblot with antibodies against 292 
Caspase3 and PARP and we did not detect signs of apoptosis neither in terms of 293 
Caspase 3 induction nor Poli ADP-ribose polymerase cleavage.  294 
 (data not shown).  To check the effect of oleic acid in the control of bovine SCD1 295 
promoter we transiently transfected BME-UV1 cells with the SCD1 promoter-296 
luciferase reporter in serum-free medium supplemented or not with 30 or 50 µM 297 
oleic acid.   298 
The combined effect of insulin and oleic acid was checked by adding insulin at a 299 
concentration of 20 ng/mL in cells treated or not with oleic acid. 24 hours after 300 
transfection, whole cell extracts were prepared and subjected to the luciferase assay. 301 
As shown in Fig. 5A, oleic acid alone did not significantly changed the basal activity 302 
of SCD1 promoter which was instead efficiently activated by insulin. Interestingly, 303 
insulin-dependent activation was almost completely abolished by oleic acid addition 304 
to the culture medium showing that, similar to serum, the repressive activity of oleic 305 
acid overrides the inductive effect of insulin. To substantiate these data, we decided 306 
to examine the level of SCD1 endogenous mRNA in BME-UV1 cells by quantitative 307 
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Real Time PCR. Cells were grown in serum-free medium supplemented or not with 308 
30 or 50 µM oleic acid for 24 hours.  The combined effect of insulin and oleic acid 309 
was checked by adding insulin at a concentration of 20 ng/mL. Total RNA was 310 
isolated and subjected to quantitative PCR using primers to specifically amplify 311 
bovine SCD1 mRNA. The level of SCD1 specific transcript was normalized against 312 
the EIF3K and GAPDH RNA and expressed as relative amount respect to the sample 313 
obtained in oleic acid and insulin-free medium. As shown in Fig. 5B, we confirmed 314 
the induction of SCD1 endogenous gene transcription by insulin which was 315 
completely suppressed by oleic acid.  316 
317 
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 318 
DISCUSSION  319 
Alignment of the highly conserved region of bovine SCD1 promoter region shows 320 
the expected high homology of the putative PUFA-RE between different farm animal 321 
species. This region is known to be involved in the response of SCD promoter to 322 
insulin, fatty acids and sterols (24). The PUFA-RE contains binding sites for 323 
SREBP1, NFY and SP1 transcription factors. Genome-wide analysis of promoter co-324 
occupancy, in human liver cells, have recently shown that SREBP1 cooperates 325 
extensively with NFY and SP1 throughout the genome, thereby suggesting that the 326 
regulatory circuitry among SREBP, NFY and SP1 is highly interconnected. 327 
Concerning the metabolic pathways, combination of all three factors was reported to 328 
be involved in the control of cholesterol biosynthesis and aminoacid activation while 329 
the combination of SREBP1 and NFY alone was shown to regulate lipid metabolism 330 
and RNA processing (13).  331 
The expression of the SCD l gene is under complex control mechanisms such as 332 
hormones and, possibly, intermediates of carbohydrate and fat metabolism therefore 333 
it is difficult to dissect all the agents that regulate SCD1 gene transcription by in vivo 334 
models. The aim of this study was to investigate the responsiveness of bovine SCD1 335 
promoter to insulin, oleic acid and NFY in BME-UV1 cells, a potential in vitro 336 
model for studying biotransformation in bovine mammary gland.  337 
In the mammary gland of ruminants, SCD1 is known to be responsible for the 338 
production of about 63-97% of c9t11 CLA coming from vaccenic acid as estimated 339 
using either direct (13C-labelled fatty acids) or indirect methods (inhibition of SCD 340 
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by sterculic acid or duodenal and milk FA flows) (25). SCD1 activity can be 341 
measured by comparing the product/substrate ratios of certain fatty acids. There are 342 
four main products of SCD1 activity in the mammary gland of ruminants: c9C14:1, 343 
c9C16:1, c9C18:1 and CLA, which are produced from C14:0, C16:0, C18:0 and 344 
trans11 C18:1, respectively. According to Lock and Garnsworthy (26), the best 345 
indicator of SCD1 activity is the c9C14:1/C14:0 ratio because all of the C14:0 in 346 
milk fat is produced via de novo synthesis in the mammary gland; consequently, 347 
desaturation is the only source of C14:1. Increasing c9C14:1/C14:0 ratio values 348 
would indicate an increase of SCD1 activity. 349 
The regulation of SCD1 by dietary factors has been largely investigated in rodents 350 
(11), while in ruminants the results are conflicting. Ahnadi et al. (27) and Harvatine 351 
and Bauman (28) found a depression of mammary SCD1 mRNA abundance when 352 
lactating cows were fed protected PUFA. Researches effected on goats showed that 353 
the supplementation of sunflower seed oil (29) and linseed oil (30) did not affect 354 
both SCD1 expression and/or activity in maize silage-based diets while the same 355 
supplementation to diets based on grass hay decreased only the SCD1 activity (31). 356 
Similar results have been reported supplementing soya beans to lucerne hay-based 357 
diets (32). Finally, supplementing grass hay-based diets with formaldehyde-treated 358 
linseed decreased mammary SCD1 mRNA without effect on the SCD1 activity (32). 359 
Tudisco et al (33) reported higher SCD1 expression  in the somatic cells of milk 360 
yielded from goats bred according either organic system than those bred in stable. 361 
The authors justify the results for the a higher amount of both C18:2 and C18:3 362 
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ingested by organic group than the stable group, as registered in previous researches 363 
(34; 35) thus probably resulting in an up-regulation of the SCD expression.  364 
Bernard et al. (36) suggest to evaluate the importance of interactions between the 365 
composition of the basal diet and lipid supplement with the implication that specific 366 
PUFA escaping metabolism in the rumen or specific biohydrogenation intermediates 367 
may inhibit SCD1 activity via transcriptional or post- transcriptional regulatory 368 
mechanisms. 369 
More recently, Tudisco et al (37) reported that the grazing season as well as lactation 370 
stage can affect the SCD1 mRNA abundance determined from milk somatic cells 371 
with values that progressively decreased from April until June, increased in July  and 372 
decreased again in August.  373 
In keeping with previous findings (38), we found that insulin treatment induces a 374 
significant increase of  SCD 1 gene promoter activity in BME-UV1 cells, providing 375 
further evidence of its pro-lipogenic role. However, attention must be paid to the 376 
evaluation of SCD1 promoter regulation in serum-supplemented cell culture as the 377 
repressive effect of serum on SCD1 promoter activity overcomes induction by 378 
insulin and this was consistently shown both in human MCF7 and bovine BME-UV1 379 
cells. Remarkably, oleic acid was also able to repress SCD1 promoter activation only 380 
in insulin treated cells thereby providing a possible explanation of the controversial 381 
literature about the inhibitory effect of oleic on SCD1 expression (11). We confirmed 382 
our data on SCD1 endogenous transcription of BME-UV1 cells, thereby 383 
demonstrating that our reporter system truly reflects the response of the endogenous 384 
SCD1 gene promoter and can be a useful tool to investigate the modulation of SCD1 385 
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promoter activity by nutrients and extracellular stimuli. Finally, our study provides 386 
evidences that NFY enforced expression represses SCD1 promoter activity. It has to 387 
be mentioned that Tabor and coworkers (22) reported that NFY transcription factor is 388 
a SCD1 transcriptional activator in adipocytes; our data are in contrast with Tabor 389 
conclusion and this might depend on the specific cell type and growing condition 390 
used. However, whether NFY works in cooperation or not with other transcription 391 
factors, deserves more attention and will be the subject of further investigations.  392 
393 
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 515 
Legends to figures 516 
Figura 1. The SCD1 gene promoter. (A) Sequence alignment of  the PUFA-RE  517 
sequence in the SCD1 proximal promoter region underlined the sequences 518 
corresponding to the Sp1 protein binding site, the Sterol Responsive Element and the 519 
NF-Y/NFI consensus. (B) The SCD1 proximal promoter region. The primers used 520 
for PCR and subsequent cloning are indicated in italic. Underlined are highlighted 521 
the sequences corresponding to the Sp1 protein binding site, the Sterol Responsive 522 
Element and the NF-Y/NFI consensus. The transcription start site (+1) is indicated  523 
in capital.  524 
Figure 2. Effect of FBS on SCD1 promoter activity. (A) The SCD1_PGL3 or 525 
p21WAF_PGL3 promoter constructs were transfected into MCF7 cells and treated 526 
with different concentrations of serum (0%, 5%,10%). After 24 h the luciferase assay 527 
was performed. The p21WAF_PGL3 promoter, was used as a serum independent 528 
control.  The basal activity of the promoters at 0% FBS was fixed as 100%.  Each 529 
experimental point was done in triplicate and the results are presented as the mean of 530 
three biological replicates. (B) The SCD1_PGL3 promoter construct was transfected 531 
into MCF7 cells grown in serum-free or 10% Fetal Bovine Serum. Insulin was added 532 
at a concentration of 20 ng/ml. After 24 hr the luciferase assay was performed. The 533 
basal activity of the promoters at 0% FBS was fixed as 100%.  Each experimental 534 
point was done in triplicate and the results are presented as the mean of three 535 
biological replicates. 536 
 537 
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Fig.3 Effect of NFY transcription factor and on SCD1 promoter activity into 538 
MCF7 cells.  539 
MCF7 cells were co-trasfected with 0.5 µg of SCD-1-PGL3 construct along with 0.5 540 
µg of each plasmid encoding NFY-A, NFY-B and NFY-C subunits. Cells  were grow 541 
in serum-free medium or media supplemented with 5 or 10%  FBS  for 24 hrs. (A) 542 
Expression of transfected NFYA and NFYB protein was evaluated by immunoblot 543 
analysis with specific antibodies.  (B) Promoter activity was evaluated by luciferase 544 
assay. Each experim ntal point was done in triplicate and the results are presented as 545 
the mean of three biological replicates.  546 
Figure 4. Effect of serum and Insulin on SCD1 promoter activity. (A) 547 
SCD1_PGL3 promoter construct was transfected into BME-UV1 cells treated with 548 
the indicated concentrations of serum (0%, 5%, 10%) with or without  insulin (20 549 
ng/mL), as indicated. After 24 hr, the promoter activity was evaluated by luciferase 550 
assay.  Each experimental point was done in triplicate and the results are presented as 551 
the mean of three biological replicates.  552 
(B) BME-UV1 cells were treated with the indicated concentrations of serum (0%, 553 
10%) with or without insulin (20 ng/mL), for 24 h. The SCD1 specific transcript was 554 
quantified by Real Time PCR and expressed as the relative amount respect to the 555 
level expressed in cells grown in serum and insulin-free medium. The results are 556 
presented as the mean of three experimental replicates 557 
 558 
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Figure 5.  Effect of insulin and oleic acid on SCD1 promoter activity 559 
(A) SCD1_PGL3 promoter construct was transfected into BME-UV1 cells cultured 560 
in serum-free medium with or without  insulin (20 ng/mL), as indicated. Oleic acid 561 
(30 and 50 µM) was supplemented to the medium as indicated. After 24 hr, the 562 
promoter activity was evaluated by luciferase assay.  Each experimental point was 563 
done in triplicate and the results are presented as the mean of three biological 564 
replicates.  565 
(B) BME-UV1 cells were treated as indicated in (A) for 24 h. The SCD1 specific 566 
transcript was quantified by Real Time PCR and expressed as the relative amount 567 
respect to the level expressed in cells grown in serum-free medium without insulin 568 
and oleic acid. The results are presented as the mean of three experimental replicates. 569 
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The SCD1 gene promoter. (A) Sequence alignment of  the PUFA-RE  sequence in the SCD1 proximal 
promoter region underlined the sequences corresponding to the Sp1 protein binding site, the Sterol 
Responsive Element and the NF-Y/NFI consensus. (B) The SCD1 proximal promoter region. The primers 
used for PCR and subsequent cloning are indicated in italic. Underlined are highlighted the sequences 
corresponding to the Sp1 protein binding site, the Sterol Responsive Element and the NF-Y/NFI consensus. 
The transcription start site (+1) is indicated  in capital.  
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Effect of FBS on SCD1 promoter activity. (A) The SCD1_PGL3 or p21WAF_PGL3 promoter constructs were 
transfected into MCF7 cells and treated with different concentrations of serum (0%, 5%,10%). After 24 h 
the luciferase assay was performed. The p21WAF_PGL3 promoter, was used as a serum independent 
control.  The basal activity of the promoters at 0% FBS was fixed as 100%.  Each experimental point was 
done in triplicate and the results are presented as the mean of three biological replicates. (B) The 
SCD1_PGL3 promoter construct was transfected into MCF7 cells grown in serum-free or 10% Fetal Bovine 
Serum. Insulin was added at a concentration of 20 ng/ml. After 24 hr the luciferase assay was performed. 
The basal activity of the promoters at 0% FBS was fixed as 100%.  Each experimental point was done in 
triplicate and the results are presented as the mean of three biological replicates.  
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Effect of NFY transcription factor and on SCD1 promoter activity into MCF7 cells.  
MCF7 cells were co-trasfected with 0.5 µg of SCD-1-PGL3 construct along with 0.5 µg of each plasmid 
encoding NFY-A, NFY-B and NFY-C subunits. Cells  were grow in serum-free medium or media supplemented 
with 5 or 10%  FBS  for 24 hrs. (A) Expression of transfected NFYA and NFYB protein was evaluated by 
immunoblot analysis with specific antibodies.  (B) Promoter activity was evaluated by luciferase assay. Each 
experimental point was done in triplicate and the results are presented as the mean of three biological 
replicates.  
 
190x275mm (96 x 96 DPI)  
 
 
Page 31 of 33
URL: http://mc.manuscriptcentral.com/labt
Animal Biotechnology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
Effect of serum and Insulin on SCD1 promoter activity. (A) SCD1_PGL3 promoter construct was transfected 
into BME-UV1 cells treated with the indicated concentrations of serum (0%, 5%, 10%) with or 
without  insulin (20 ng/mL), as indicated. After 24 hr, the promoter activity was evaluated by luciferase 
assay.  Each experimental point was done in triplicate and the results are presented as the mean of three 
biological replicates.  
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Effect of insulin and oleic acid on SCD1 promoter activity  
(A) SCD1_PGL3 promoter construct was transfected into BME-UV1 cells cultured in serum-free medium with 
or without  insulin (20 ng/mL), as indicated. Oleic acid (30 and 50 µM) was supplemented to the medium as 
indicated. After 24 hr, the promoter activity was evaluated by luciferase assay.  Each experimental point 
was done in triplicate and the results are presented as the mean of three biological replicates.  
(B) BME-UV1 cells were treated as indicated in (A) for 24 h. The SCD1 specific transcript was quantified by 
Real Time PCR and expressed as the relative amount respect to the level expressed in cells grown in serum-
free medium without insulin and oleic acid. The results are presented as the mean of three experimental 
replicates.  
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